Cultured meat products using genetically modified cells

By introducing carotenoid biosynthesis pathway enzymes into mammalian cells, the endogenous synthesis and optimization of carotenoids is achieved, which solves the problem of limited application of mammalian cell metabolism engineering and transformation, and improves the nutritional value of meat and Antioxidant capacity.

CN114173817BActive Publication Date: 2024-11-26TRUSTEES OF TUFTS COLLEGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080054515.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-06-14
Filing Date
2020-06-01
Publication Date
2024-11-26
Estimated Expiration
2040-06-01

AI Technical Summary

Technical Problem

The development of mammalian cell metabolism engineering transformation technology is lagging behind, especially in mammalian systems, and the widespread application is limited. The existing technology mainly focuses on therapeutic protein production and disease research. It lacks cross-classification metabolic engineering transformation applications, making it difficult to achieve non-natural compounds. Endogenous synthesis.

Method used

Endogenous synthesis of carotenoids is achieved by introducing heterologous polynucleotides encoding octahydrol lycopene synthase, octahydrol lycopene desaturase and lycopene cyclase into mammalian cells and through The optimization of enzyme expression and inducing precursor accumulation to increase yield demonstrated successful transgene and optimization of carotenoid biosynthesis pathways in bovine and mouse muscle stem cells.

Benefits of technology

Significantly improves the endogenous yield of carotenoids, optimized yields are higher than those in beef, and demonstrates its antioxidant capacity, demonstrating the potential of metabolic engineering transformation in cultured meat, improving cell growth and meat quality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114173817B_ABST
    Figure CN114173817B_ABST
Patent Text Reader

Abstract

Provided herein are genetically engineered mammalian cells that endogenously express one or more phytochemicals, vitamins or therapeutic agents and are suitable for cultured meat products. Also provided are methods of making and using the genetically engineered mammalian cells and the cultured meat products.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 62 / 855,698, filed May 31, 2019, and U.S. Provisional Application No. 62 / 861,606, filed June 14, 2019, each of which is incorporated herein by reference in its entirety.

[0003] Statement Regarding Federally Funded Research

[0004] This invention was made with government support under Grant No. EB002520 awarded by the National Institutes of Health. The government has certain rights in this invention.

[0005] References to sequence listings submitted via EFS-WEB

[0006] The contents of the 114 kb ASCII text file of the sequence listing, entitled "166118_00970_ST25.txt," created on June 1, 2020, and submitted electronically with this application via EFS-Web, are incorporated herein by reference in their entirety. Background Art

[0007] Synthetic biology and metabolic engineering have become important tools across multiple disciplines (Keasling, 2010). However, widespread use in mammalian systems has been slow, and progress within these systems has been largely limited to applications such as therapeutic protein production (e.g., monoclonal antibodies) or disease research and treatment (e.g., metabolic reprogramming) (Davy et al., 2017; Schukur and Fussenegger, 2016). Within these efforts, little attention has been paid to heterologous engineering of mammalian cells using genes from other taxa (i.e., bacteria or plants), with the exception of genetic tools such as viral or bacterial editing or regulatory systems (Mojica and Montoliu, 2016; Zhang et al., 2006). In contrast, metabolic engineering efforts in bacteria, yeast, or plants have employed transgenes from a wide variety of taxa for applications ranging from pharmaceuticals and cosmetics to energy and agriculture (Heider and Wendisch, 2015; Nielsen, 2015; Sack et al., 2015). Recent advances in tissue engineering have broadened our view of the possible applications of animal cell culture in food and nutrition, robotics, and biosensors (Banerjee and Bhunia, 2009; Rubio et al., 2019). This shift provides an opportunity to rethink mammalian metabolic engineering and expand efforts to include cross-class engineering for a wide range of applications.

[0008] One such application is the production of meat by cell culture (known by various terms, "cultured meat" will be used herein), which has been proposed as a means of addressing the environmental, ethical and public health issues of animal husbandry (Mattick et al., 2015; Post, 2012). Summary of the Invention

[0009] In a first aspect, the present invention provides an engineered cell that endogenously synthesizes phytoene and comprises a heterologous polynucleotide encoding a phytoene synthase. In some embodiments, the phytoene synthase has a sequence that is at least 90% identical to SEQ ID NO: 1 or SEQ ID NO: _. In some embodiments, the cell endogenously synthesizes lycopene and comprises a heterologous polynucleotide encoding a phytoene desaturase. In some embodiments, the phytoene desaturase has a sequence that is at least 90% identical to SEQ ID NO: 3. In some embodiments, the cell endogenously synthesizes β-carotene and comprises a heterologous polynucleotide encoding a lycopene cyclase. In some embodiments, the lycopene cyclase has a sequence that is at least 90% identical to SEQ ID NO: 5 or SEQ ID NO: _. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a Pax7 + Mammalian muscle precursor cells. In some embodiments, the cells are actin + Myosin heavy chain (MHC) + Mammalian multinucleated myotubes. In some embodiments, the total carotenoid production in the engineered cells is at least 5-fold higher than the total carotenoid production in the cells without the heterologous polynucleotides encoding phytoene synthase, phytoene desaturase, and lycopene cyclase.

[0010] In a second aspect, provided herein is a method for producing an engineered cell as described herein, comprising introducing into a cell that naturally synthesizes geranylgeranyl pyrophosphate (i) a heterologous polynucleotide encoding a phytoene synthase; (ii) a heterologous polynucleotide encoding a phytoene desaturase; (iii) a heterologous polynucleotide encoding a lycopene cyclase; or (iv) a combination thereof. In some embodiments, the cell is a Pax7+ mammalian muscle precursor cell.

[0011] In a third aspect, provided herein is an engineered cell that endogenously synthesizes vitamin C and comprises one or more exogenous polynucleotides encoding UDP-glucose 6-dehydrogenase (UGDH), UDP glucuronosyltransferase 1 (UGT1A1), aldo-keto reductase family 1 (AKR1A1), calmodulin (RGN), and L-gulono-γ-lactone oxidase (GULO).

[0012] In a fourth aspect, provided herein is an engineered cell that endogenously synthesizes curcumin and comprises one or more heterologous polynucleotides encoding tyrosine ammonia lyase (PTAL), 4-coumarate-CoA ligase (4CL), phenylpropionyl-diketo-CoA synthetase (DCS), and curcumin synthase (CURS3).

[0013] In a fifth aspect, provided herein is an engineered cell that endogenously synthesizes cannabidiol (CBD) and comprises one or more heterologous polynucleotides encoding 3,5,7-trioxodecanoyl-CoA synthase (OLS), oleuronate cyclase (OAC), cannabigerolic acid synthase (CBGAS), and cannabidiolic acid synthase (CBDAS).

[0014] In a sixth aspect, provided herein is an engineered cell comprising a heterologous polynucleotide encoding Nanobody V565 having a sequence at least 95% identical to SEQ ID NO: 7. In some embodiments, said polynucleotide encodes said V565 Nanobody covalently linked to tumor necrosis factor alpha (TNFα) via a cleavable polypeptide linker. In some embodiments, said cleavable polypeptide linker comprises SEQ ID NO: 9.

[0015] In a seventh aspect, provided herein is an engineered cell comprising a heterologous polynucleotide encoding an antimicrobial peptide 16 (AMP16) having a sequence at least 95% identical to SEQ ID NO: 8. In some embodiments, the polynucleotide encodes at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 repeats of AMP16, each repeat separated by a linker polypeptide comprising Asn-Pro-Val repeats.

[0016] In an eighth aspect, the present invention provides a cultured meat product comprising a confluent serum-free culture comprising engineered cells as described herein seeded on a food-safe matrix. In some embodiments, the matrix is ​​a membrane. In some embodiments, the matrix is ​​a sponge or a three-dimensional matrix. In some embodiments, the matrix is ​​a chitosan matrix. In some embodiments, the cell culture comprises multinuclear myotubes derived from Pax7+ mammalian satellite cells. In some embodiments, the multinuclear myotubes express myosin heavy chain (MHC) and actin. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] This patent or patent application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0018] Figure 1 Gene constructs and their corresponding end products in the carotenoid biosynthetic pathway are shown. All gene constructs contain a puromycin resistance gene and a target gene simultaneously driven by a bidirectional synthetic RBPSA / CMV promoter. All target gene regions contain a green fluorescent protein (GFP) sequence produced either alone or as part of a polycistronic mRNA transcript. Constructs are designated (from top to bottom) as pGFP, pCrtB, pCrtB / I, and pCrtB / I / Y.

[0019] Figures 2A-2B show characterization of bovine satellite cells. (Figure 2A) Immunofluorescent staining for Pax7, a transcription factor and satellite cell marker (green), with counterstaining for cellular actin (phalloidin, re(D)) and nuclei (DAPI, blue). (Figure 2B) Immunofluorescent staining for myosin heavy chain (MF20), a skeletal muscle contractile protein (green), with counterstaining for cellular actin and nuclei. High-objective staining of differentiated cells reveals a striped pattern in actin and myosin heavy chain, indicative of skeletal muscle sarcomere formation. Scale bar, 100 μm.

[0020] Figures 3A-3C show engineered cell growth and development. (Figure 3A) Fluorescent images of GFP expression in C2C12 and BSCs engineered with all four constructs (carotenoid-producing constructs and control constructs). Due to the structure of the constructs, GFP expression suggests successful expression of other enzymes in the genetic constructs. (Figure 3B) Growth curves over eight days for C2C12 and BSCs engineered with all four constructs, n=3 different samples, * indicates significant difference from pGFP for the corresponding color, p<0.05. (Figure 3C) Immunofluorescence staining of Pax7 (re(D)) and myosin heavy chain (re(D)) in pCrtB / I / YBSCs before (top) and after (bottom) differentiation. DAPI counterstaining (blue) shows cell nuclei, and endogenous GFP (green) shows cell morphology. Scale bar is 100 μm.

[0021] Figures 4A-4B show carotenoid production in engineered cells. Carotenoid production in engineered cells. (Figure 4A) Carotenoid production in C2C12 cells engineered with pCrtB, pCrtB / I, and pCrtB / I / Y. In pCrtB cells, only phytoene was produced. In pCrtB / I cells, most of the phytoene was converted to lycopene. In pCrtB / I / Y cells, carotenoids accumulated as β-carotene, but total carotenoid levels were significantly reduced compared to pCrtB and pCrtB / I. n = 3 different samples; different letters indicate statistical differences between bars, p < 0.05. (Figure 4B) Carotenoid production in BSCs engineered with pCrtB, pCrtB / I, and pCrtB / I / Y. The trend followed that of C2C12, with total carotenoid content reduced approximately 10-fold compared to C2C12 in all cases. n = 3 different samples; different letters indicate statistical differences between bars, p < 0.05. Carotenoid data are presented in μg / g protein. Individual values ​​and data comparing carotenoids relative to protein are presented in Figures 4C and 4D.

[0022] Figures 4C-4D show carotenoid and protein quantification data. Individual carotenoid and protein data points were used to generate μg / g data. (Figure 4C) C2C12 carotenoid and protein quantification per million cells for all cell types and treatments. The trends are the same as in Figures 4 and 5. (Figure 4D) BSC carotenoid and protein quantification per million cells for all cell types and treatments. The trends are the same as in Figures 4A-4B and 5A-5C. For all, n = 3 different samples. Within the figures, different letters indicate statistical differences between bars (p < 0.05).

[0023] Figure 5A-Figure 5C shows carotenoid optimization. (Figure 5A) Carotenoid biosynthetic pathway in the context of its shared pathway as a precursor in cholesterol synthesis. Shown is the possible mechanism of optimization. Puromycin (purple) works by selecting cells that provide higher enzyme expression and therefore increase carotenoid synthesis flux. Ketoconazole (re (D) works by inhibiting the conversion of lanosterol into yeast sterol, by causing the upstream accumulation of lanosterol, squalene and FPP, or by reducing the influence of cholesterol as a feedback inhibitor of the upstream FPP synthesis reaction to increase the level of carotenoid precursor farnesyl pyrophosphate (FPP). (Figure 5B) Cell mass image of engineered BSC. The coloring effect of carotenoids can be seen, with pGFP cells being slightly green, pCrtB not containing pigment, and pCrtB / I and pCrtB / Y cells containing some orange pigment. Optimized pCrtB / I / Y cells are significantly more orange, indicating increased carotenoid levels. (Figure 5C) Quantitative HPLC analysis of β-carotene in optimized cells. In BSC, ketoconazole and puromycin treatment conditions increased β-carotene accumulation. In C2C12, ketoconazole and puromycin together did not significantly increase β-carotene. n = 3 different samples; *p < 0.05. Carotenoid data are presented in μg / g protein. Individual values ​​and data comparing carotenoids relative to protein are presented in Figures 4C-4D.

[0024] Figure 6 Figure 3 Thiobarbituric acid reactive substances (TBARS) analysis of engineered BSCs with or without heating is shown. All heated samples showed a significant increase in malondialdehyde (MDA) compared to raw samples, indicating significant oxidative stress from this "cooking" process. In heated samples, pCrtB, pCrtB / I, and pCrtB / I / Y cells showed a significant decrease in malondialdehyde (MDA) compared to the control group. In unheated samples, pCrtB / I and pCrtB / I / Y samples showed a significant decrease in MDA compared to control pGFP cells, and pCrtB did not show a significant change. n = 3 different samples. Bars sharing the same letter are statistically different (p < 0.05).

[0025] Figures 7A-7B show carotenoid optimization treatment. (Figure 7A) Flow cytometric measurements of mean fluorescence intensity in C2C12 and BSC engineered with pCrtB / I / Y (full flow cytometric data are in Figures 8A-8B). Cells were cultured with 2.5 μg / mL puromycin (1×), 5 μg / mL puromycin (2×), or 10 μg / mL puromycin (4×). Higher fluorescence intensity indicates higher mean GFP expression, which corresponds to higher mean enzyme expression. Errors are given as mean ± standard deviation. For each condition, n>1,500 events. (Figure 7B) 8-day cell growth of pCrtB / I / Y C2C12 and BSC cultured in 0, 2.5, 5, 10, or 20 μg / mL ketoconazole. n=3 different samples. In both a and b, * indicates p<0.05.

[0026] Figure 8A-Figure 8B shows flow cytometry data. (Figure 8A) BSC data of cells treated with different levels of puromycin. From left to right: non-engineered cells (GFP negative control group), pGFP (GFP positive control group), pCrtB / I / Y with 2.5μg / mL puromycin (1×puro), pCrtB / I / Y with 5μg / mL puromycin (2×puro) and pCrtB / I / Y with 10μg / mL puromycin (4×). The top row is forward scatter (FSC) and side scatter (SSC) data, showing the gate for live cells (determined using the non-engineered control group), where the gate value is the percentage relative to the total count (7,500). The bottom row is GFP data, showing the gate for GFP-positive cells (determined using the non-engineered control group), where the gate value is the percentage relative to the total count (7,500). (Figure 8B) C2C12 data of cells treated with different levels of puromycin. From left to right: non-engineered cells (GFP negative control), pGFP (GFP positive control), pCrtB / I / Y with 2.5 μg / mL puromycin (1×puro), pCrtB / I / Y with 5 μg / mL puromycin (2×puro), and pCrtB / I / Y with 10 μg / mL puromycin (4×). The top row is FSC and SSC data, showing the gate for live cells (determined using the non-engineered control), where the gate value is the percentage relative to the total count (7,500). The bottom row is GFP data, showing the gate for GFP-positive cells (determined using the non-engineered control), where the gate value is the percentage relative to the live cells (gated in the top row).

[0027] Figures 9A-9B show the carotenoid profiles of optimized cells. (Figure 9A) Phytoene, lycopene, and β-carotene content of pCrtB / I / Y C2C12 cells without optimization (top) or with puromycin and ketoconazole treatment (bottom). n = 3 different samples. (Figure 9B) Phytoene, lycopene, and β-carotene content of pCrtB / I / YBSC cells without optimization (top left), without puromycin treatment but with ketoconazole treatment (top right), with puromycin treatment but without ketoconazole treatment (bottom left), or with puromycin and ketoconazole treatment (bottom left). n = 3 different samples. Within the figure, different letters indicate statistical differences between bars, p < 0.05).

[0028] Figure 10 The synthesis pathways of vitamin C, curcumin, and cannabidiol from precursors in BSC are shown.

[0029] Figure 11 An overview of Example 2 is shown. In 1, cell composition will be analyzed before and after differentiation. In 2, cells will be engineered to synthesize various compounds, which will be analyzed before and after differentiation. In 3, cell growth and development, nutrient bioavailability, and nutrient function will be analyzed.

[0030] Figure 12 The overview of Example 3 is shown. Drug expression vectors (A) and excipients (B) are engineered into bovine muscle and adipocytes to explore in vitro drug synthesis. The simultaneous expression of green fluorescent protein (GFP) and therapeutic components serves as a simple marker for gene expression. Drug expression vectors (V565 and AMP16, each comprising a GFP marker) are further engineered to incorporate various disease-responsive mechanisms for drug activity, including lysine-rich linkers for cleavable trypsin, NPV-linkers for cleavable elastase, or a combination of the two. Disease-responsive edible therapeutic agents in bovine muscle cells (proliferation or differentiation) are tested in a 3D model of IBD and Salmonella enterica infection, followed by in vitro digestion, and with and without heat treatment (i.e., cooking).

[0031] Figure 13A-Figure 13E shows the results of bovine satellite cell (BSC) culture. (Figure 13A) Characterization of primary BSC. Proliferating cells show the ubiquitous expression of Pax7 (a muscle stem cell marker) (scale bar: 100 μm). (Figure 13B) Differentiated cells show myotube formation and expression of myosin heavy chain (MF20), indicating myogenic differentiation (scale bar is 100 μm). (Figure 13C) Four-day growth of BSC cultured in dilutions of serum-containing growth medium (GM) and serum-free medium (B8). In all cases, including B8 used alone (i.e., serum-free, rightmost column), compared to GM used alone (leftmost column), dilutions containing B8 showed significantly increased growth within four days. Statistical significance (p<0.05) between different letter indication groups. (Figure 13D) Adipogenic transdifferentiation of BSCs using free fatty acids (FFA). Oil red O staining of BSCs treated with 0 to 150 μM linoleic acid and a combination of linoleic acid, erucic acid, and elaidic acid. Rare lipid accumulation was observed in BSCs treated with 100 μM to 150 μM linoleic acid. Robust lipid accumulation was observed in BSCs treated with a combination of FFAs from 75 μM to 125 μM. At 150 μM, the FFA mixture was detrimental to cell health (scale bar: 250 μm). ( FIG. 13E ) AdipoRed analysis results for quantitative analysis of lipid accumulation induced by FFAs in BSCs.

[0032] Figures 14A-14D show BSC compositional engineering. (Figure 14A) Carotenoid production in BSCs engineered with pCrtB, pCrtB / I, and pCrtB / I / Y. In pCrtB cells, only phytoene was produced. In pCrtB / I cells, the majority of phytoene was converted to lycopene. In pCrtB / I / Y cells, carotenoids accumulated as β-carotene, but total carotenoid levels were significantly reduced compared to pCrtB and pCrtB / I. Different letters indicate statistical differences between bars, p < 0.05. (Figure 14B) In BSCs, ketoconazole and puromycin treatment provided an additive increase in β-carotene production by increasing enzymes. * indicates significance (p < 0.05). (Figure 14C) Thiobarbituric acid-reactive substances (TBARS) analysis of engineered BSCs with and without heating. All heated samples showed a significant increase in malondialdehyde (MDA) compared to the raw samples, indicating a significant oxidative challenge from this "cooking" process. In the heated samples, pCrtB, pCrtB / I and pCrtB / I / Y cells showed a significant reduction in MDA compared to the control group. In the unheated samples, pCrtB / I and pCrtB / I / Y samples showed a significant reduction in MDA compared to the control pGFP cells, and pCrtB did not show significant changes. Bars sharing the same letter are statistically different (p < 0.05). (Figure 14D) Fluorescence and optical microscopy images of BSCs engineered to express GFP (pGFP) alone or to express GFP and CBD synthase (pCBD). Green fluorescence indicates gene expression. After puromycin selection, all cells expressed GFP and enzyme (data not shown) (scale bar: 250 μm).

[0033] Figures 15A-15H show a 3D intestinal model. Figures 15A-15D show an intestinal scaffold. 57 . (FIG. 15A-FIG. 15B) Schematic diagram of the generation of silk-based 3D porous scaffolds for constructing patterned and non-patterned model intestines. The scaffolds were prepared by casting the silk solution into a PDMS mold and inserting a Teflon-coated wire or nylon screw through the cylinder, freeze-dried and inducing β-sheet formation (scale bar: 4 mm). (FIG. 15C) Fluorescent staining of enterocyte markers (ZO-1 and MUC2) in the scaffolds and in 2D cultures showed increased expression in the 3D scaffolds (scale bar: 200 μm). Optical microscopy observation of mucus deposition in the scaffolds and in 2D cultures in FIG15D by toluidine blue staining showed increased mucus thickness in the 3D scaffolds compared to the 2D, and increased mucus thickness in the patterned scaffolds compared to the non-patterned (scale bar: 200 μm). Quantification (data not shown) revealed a 2-fold and 3-fold increase in mucus deposition in the non-patterned and patterned scaffolds, respectively, compared to the 2D cultures. FIG15E-FIG. 15H shows that IBD modeling 55. Figure 15E Inflammation was induced by treatment with E. coli O111:B4 LPS and IFNγ. Staining for e-cadherin in the inflammation model shows the difference in epithelial coverage between the inflamed and non-inflamed groups on day 7 (scale bar: 100 μm). F) MUC2 staining shows that all groups stained positively, indicating the presence of goblet cells (scale bar: 100 μm). Figure 15G Cross-sections of the model on day 7 show different epithelial coverage as observed by e-cadherin (scale bar 1 mm). Figure 15H Further observation of the epithelium shows a single layer in the non-inflamed group and a spherical structure in the inflamed group (scale bar: 100 μm).

[0034] Figures 15I-15L show a 3D intestinal model of Cryptosporidium parvum infection 56 . Figure 15I Uninfected cells show regular microvilli (Scale bar: 2 μm). Figure 15J Cryptosporidium parvum type I meront (thick arrow) and empty parasitophorous vacuole (thin arrow) on day 3 (Scale bar: 2 μm). Figure 15K Type I schizont containing eight merozoites on day 3 (enlarged view of J; scale bar: 1 μm). Figure 15L Type I schizont excysting on day 2 (Scale bar: 1 μm). Figure adapted from the following reference: AD 57 , EH 55 , IL 56 .

[0035] Figure 16A-Figure 16B shows bovine satellite cell (BSC) culture results. (Figure 16A) Characterization of primary BSC. Proliferating cells (left panel) show the ubiquitous expression of Pax7 (a muscle stem cell marker). Differentiated cells (right panel) show the expression of myotube formation and myosin heavy chain (MF20), indicating myogenic differentiation. (Figure 16B) BSC (left panel) cultured in dilutions of serum-containing growth medium (GM) and serum-free medium (B8). In all cases, including B8 used alone (i.e., serum-free, rightmost column), compared to GM used alone (leftmost column), dilutions containing B8 showed significantly increased growth within four days. The FGF-2 dilutions in the B8 culture medium (right panel) reveal that, compared to the B8 culture medium without FGF-2, FGF-2 concentrations greater than or equal to 1.25ng / mL showed significantly increased growth within four days. In the left panel, the statistical significance (p<0.05) between the different letter indication groups is shown. In the right panel, * indicates significant differences (p<0.05).

[0036] Figures 17A-17B show adipogenic transdifferentiation of bovine satellite cells (BSCs) using free fatty acids (FFA). (Figure 17A) Oil Red O staining of BSCs treated with 0 to 150 μM linoleic acid and a combination of linoleic, erucic, and elaidic acids. Sparse lipid accumulation was observed in BSCs treated with 100 to 150 μM linoleic acid. Robust lipid accumulation was observed in BSCs treated with a combination of 75 to 125 μM FFAs. At 150 μM, the FFA mixture was detrimental to cell health. (Figure 17B) AdipoRed analysis results for quantitative analysis of FFA-induced lipid accumulation in BSCs.

[0037] Figure 18 An overview of Example 4 is shown. Culture media will be formulated to explore various approaches to serum-free and antibiotic-free culture of bovine muscle and adipose tissue. Cell proliferation and differentiation will be analyzed, as will nutritional and meat quality characteristics.

[0038] Incorporated by reference

[0039] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. DETAILED DESCRIPTION

[0040] The present disclosure describes engineered cells and their use in cultured meat products. Cells can be engineered to endogenously produce one or more metabolites by expressing one or more exogenous biosynthetic pathway enzymes in the cells. Cells can also be engineered to increase or decrease the endogenous production of one or more metabolites by increasing or decreasing the biosynthetic pathway enzymes naturally present in the cells, or to increase the endogenous production of native metabolites by introducing non-native biosynthetic pathway enzymes into the cells.

[0041] As used herein, "metabolite" refers to a compound that is an intermediate or end product of primary or secondary metabolism in a cell through one or more biosynthetic pathways. Cellular metabolites have various functions (e.g., pigments, odorants, pheromones, quorum sensing, etc.) in terms of energy supply, structure, signaling, stimulation, and inhibition of proteins and enzymes, enzyme cofactors or enzyme cosubstrates, defense, and interactions with other organisms or cells. Metabolites may include, but are not limited to, alcohols, amino acids, nucleotides, antioxidant factors, organic acids, polyols, and vitamins. The cells described herein can be engineered to endogenously produce one or more metabolites, including, but not limited to, phytochemicals, phytonutrients, vitamins, and therapeutic molecules.

[0042] As used herein, "phytochemical" refers to a biologically active compound found in and produced by plants that generally plays a role in plant growth or defense against competitors, pathogens, or predators. Phytochemical biosynthetic pathways can be primary or secondary metabolic pathways. Although phytochemicals can be extracted and isolated from source plants, biosynthetic pathways that produce phytochemicals can also be genetically engineered into bacteria, fungi, or other eukaryotic cells, or phytochemicals can be produced synthetically.

[0043] "Phytonutrients" refers to plant chemicals that are essential nutrients in the diet of mammals or have specific biological activities that support mammalian health / wellness. Phytonutrients can include, but are not limited to, polyphenols, terpenes, resveratrol, flavonoids, isoflavonoids, carotenoids, limonoids, glucosinolates, phytoestrogens, plant sterols, anthocyanins, ω-3 fatty acids, and probiotics. Phytonutrients have specific pharmacological effects, such as antimicrobial, antioxidant, anti-inflammatory, non-tolerogenic, antispasmodic, anticancer, anti-aging, hepatoprotective, hypolipidemic, neuroprotective, hypotensive, CNS stimulating, analgesic, UVB-induced carcinogenesis protection, immunomodulatory, and carminative properties. Phytonutrients and their functions in mammalian and human health / wellness are described in the art. See, for example, Gupta et al. (“Phytonutrients as therapeutic agents,” J. Complement Integr. Med., 2014, 11(3): 151-169), which is incorporated herein by reference.

[0044] In general, one or more heterologous and / or exogenous polynucleotides encoding one or more biosynthetic pathway enzymes necessary to produce one or more metabolites of interest are introduced into mammalian cells to produce genetically engineered cells that endogenously produce one or more metabolites of interest. Cells can be engineered to transiently express the desired biosynthetic pathway enzymes of interest, or cells can be engineered to stably express the desired biosynthetic pathway enzymes of interest. Heterologous polynucleotides encoding biosynthetic pathway enzymes can be introduced into cells using any transfection or transduction method known in the art.

[0045] As used herein, "polypeptide," "protein," and "peptide" are used interchangeably and refer to the common primary, secondary, tertiary, and quaternary amino acid sequences and structures necessary to confer upon the described macromolecule its function and properties. As used herein, "enzyme" or "biosynthetic pathway enzyme" are used interchangeably and refer to a protein that catalyzes a chemical reaction. Reference to any particular enzyme, whether alone or as part of a biosynthetic pathway, is to be understood as including the enzyme's cofactors, coenzymes, and metals necessary for the proper functioning of the enzyme.

[0046] As used herein, the terms "polynucleotide," "polynucleotide sequence," "nucleic acid," and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide (the terms are used interchangeably), or any fragment thereof. These phrases also refer to DNA or RNA (which may be single-stranded or double-stranded and may represent the sense or antisense strand) of natural or synthetic origin. The polynucleotide may be cDNA or genomic DNA.

[0047] Also provided are polynucleotides homologous to the polynucleotides described herein. Those skilled in the art will appreciate that the degeneracy of the gene code and multiple polynucleotides can encode the same polypeptide. In some embodiments, polynucleotides (i.e., polynucleotides encoding biosynthetic pathway enzymes to synthesize the metabolites of interest) can be codon-optimized for expression in specific cells, including but not limited to mammalian cells, plant cells, bacterial cells, or fungal cells. In some embodiments, polynucleotides are codon-optimized for genus or species-specific expression (e.g., expressed in cattle cells). Although embodiments of specific polynucleotide sequences are disclosed herein, any polynucleotide sequence encoding the desired form of the polypeptides described herein can be used. Therefore, non-naturally occurring sequences can be used. These can be desirable, for example, to enhance expression in a heterologous expression system of a polypeptide or protein. Computer programs for generating degenerate coding sequences can be used and used for this purpose. Pen, paper, gene code, and artificial methods can also be used to generate degenerate coding sequences.

[0048] In another aspect of the present invention, a construct is provided. As used herein, the term "construct" refers to a recombinant polynucleotide, including but not limited to DNA and RNA, which may be single-stranded or double-stranded and may represent an antisense strand or antisense strand. A recombinant polynucleotide is a polynucleotide formed by a laboratory method, which includes a polynucleotide sequence derived from at least two different natural sources or which may be synthesized. Therefore, a construct may include new modifications to an endogenous gene introduced by, for example, genome editing technology. A construct may also include a recombinant polynucleotide produced using, for example, a recombinant DNA method.

[0049] The construct provided herein can be prepared by the available method of those skilled in the art.It should be noted that each in the construct described herein is a recombinant molecule, and therefore does not exist in nature.In general, nomenclature used herein and used laboratory procedures in the present invention comprise well-known and conventional molecular techniques, biochemical techniques and recombinant DNA techniques in this area.The standard techniques that can be used for those skilled in the art can be used for cloning, DNA and RNA separation, amplification and purification.These technologies are fully explained in the literature.

[0050] The constructs provided herein can comprise a promoter operably linked to any of the polynucleotides described herein. The promoter can be a heterologous promoter or an endogenous promoter associated with the biosynthetic pathway described herein.

[0051] As used herein, the terms "heterologous promoter," "promoter," "promoter region," or "promoter sequence" generally refer to the transcriptional regulatory region of a gene, which may be found on the 5' or 3' side of a polynucleotide as described herein, or within the coding region of a polynucleotide, or within an intron in a polynucleotide. Typically, a promoter is a DNA regulatory region that is capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. A typical 5' promoter sequence is bounded at its 3' end by a transcription start site and extends upstream (5' direction) to include the minimum number of bases or elements necessary for transcription initiation at a detectable level above background. Within the promoter sequence are the transcription start site (conveniently defined by localization with nuclease S1) and the protein binding domain (consensus sequence) responsible for RNA polymerase binding.

[0052] In some embodiments, a polynucleotide encoding a biosynthetic pathway enzyme described herein is operably linked to a promoter. As used herein, a polynucleotide is "operably connected" or "operably linked" when it is in a functional relationship with a second polynucleotide sequence. For example, a promoter is operably linked to a polynucleotide if it is linked to the polynucleotide such that it can affect the transcription of the polynucleotide. In various embodiments, the polynucleotide can be operably linked to at least 1, at least 2, at least 3, at least 4, at least 5, or at least 10 promoters.

[0053] Heterologous promoters that can be used for practice of the present invention include but are not limited to constitutive, inducible, temporally regulated, developmentally regulated, chemically regulated, tissue preference and tissue-specific promoters.Heterologous promoters can be plants, animals, bacteria, fungi or synthetic promoters.Promoters that are suitable for expressing in plants include but are not limited to 35S promoters, ubiquitin, tCUP concealed constitutive promoters, Rsyn7 promoters, pathogen-inducible promoters, corn In2-2 promoters, tobacco PR-1a promoters, glucocorticoid-inducible promoters, estrogen-inducible promoters and tetracycline-inducible and tetracycline-repressible promoters of cauliflower mosaic virus (cauliflower mosaic virus).Other promoters include T3, T7 and SP6 promoter sequences, which are generally used for the in vitro transcription of RNA. In mammalian cells, typical promoters include, but are not limited to, the following promoters: Rous sarcoma virus (RSV), human immunodeficiency virus (HIV-1), cytomegalovirus (CMV), Dox-inducible promoters (e.g., Tet response element (TRE)), ubiquitin C (Ubc), CMV early enhancer / chicken β-actin (CAG), human β-actin, phosphoglycerate kinase 1 (PGK1), SV40 virus, etc.; and translation elongation factor EF-1α promoter or ubiquitin promoter. In insect cells, typical promoters include, but are not limited to, upstream activating sequence (UAS), actin 5c (Ac5), and polyhedrin. In fish cells, typical promoters include, but are not limited to, the African clawed frog (Xenopus laevis) elongation factor 1α promoter (XlEef1a1) and the ocean cod (ocean pout) antifreeze protein promoter (OP5a). Those skilled in the art are familiar with a wide variety of other promoters for different cell types. In some embodiments, the heterologous promoter includes a plant promoter that is endogenous or heterologous to the plant host.

[0054] Provide a vector comprising any of the constructs or polynucleotides described herein. The term "vector" is intended to refer to a polynucleotide that is capable of transporting another polynucleotide to which it has been connected. In some embodiments, a vector can be a "plasmid," which refers to a circular double-stranded DNA loop to which additional DNA fragments can be connected. Some vectors can replicate autonomously in the host cell to which they are introduced (e.g., bacterial vectors and additional mammalian vectors with bacterial replication origins). Other vectors can be integrated into the genome of the host cell after being introduced into the host cell, and thus replicate together with the host genome, such as some viral vectors or transposons. For example, suitable vectors for the compositions and methods of the present invention include additional vectors, viral vectors (e.g., retroviruses, adenoviruses, baculoviruses), plasmids, RNA vectors, or linear or circular DNA or RNA molecules that may comprise or be composed of the following: chromosomes, non-chromosomes, semisynthetic or synthetic nucleic acids. Many suitable vectors are known to those skilled in the art and are commercially available. In some embodiments, a vector is an additional vector that is capable of autonomous replication owing to the presence of a replication origin. Plant minichromosomes are also included as vectors. In some embodiments, the vector is a polycistronic vector comprising one or more internal ribosome entry sites (IRES) and / or one or more 2A peptide sequences, thereby allowing co-expression of multiple polynucleotides from a single construct or vector. The vector may carry genetic elements, such as genetic elements that confer resistance to certain drugs or chemicals.

[0055] In some embodiments, construct as herein described or vector can comprise selectable marker.As used herein, " selectable marker " refers to a kind of gene element, and it allows to identify and select the cell containing the construct with described gene element or vector by expressing described gene element in cell.In some embodiments, selectable marker is the polynucleotide of encoding fluorescent protein, makes it possible to visually or by being applicable to cell sorting method (such as fluorescence activated cell sorting (FACS)) identification expression fluorescent protein cell.In some embodiments, selectable marker is the polynucleotide (such as puromycin, penicillin, streptomycin or hygromycin resistance gene) that makes the cell expressing selectable marker be with antibiotic resistance.Can be exposed to the cell that selectable marker is had specific selection chemical substance to select the cell containing described carrier with the vector transduction with selectable marker.Selectable marker gives the resistance for selecting chemical substance, makes the cell containing carrier and selectable marker survive, and the cell that does not contain carrier and selectable marker is killed.

[0056] As used herein, "introduction" describes the process of introducing an exogenous polynucleotide (e.g., DNA or RNA) into a recipient cell. Methods for introducing polynucleotides into cells are known in the art and may include, but are not limited to, microinjection, transformation, and transfection methods. Transformation or transfection can be performed under natural or artificial conditions according to various methods well known in the art and can rely on any known method for inserting foreign nucleic acid sequences into host cells. The method for transformation or transfection is selected based on the type of host cell being transformed and may include, but is not limited to

[0057] In some embodiments, the exogenous polynucleotides, constructs, or vectors described herein are transfected into cells using a suitable carrier. Suitable carriers are known and used in the art, including but not limited to lipid carriers (e.g., lipofetamine), polymeric nanocarriers,

[0058] If a cell comprises a modification to its genome compared to a cell without genome editing of the same type, the cell is "genome editing" or "genetically modified". In some cases, the cell without genome editing is a wild-type cell. As used herein, the terms "genetically modified" and "genetically engineered" are used interchangeably and refer to a prokaryotic or eukaryotic cell comprising an exogenous polynucleotide, regardless of the method used for insertion. In some cases, the cell has been modified to comprise a non-naturally occurring nucleic acid molecule produced or modified artificially (e.g., using recombinant DNA technology) or derived from the molecule (e.g., by transcription, translation, etc.). Cells containing exogenous, recombinant, synthetic and / or otherwise modified polynucleotides are considered to be engineered or "genome editing" cells. Gene editing or modified cells refer to cellular nucleic acids in modified cells, including endogenous and / or exogenous nucleic acids in genetically modified cells. Genetic modification can include deletion, insertion, integration of exogenous DNA, gene correction and / or gene mutation. For example, gene editing can be performed using nucleases (e.g., naturally occurring nucleases or artificially engineered nucleases) or transposases. Other methods for genetic modification suitable for use according to the methods provided herein include, but are not limited to, somatic cell nuclear transfer (SCNT) and transgene introduction. Procedures for obtaining recombinant or genetically modified cells are generally known in the art and are described in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989), which is incorporated herein by reference.

[0059] In some embodiments, CRISPR / Cas mediated gene editing (e.g., type II CRISPR / cas system) is used to integrate polynucleotides encoding the biosynthetic pathway enzymes required for producing the metabolite of interest into the genome of the cell. In some cases, the CRISPR / cas system is used to reduce protein expression of one or more endogenous genes. In some embodiments, the CRISPR / Cas system can be used to perform site-specific insertion. For example, the point cut on the insertion site in the genome can be performed by CRISPR / cas to promote the insertion of transgenes at the insertion site. The technology of CRISPR / Cas mediated gene editing suitable for host cells is known and as described in the art.

[0060] In some embodiments, a polynucleotide encoding a biosynthetic pathway enzyme required for producing a metabolite of interest is integrated into the genome of the cell using a transposon. Suitable transposons are known and as described in the art, including but not limited to SleepingBeauty, PiggyBac, Toll, Tol2, Minos, Frog Prince, Passport, Hsmar1, and Harbinger3-DR. See, for example, Ivics et al. ("The expanding universe of transposon technologies for gene and cell engineering," Mobile DNA, 1(25), 2010), which describe transposon systems and uses in this area.

[0061] In some embodiments, transgenes are used to integrate polynucleotides encoding biosynthetic pathway enzymes required for production of a metabolite of interest into the genome of a cell.As used herein, the term "transgene" refers to a gene or genetic material that can be transferred into an organism or a cell thereof.

[0062] In some embodiments, cells are engineered to endogenously produce the carotenoid phytoene. Phytoene is synthesized from two geranylgeranyl pyrophosphate molecules by the enzyme phytoene synthase. A polynucleotide encoding the phytoene synthase is introduced into cells that naturally produce geranylgeranyl pyrophosphate to produce cells that express the phytoene synthase and endogenously synthesize phytoene. In some embodiments, the phytoene synthase is from the bacterium Pantoea ananatis and has the polypeptide sequence of SEQ ID NO: 1 or SEQ ID NO: 10. In some embodiments, the phytoene synthase has a sequence that is at least 85%, 90%, 95%, 98%, 99%, or 99.9% identical to SEQ ID NO: 1 or SEQ ID NO: 10. In Pantoea ananatis, the phytoene synthase is encoded by the gene crtB having the sequence of SEQ ID NO: 2. In some embodiments, the crtB sequence can be codon-optimized for expression in a particular cell of interest. In some embodiments, the crtB sequence is codon-optimized for expression in bovine cells (eg, SEQ ID NO: 38).

[0063] SEQ ID NO: 1 Phytoene synthase (Uniprot P21683):

[0064] MNNPSLLNHAVETMAVGSKSFATASKLFDAKTRRSVLMLYAWCRHCDDVIDDQTLGFQARQPALQTPEQRLMQLEMKTRQAYAGSQMHEPAFAAFQEVAMAHDIAPAYAFDHLEGFAMDVREAQYSQLDDTLRYCYHVAGVVGLMMAQIMGVRD KATLDRACDLGLAFQLTNIARDIVDDAHAGRCYLPASWLEHEGLNKENYAAPENRQALSRIARRLVQEAEPYYLSATAGLAGLPLRSAWAIATAKQVYRKIGVKVEQAGQQAWDQRQSTTTPEKLTLLLAASGQALTSRMRAHPPRPAHLWQRPL

[0065] SEQ ID NO: 10 Phytoene synthase:

[0066] MVNNPSLLNHAVETMAVGSKSFATASKLFDAKTRRSVLMLYAWCRHCDDVIDDQTLGFQARQPALQTPEQRLMQLEMKTRQAYAGSQMHEPAFAAFQEVAMAHDIAPAYAFDHLEGFAMDVREAQYSQLDDTLRYCYHVAGVVGLMMAQIMGVRDNATLDRACDLGLAFQLTNIARDIVDDAHAGRCYLPASWLEHEGLNKENYAAPENRQALSRIARRLVQEAEPYYLSATAGLAGLPLRSAWAIATAKQVYRKIGVKVEQAGQQAWDQRQSTTTPEKLTLLLAASGQALTSRMRAHPPRPAHLWQRPL

[0067] SEQ ID NO:2crtB:

[0068] ATGAATAATCCGTCGTTACTCAATCATGCGGTCGAAACGATGGCAGTTGGCTCGAAAAGTTTTGCGACAGCCTCAAAGTTATTTGATGCAAAAACCCGGCGCAGCGTACTGATGCTCTACGCCTGGTGCCGCCATTGTGACGATGTTATTGACGATCAGACGCTGGGCTTTCAGGCCCGGCAGCCTGCCTTACAAACGCCCGAACAACGTCTGATGCAACTTGAGATGAAAACGCGCCAGGCCTATGCAGGATCGCAGATGCACGAACCGGCGTTTGCGGCTTTTCAGGAAGTGGCTATGGCTCATGATATCGCCCCGGCTTACGCGTTTGATCATCTGGAAGGCTTCGCCATGGATGTACGCGAAGCGCAATACAGCCAACTGGATGATACGCTGCGCTATTGCTATCACGTTGCAGGCGTTGTCGGCTTGATGATGGCGCAAATCATGGGCGTGCGGGATAACGCCACGCTGGACCGCGCCTGTGACCTTGGGCTGGCATTTCAGTTGACCAATATTGCTCGCGATATTGTGGACGATGCGCATGCGGGCCGCTGTTATCTGCCGGCAAGCTGGCTGGAGCATGAAGGTCTGAACAAAGAGAATTATGCGGCACCTGAAAACCGTCAGGCGCTGAGCCGTATCGCCCGTCGTTTGGTGCAGGAAGCAGAACCTTACTATTTGTCTGCCACAGCCGGCCTGGCAGGGTTGCCCCTGCGTTCCGCCTGGGCAATCGCTACGGCGAAGCAGGTTTACCGGAAAATAGGTGTCAAAGTTGAACAGGCCGGTCAGCAAGCCTGGGATCAGCGGCAGTCAACGACCACGCCCGAAAAATTAACGCTGCTGCTGGCCGCCTCTGGTCAGGCCCTTACTTCCCGGATGCGGGCTCATCCTCCCCGCCCTGCGCATCTCTGGCAGCGCCCGCTCTAG

[0069] In some embodiments, the cell endogenously produces phytoene in an amount of about 1 μg / g protein to about 800 μg / g protein, about 5 μg / g protein to about 600 μg / g protein, about 10 μg / g protein to about 500 μg / g protein, about 25 μg / g protein to about 300 μg / g protein, about 30 μg / g protein to about 250 μg / g protein, or about 30 μg / g protein to 100 μg / g protein. In some embodiments, the cell endogenously produces at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, or at least 14-fold more phytoene than a cell that does not contain a polynucleotide encoding a phytoene synthase.

[0070] In some embodiments, cells are engineered to endogenously produce the carotenoid lycopene. Lycopene is synthesized from phytoene by a phytoene desaturase. A polynucleotide encoding a phytoene desaturase is introduced into a phytoene-producing cell to generate a cell that expresses the phytoene desaturase and endogenously synthesizes lycopene. In some embodiments, the phytoene desaturase is from Pantoea ananas and has the polypeptide sequence of SEQ ID NO:3. In some embodiments, the phytoene desaturase has a sequence that is at least 85%, 90%, 95%, 98%, 99%, or 99.9% identical to SEQ ID NO:3. In Pantoea ananas, the phytoene desaturase is encoded by the gene crtI having the sequence of SEQ ID NO:4. In some embodiments, the crtI sequence can be codon-optimized for expression in a specific cell of interest. In some embodiments, the crtI sequence is codon-optimized for expression in bovine cells (e.g., SEQ ID NO:39).

[0071] SEQ ID NO: 3 Phytoene desaturase (Uniprot P21685):

[0072]

[0073] SEQ ID NO:4ctrI:

[0074]

[0075] In some embodiments, the cell endogenously produces lycopene in an amount of about 1 μg / g protein to about 800 μg / g protein, about 5 μg / g protein to about 600 μg / g protein, about 10 μg / g protein to about 500 μg / g protein, about 25 μg / g protein to about 300 μg / g protein, about 30 μg / g protein to about 250 μg / g protein, or about 30 μg / g protein to 100 μg / g protein. In some embodiments, the cell endogenously produces at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, or at least 14-fold more lycopene than a cell that does not contain the polynucleotides encoding the phytoene synthase and phytoene desaturase.

[0076] In some embodiments, the cells are engineered to endogenously produce the carotenoid β-carotene. β-carotene is synthesized from lycopene by the enzyme lycopene cyclase. A polynucleotide encoding lycopene cyclase is introduced into a lycopene-producing cell to produce a cell that expresses lycopene cyclase and endogenously synthesizes β-carotene. In some embodiments, the lycopene cyclase is from the bacterium Pantoea ananas and has a polypeptide sequence of SEQ ID NO:5 or SEQ ID NO:11. In some embodiments, the lycopene cyclase has a sequence that is at least 85%, 90%, 95%, 98%, 99%, or 99.9% identical to SEQ ID NO:5 or SEQ ID NO:11. In Pantoea ananas, the lycopene cyclase is encoded by the gene crtY having the sequence of SEQ ID NO:6. In some embodiments, the crtY sequence can be codon-optimized for expression in a specific cell of interest. In some embodiments, the crtY sequence is codon-optimized for expression in bovine cells (e.g., SEQ ID NO:40). Although the sequences listed below are from Pantoea ananas, one skilled in the art will recognize that homologous sequences can be identified from other species for use in the engineered cells and methods described herein.

[0077] SEQ ID NO: 5 Lycopene cyclase (Uniprot P21687):

[0078]

[0079] SEQ ID NO: 11 Lycopene cyclase:

[0080]

[0081] SEQ ID NO:6ctrY:

[0082]

[0083] In some embodiments, the cell endogenously produces beta-carotene in an amount of about 1 μg / g protein to about 800 μg / g protein, about 5 μg / g protein to about 600 μg / g protein, about 10 μg / g protein to about 500 μg / g protein, about 25 μg / g protein to about 300 μg / g protein, about 30 μg / g protein to about 250 μg / g protein, or about 30 μg / g protein to 100 μg / g protein. In some embodiments, the cell endogenously produces at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, or at least 14-fold more beta-carotene than a cell that does not contain the polynucleotides encoding the phytoene synthase, phytoene desaturase, and lycopene cyclase.

[0084] In some embodiments, the total carotenoid production in the engineered cells is from about 1 μg / g protein to about 800 μg / g protein, from about 5 μg / g protein to about 600 μg / g protein, from about 10 μg / g protein to about 500 μg / g protein, from about 25 μg / g protein to about 300 μg / g protein, from about 30 μg / g protein to about 250 μg / g protein, or from about 30 μg / g protein to 100 μg / g protein. In some embodiments, the total carotenoid production in the engineered cells is at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 11-fold, at least 12-fold, at least 13-fold, or at least 14-fold greater than the total carotenoid production in a cell that does not contain polynucleotides encoding phytoene synthase, phytoene desaturase, and lycopene cyclase.

[0085] In some embodiments, the cells are engineered to endogenously produce vitamin C. Although mammalian cells, for example, naturally produce the vitamin C precursor UDP-glucose and have genes encoding enzymes of the vitamin C biosynthetic pathway, the vitamin C biosynthetic pathway is typically silent in mammalian cells. A schematic diagram of vitamin C biosynthesis, including intermediates, is shown in Figure 10In some embodiments, a heterologous polynucleotide encoding UGT1A1 is introduced into the cell. In some embodiments, a heterologous polynucleotide encoding UGDH is introduced into the cell. In some embodiments, a heterologous polynucleotide encoding AKR1A1 is introduced into the cell. In some embodiments, a heterologous polynucleotide encoding RGN is introduced into the cell. In some embodiments, a heterologous polynucleotide encoding GULO is introduced into the cell. In some embodiments, one or more heterologous polynucleotides encoding one, two, three, four, or all five of UGT1A1, UGDH, AKR1A1, RGN, and GULO are introduced into the cell. In some embodiments, the amino acid sequences of UGT1A1, UGDH, AKR1A1, RGN, and GULO are endogenous to the cell into which the polynucleotide sequence is introduced. In some embodiments, the amino acid sequences of UGT1A1, UGDH, AKR1A1, RGN, and GULO are exogenous to the cell into which the polynucleotide sequence is introduced. In some embodiments, the UGDH, UGT1A1, AKR1A1, RGN, and GULO enzymes are from European cattle (Bos taurus) and have the polypeptide sequences of SEQ ID NOs: 12-16, respectively, and the cell into which the polynucleotide sequence is introduced is a bovine cell. In some embodiments, the UGDH, UGT1A1, AKR1A1, RGN, and GULO enzymes have sequences that are at least 85%, 90%, 95%, 98%, 99%, or 99.9% identical to SEQ ID NOs: 12-16, respectively. While the sequences listed below are from Bos bovis, one skilled in the art will recognize that homologous sequences can be identified from other species for use in the engineered cells and methods described herein.

[0086] SEQ ID NO:12 UGDH(UniProt:P12378):

[0087]

[0088] SEQ ID NO:13 UGT1A1(UniProt:E1BBB3):

[0089]

[0090] SEQ ID NO:14 AKR1A1(UniProt:Q3ZCJ2):

[0091]

[0092] SEQ ID NO:15 RGN(UniProt:Q9TTJ5):

[0093]

[0094] SEQ ID NO:16 GULO(UniProt:Q3ZC33):

[0095]

[0096] In some embodiments, cells are engineered to endogenously produce curcumin. Tyrosine, which is naturally produced in mammalian cells, is a precursor for curcumin biosynthesis using the biosynthetic pathway enzymes tyrosine ammonia lyase (PTAL), 4-coumarate-CoA ligase (4CL), phenylpropionyl-diketo-CoA synthetase (DCS), and curcumin synthase (CURS3). A schematic diagram of the biosynthetic pathway, including intermediates, is shown in Figure 10 In some embodiments, one or more polynucleotides encoding PTAL, 4CL, DCS and CURS3 are introduced into cells that naturally produce tyrosine to produce cells that express PTAL, 4CL, DCS and CURS3 and endogenously synthesize curcumin. In some embodiments, the PTAL, 4CL, DCS and CURS3 biosynthetic enzymes are from rice (Oryza sativa) and turmeric (Curcuma longa) and have the polypeptide sequences of SEQ ID NOs: 17-20, respectively. In some embodiments, PTAL, 4CL, DCS and CURS3 have sequences that are at least 85%, 90%, 95%, 98%, 99% or 99.9% identical to SEQ ID NOs: 17-20, respectively. In some embodiments, only one, two or three of the biosynthetic pathway enzymes are engineered into the cell to produce pathway intermediates. Although the sequences listed below are from rice and turmeric, those skilled in the art will recognize that homologous sequences can be identified from other species for the engineered cells and methods described herein.

[0097] SEQ ID NO: 17 PTAL japonica rice (Oryza sativa japonica) (Uniprot: P14717):

[0098]

[0099] SEQ ID NO: 18 4CL japonica rice (UniProt: Q6ETN3):

[0100]

[0101] SEQ ID NO: 19 DCS Curcuma longa (UniProt: COSVZ5):

[0102]

[0103] SEQ ID NO: 20 CURS3 Curcuma longa (UniProt: C6L7V9):

[0104]

[0105] In some embodiments, cells are engineered to endogenously produce curcumin using the biosynthetic pathway enzymes PTAL, 4CL, and bisdemethoxycurcumin synthase. One or more polynucleotides encoding PTAL, 4CL, and bisdemethoxycurcumin synthase are introduced into cells that naturally produce tyrosine to generate cells that express PTAL, 4CL, and bisdemethoxycurcumin synthase and endogenously synthesize curcumin. In some embodiments, PTAL, 4CL, and bisdemethoxycurcumin synthase have the amino acid sequences of SEQ ID NOs: 17, 18, and 21, respectively. In some embodiments, PTAL, 4CL, and bisdemethoxycurcumin synthase have amino acid sequences that are at least 85%, 90%, 95%, 98%, 99%, or 99.9% identical to SEQ ID NOs: 17, 18, and 21, respectively. While the sequences listed below are from rice, those skilled in the art will recognize that homologous sequences can be identified from other species for use in the engineered cells and methods described herein.

[0106] SEQ ID NO: 21 Bisdemethoxycurcumin synthase Japonica rice (UniProt: Q8LIL0):

[0107]

[0108] In some embodiments, cells are engineered to endogenously produce cannabidiol. Malonyl-CoA, which is naturally produced in mammalian cells, is a precursor for the biosynthesis of cannabidiol (CBD) using the biosynthetic pathway enzymes 3,5,7-trioxodecanoyl-CoA synthase (OLS), oleuronate cyclase (OAC), cannabigerolic acid synthase (CBGAS, also known as prenyltransferase 1 or PT1), and cannabidiolic acid synthase (CBDAS). A schematic diagram of the biosynthetic pathway, including intermediates, is shown in Figure 10In some embodiments, one or more polynucleotides encoding OLS, OAC, CPGAS, and CBDAS are introduced into cells that naturally produce malonyl-CoA to produce cells that express OLS, OAC, CPGAS, and CBDAS and endogenously synthesize CBD. In some embodiments, the prenyltransferase NphB can be used instead of CPGAS in the CBD biosynthetic pathway. In some embodiments, the OLS, OAC, CPGAS, CBDAS, and NphB biosynthetic enzymes are from Cannabis sativa and have the polypeptide sequences of SEQ ID NOs: 22-26, respectively. In some embodiments, OLS, OAC, CPGAS, CBDAS, and NphB have sequences that are at least 85%, 90%, 95%, 98%, 99%, or 99.9% identical to SEQ ID NOs: 22-26, respectively. In some embodiments, only one, two, or three of the biosynthetic pathway enzymes are engineered into the cell to produce pathway intermediates. While the sequences listed below are from Cannabis sativa, one skilled in the art will recognize that homologous sequences can be identified from other species for use in the engineered cells and methods described herein.

[0109] SEQ ID NO:22 OLS(UniProt:B1Q2B6):

[0110]

[0111] SEQ ID NO:23 OAC(UniProt:I6WU39):

[0112]

[0113] SEQ ID NO:24 CBGAS or PT1(UniProt:A0A455ZIK6):

[0114]

[0115] SEQ ID NO:25 CBDAS(UniProt:A6P6V9):

[0116]

[0117] SEQ ID NO:26 NphB(UniProt:A0A2Z4JFA9):

[0118]

[0119] The following gene sequences are codon optimized for expression in bovine cells. One skilled in the art will recognize that the gene sequences may be optimized for expression in cells from anther species, or that wild-type sequences from cannabis may be used.

[0120] SEQ ID NO: 27 OLS:

[0121]

[0122] SEQ ID NO:28 OAC

[0123]

[0124] SEQ ID NO:29 CBGAS or PT1

[0125]

[0126] SEQ ID NO:30 CBDAS

[0127]

[0128] In some embodiments, cells are engineered to express anti-TNFα nanobody V565 (SEQ ID NO: 7). Cells are transfected with heterologous polynucleotides encoding nanobody V565 to produce cells expressing nanobody V565. In some embodiments, the polynucleotide encodes a polypeptide that is at least 85%, 90%, 95%, 98%, 99% or 99.9% identical to SEQ ID NO: 7. In some embodiments, the polynucleotide encoding V565 is codon-optimized for expression in a specific cell of interest. In some embodiments, the polynucleotide encoding V565 is codon-optimized for expression in bovine cells.

[0129] SEQ ID NO: 7 Nanobody V565:

[0130]

[0131] In some embodiments, V565 is connected to human TNF α by a flexible cleavable linker, and the polynucleotide expressing V565 connected to human TNF α by a flexible cleavable linker is introduced into the cell. Without wishing to be bound by any particular theory or mechanism, the V565 nanobody is connected to TNF α to inhibit the binding of V565 to the target TNF α in the subject, and the cracking of the flexible cleavable linker under specific conditions will release V565 to bind to the target TNF α in the subject. In some embodiments, the flexible cleavage linker is a trypsin cleavable linker with at least one, two, three, four or five lysine residues. In some embodiments, the length of the linker is between about 10 and about 50 amino acids. In some embodiments, the length of the linker is between about 15 and about 40 amino acids. In some embodiments, the linker has the sequence of SEQ ID NO: 9 (GGG SGG GSG GGS GGK GGK GGK GGK GGG SGG GSGAQG).

[0132] In some embodiments, cells are engineered to express antimicrobial peptide 16 (AMP16; SEQ ID NO:8). Cells are transfected with a heterologous polynucleotide encoding AMP16 to produce cells expressing AMP16. In some embodiments, the polynucleotide encodes a polypeptide that is at least 85%, 90%, 95%, 98%, 99%, or 99.9% identical to SEQ ID NO:8. In some embodiments, the polynucleotide encoding AMP16 is codon-optimized for expression in a specific cell of interest. In some embodiments, the polynucleotide encoding AMP16 is codon-optimized for expression in bovine cells.

[0133] SEQ ID NO:8 AMP16:

[0134] IRPI IRPI IRPI IRPI IRPI IRPI IRPI

[0135] In some embodiments, AMP16 is linked to an elastase-cleavable linker comprising Asn-Pro-Val (NPV) repeats. In some embodiments, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 repeats of AMP16 are assembled in the construct, each repeat separated by an NPV linker.

[0136] In some embodiments, the cells are engineered to express a serine protease inhibitor (SPI) to inhibit pepsin digestion of V565 or AMP 16. In some embodiments, the SPI is TspO3044, which has the amino acid sequence of SEQ ID NO: 31, or a sequence at least 85%, 90%, 95%, 98%, 99%, or 99.9% identical thereto. In some embodiments, the SPI is TspAd5, which has the amino acid sequence of SEQ ID NO: 33, or a sequence at least 85%, 90%, 95%, 98%, 99%, or 99.9% identical thereto.

[0137] SEQ ID NO:31 Tsp03044 (NCBI Reference Sequence XM_003379333)

[0138]

[0139] SEQ ID NO:32 Tsp03044

[0140]

[0141] SEQ ID NO:33 TspAd5(GenBank:EU263307.1)

[0142]

[0143] SEQ ID NO:34

[0144]

[0145] In some embodiments, the cells are engineered to increase expression of one or more growth factors selected from the group consisting of FGF-2, TGFβ-3, NRG-1, and IGF-1. In some embodiments, the cells are engineered to increase expression of insulin and transferrin.

[0146] In some embodiments, the cells are engineered to endogenously produce cinnamaldehyde from the precursor phenylalanine by introducing one or more polynucleotides encoding phenylalanine ammonia lyase, 4-coumarate-CoA ligase, and cinnamoyl-CoA reductase into the cells.

[0147] In some embodiments, the cell is engineered to endogenously produce (R)-limonene from the precursor geranyl pyrophosphate by introducing a polynucleotide encoding an (R)-limonene synthase into the cell. In some embodiments, the (R)-limonene synthase has the amino acid sequence of SEQ ID NO: 35, or a sequence at least 85%, 90%, 95%, 98%, 99%, or 99.9% identical thereto. In some embodiments, the cell is engineered to endogenously produce (S)-limonene from the precursor geranyl pyrophosphate by introducing a polynucleotide encoding an (S)-limonene synthase. In some embodiments, the (S)-limonene synthase has the amino acid sequence of SEQ ID NO: 36, or a sequence at least 85%, 90%, 95%, 98%, 99%, or 99.9% identical thereto.

[0148] SEQ ID NO: 35 Citrus limon (UniProt: Q8L5K3):

[0149]

[0150] SEQ ID NO:36 Abies grandis (UniProt:022340)

[0151]

[0152] With respect to enzymes and polypeptides described herein, the phrases "% sequence identity," "percentage identity," or "% identity" are used interchangeably and refer to the percentage of residue matches between at least two amino acid sequences aligned using a standardized algorithm. Methods for amino acid sequence alignment are well known. Some alignment methods take into account conservative amino acid substitutions. The conservative substitutions generally maintain the charge and hydrophobicity at the substitution site, thereby maintaining the structure (and therefore function) of the polypeptide, as explained in more detail below. The percent identity of an amino acid sequence can be determined as understood in the art. (See, for example, U.S. Patent No. 7,396,664, which is incorporated herein by reference in its entirety). A set of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST), which is available from several sources, including the website of the NCBI in Bethesda, Maryland. The BLAST software suite contains various sequence analysis programs, including "blastp" for aligning a known amino acid sequence with other amino acid sequences from multiple databases.

[0153] Polypeptide sequence identity can be measured over the full length of a specific polypeptide sequence, for example, as defined by a particular SEQ ID number, or can be measured over a shorter length, for example, a fragment taken from a larger specific polypeptide sequence, for example, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70, or at least 150 consecutive residues. The lengths described are exemplary only, and it will be understood that any fragment length supported by the sequences shown herein in the tables, figures, or sequence listing can be used to describe the length over which a percentage identity can be measured.

[0154] Cells suitable for the methods described herein may include, but are not limited to, primary cells, immortalized cells, pluripotent cells, or embryonic cells. Genetically modified or engineered cells may be plant cells or animal cells suitable for stable maintenance, growth, and expansion in in vitro culture. Animal cells suitable for the compositions and methods described herein may be mammalian cells, insect cells, fish cells, or avian cells. The use of insect cells in cultured meat products is described, for example, in Publication No. ____ of International Application No. PCT / US2019 / 066452, which is incorporated herein by reference in its entirety.

[0155] Mammalian cells can be any mammalian cell that can be stably maintained, grown, and expanded in vitro culture. Mammalian cells can be porcine, bovine, deer, goat, rabbit, or murine cells. Mammalian cells can be from ruminant mammals (e.g., cattle, sheep, goat, buffalo, deer, elk, etc.). For use in cultured meat products as outlined below, mammalian cells are non-human mammalian cells.

[0156] The mammalian cells can be primary mammalian cells, immortalized mammalian cells, or mammalian cells differentiated from pluripotent cells (e.g., embryonic stem cells, induced pluripotent cells, etc.). Prior to transduction, the primary mammalian cells can be grown and proliferated in culture for 1, 2, 3, 4, 5, 6, or more generations. In some embodiments, the mammalian cells are immortalized cells that express TERT and CDK4.

[0157] In some embodiments, the animal cell is a muscle cell.Muscle cells are characterized by the production of actin, myosin, and myosin heavy chain (MHC) and the formation of multinucleated myotubes.

[0158] In some embodiments, the mammalian cell is a muscle cell. The mammalian muscle cell is characterized by the expression of actin, myosin, and myosin heavy chain (MHC) and the formation of multinucleated myotubes. In some embodiments, the mammalian cell is an MHC + Actin + Bovine muscle cells.

[0159] In some embodiments, the animal cell is a muscle precursor cell expressing paired box protein 7 (Pax7). In some embodiments, the mammalian cell is a muscle precursor satellite cell expressing paired box protein 7 (Pax7). In some embodiments, the mammalian cell is a Pax7+ bovine satellite cell. In some embodiments, the mammalian cell is a Pax7+ primary bovine satellite cell (BSC). In some embodiments, the mammalian cell is from a cow of the European bovine species.

[0160] In some embodiments, mammalian myotube cells are produced by myogenic differentiation of mammalian satellite cells. Mammalian satellite cells can be cultured to confluence in any culture medium that supports the growth and expansion of mammalian satellite cells. In some embodiments, mammalian satellite cells are cultured to confluence in B8 medium, growth medium containing serum (e.g., DMEM + 20% fetal bovine serum) or other serum-free culture medium. Confluent mammalian satellite cells are then cultured in a culture medium comprising Neurobasal / L15 (1:1) basal medium supplemented with epidermal growth factor (EGF; 0.01-5ng / ml; preferably 0.5ng / mL), insulin-like growth factor 1 (IGF-1; 0.01-5ng / ml; preferably 0.05ng / mL) and 1% antibiotic-antimycotic. 61 In some embodiments, confluent mammalian satellite cells are cultured in DMEM supplemented with about 2% fetal bovine serum. The cells are allowed to differentiate for about 1 to 2 weeks.

[0161] B8 medium includes DMEM:F12 (1:1) basal medium supplemented with: L-ascorbic acid 2-phosphate (0.1 μg / ml to 500 μg / ml; preferably about 200 μg / mL), insulin (0.1 μg / ml to 100 μg / ml; preferably about 20 μg / mL), transferrin (0.1 μg / ml to 100 μg / ml; preferably about 20 μg / mL), sodium selenite (0.1 μg / ml to 100 μg / ml; preferably 20 ng / mL), FGF-2 (0.01 μg / ml to 100 μg / ml; preferably 10 ng / mL), neuregulin 1 (NRG-1; 0.001 ng / ml to 50 ng / ml; preferably 0.1 ng / mL), and TGFβ-3 (0.001 ng / ml to 50 ng / ml; preferably 0.1 ng / μL). In some embodiments, the B8 medium further comprises insulin-like growth factor 1 (IGF-1; about 10 ng / mL).

[0162] In some embodiments, the culture medium further comprises cinnamon, monolaurin (a derivative of coconut lauric acid), honey, or a combination thereof in addition to or in place of the antibiotic component.

[0163] In some embodiments, instead of serum, the culture medium may contain plant-based or yeast-based extracts. For example, yeast- and plant-based serum replacements include hydrolyzed proteins from soy, yeast, wheat gluten, cottonseed, or corn, as well as rapeseed peptide fractions, maitake mushroom extract, and sericin derived from silk.

[0164] In some embodiments, the mammalian cell is an adipocyte. Mammalian adipocytes are characterized by increased expression of peroxisome proliferator-activated receptor gamma (PPARγ) and lipid production.

[0165] In some embodiments, mammalian cells are produced by adipogenic differentiation from mammalian satellite cells. Lipid accumulation in mammalian satellite cells can be triggered using a differentiation medium containing a combination of free fatty acids (FFA). Specifically, a 3-FFA mixture of linoleic acid, erucic acid, and elaidic acid at equal concentrations of 125 μM is used in culture for about six days to induce the accumulation of intracellular lipids. Fish et al. describe additional details of adipogenic differentiation by mammalian satellite cells (“Prospects and challenges for cell-cultured fat as a novel foodingredient,” Trends Food Sci Technol., 2020, 98: 53-67), which is incorporated herein by reference.

[0166] In some embodiments, the production of a metabolite of interest can be increased or decreased by altering enzyme expression levels or by altering the availability of intermediate or precursor metabolites in the cell.

[0167] In some embodiments, the metabolite of interest is phytoene, lycopene or beta-carotene, and the output of these metabolites is increased by treating cells with ketoconazole. Ketoconazole inhibits the synthesis of cellular cholesterol (cellular cholesterol competes for carotenoid precursor compounds). In order to increase carotenoid output, cells can be cultivated with ketoconazole between about 0.5 μg / ml and about 50 μg / ml. In some embodiments, cells are cultivated with ketoconazole between about 1 μg / ml and about 20 μg / ml. In some embodiments, cells are cultivated with ketoconazole of about 5 μg / ml.

[0168] In some embodiments, cells are transduced with a vector comprising a polynucleotide encoding a biosynthetic pathway enzyme and a selectable marker to increase expression of the biosynthetic pathway enzyme by increasing the selective pressure on the cells. For example, when the selectable marker is an antibiotic resistance gene, increasing the concentration of the antibiotic in the selective culture medium can exert selective pressure on the cells to increase expression of the introduced vector, thereby also increasing expression of the biosynthetic pathway enzyme. Similarly, expression of the biosynthetic pathway enzyme can be reduced by reducing the selective pressure on the cells, for example, by reducing the concentration of the selection chemical in the culture.

[0169] As used herein, "cultured meat product" refers to an edible meat product produced from a cell culture, rather than a whole organism. Generally, cultured meat products are visually identical to farmed meat, are acceptable to consumers, and provide nutritional benefits. The cultured meat products described herein comprise a culture of mammalian satellite, muscle, and / or adipocytes seeded on an edible, food-safe substrate and cultured to confluence. The culture of mammalian satellite, muscle, and / or adipocytes is grown at a density of approximately 20,000 cells / cm 2 to approximately 400,000 cells / cm 2 , about 30,000 cells / cm 2 to approximately 350,000 cells / cm 2 or approximately 35,000 cells / cm 2 to approximately 300,000 cells / cm 2 In some embodiments, cells are seeded at a density of about 50,000 cells / cm 2 In some embodiments, cells are seeded at a density of about 40,000 cells / cm 2 , about 50,000 cells / cm 2 , about 60,000 cells / cm 2 , about 70,000 cells / cm 2 , about 80,000 cells / cm 2 , about 100,000 cells / cm 2 , about 150,000 cells / cm 2 , about 200,000 cells / cm 2 , approximately 250,000 cells / cm 2 , about 300,000 cells / cm 2 or approximately 350,000 cells / cm 2In some embodiments, the cells are inoculated at a density of 100 μm. In some embodiments, the cells are not attached to the food safety matrix once they reach confluence, and are peeled off from the food safety matrix in the absence of enzyme dissociation. In some embodiments, the edible food safety matrix is ​​in the form of a two-dimensional film. In some embodiments, the edible food safety matrix is ​​in the form of a three-dimensional matrix or a sponge, and the mammalian muscle cells form continuous muscle fibers when cultivated in a matrix or a sponge matrix. Suitable edible food safety matrices are known in the art, and include but are not limited to chitosan matrices, cellulose matrices, silk matrices, alginate matrices, starch matrices, textured plant protein matrices, mycelium matrices, and whey matrices.

[0170] Additional methods for cultured meat production are known and described in the art. See, for example, Post (“Cultured meat from stem cells: Challenges and prospects,” Meat Science, 2012, 92, 297-301), Warner (“Review: analysis of the process and drivers for cellular meat production,” Animal, 2019, 13(12): 3041-3058), U.S. Pat. No. 6,835,390, and U.S. Pat. No. 7,270,829.

[0171] In some embodiments, cultured meat products are produced using a chitosan matrix. The chitosan matrix can be adjusted to alter the adhesion and growth of mammalian muscle cell cultures. Generally, increasing the chitosan concentration in the matrix reduces the adhesion of mammalian muscle cells. The chitosan concentration in the food-safe matrix for cultured meat products can be 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, or 14%. In some embodiments, the chitosan concentration is between about 1% and about 8%. In some embodiments, the chitosan concentration is between about 2% and about 6%. In some embodiments, the chitosan concentration is at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, or at least about 8%. Chitosan can be derived from any suitable source. Chitosan sources include, but are not limited to, mushrooms, crustaceans, insects, green algae, and yeast. In some embodiments, the chitosan is chitosan derived from mushrooms.

[0172] Three-dimensional chitosan matrices or sponges suitable for forming the muscle fibers and cultured meat products described herein can be formed using methods known in the art. In some embodiments, chitosan sponges are formed using directional freezing of chitosan. To form a chitosan sponge by directional freezing, chitosan is dissolved in a solvent, such as, but not limited to, acetic acid, and the chitosan solution is poured into a tube. One end of the tube is exposed to liquid nitrogen or another suitable cryogen, such as a slurry of dry ice and ethanol, until the entire solution is frozen. The frozen chitosan is then freeze-dried to form a chitosan sponge. The mechanical properties of the chitosan sponge can be adjusted by varying the chitosan concentration. Sponges formed using low-concentration chitosan (e.g., 1%, 2%, 3% chitosan solutions) have a lower elastic modulus, while sponges formed using high-concentration chitosan (e.g., 6%, 7%, 8% chitosan solutions) have a higher elastic modulus. Chitosan can be derived from any suitable source. Chitosan sources include, but are not limited to, mushrooms, crustaceans, insects, green algae, and yeast. In some embodiments, the chitosan is chitosan derived from mushrooms.

[0173] As used herein, "food-safe matrix" refers to a matrix that is edible or safe for human consumption if at least a portion of the matrix remains attached to or associated with the cultured meat product. In some embodiments, the food-safe matrix is ​​a chitosan matrix. The chitosan used as the food-safe matrix can be derived from organisms including, but not limited to, chitin from mushrooms, crustaceans, insects, green algae, and yeast. In some embodiments, the food-safe matrix is ​​a mushroom chitosan matrix. In some embodiments, the food-safe matrix is ​​a cellulose-based matrix, such as a matrix formed from decellularized plants (e.g., decellularized spinach or apple).

[0174] In some embodiments, the cultured meat product comprises an engineered cell, a plant-based protein, an unmodified (i.e., wild-type) plant or animal cell, or a combination thereof, as described herein. In some embodiments, the cultured meat product comprises between about 1% and about 100% by weight or by cell count of an engineered cell as described herein.

[0175] As used herein, "high density" refers to a density of over 160,000 cells / mL to about 480,000 cells / ml for suspension culture or over 100,000 cells / cm for adherent culture. 2 to approximately 300,000 cells / cm 2 The cells were seeded at a density of 1:1.

[0176] As used herein, "medium density" refers to a density of more than 64,000 cells / ml to about 160,000 cells / ml for suspension cultures or more than 40,000 cells / cm for adherent cultures. 2 to approximately 100,000 cells / cm2 The cells were seeded at a density of 1:1.

[0177] As used herein, "low density" refers to a density of about 16,000 cells / ml to about 64,000 cells / ml for suspension culture or about 10,000 cells / cm for adherent culture. 2 to approximately 40,000 cells / cm 2 The cells were seeded at a density of 1:1.

[0178] As used herein, "serum-free" refers to culture conditions and culture medium that do not contain serum or serum substitutes or are substantially free of serum or serum substitutes. For example, a substantially serum-free culture medium may contain less than about 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2% or 0.1% serum. As used herein, "serum substitute" refers to an animal serum and animal cell product-based substitute for serum traditionally used in culture medium. Any plant-based or yeast-based serum substitute described herein does not fall within the definition of "serum substitute" when determining that the culture medium is serum-free. In other words, a culture medium can be serum-free and contain a plant-based or yeast-based serum substitute described herein.

[0179] As used herein, the terms "defined culture medium" or "defined medium" and the like indicate that the nature and quantity of each medium component are known. When used with respect to a culture medium or culture conditions, the term "defined" refers to a culture medium or culture conditions in which the nature and quantities of substantially all components are known. A culture, composition, or medium is "substantially free" of certain agents, such as signal transduction inhibitors, animal components, or feeder cells, when the levels of such agents, respectively, are below detectable levels using conventional detection methods known to those of ordinary skill in the art, or when such agents have not been added to the culture, composition, or medium.

[0180] As used herein, "effective amount" means an amount of an agent sufficient to elicit a specified cellular effect according to the present invention.

[0181] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It should be understood that all definitions, as defined and used herein, take precedence over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.

[0182] All references, patents, and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which they are respectively cited, in some cases in their entireties.

[0183] As used herein in the specification and claims, the indefinite articles "a" and "an" should be understood to mean "at least one" unless explicitly indicated to the contrary.

[0184] As used herein in the specification and claims, the phrase "and / or" should be understood to mean "either or both" of the elements so combined, i.e., the elements are present in combination in some cases and separately in other cases. Multiple elements listed by "and / or" should be interpreted in the same manner, i.e., "one or more" of the elements so combined. In addition to the elements specifically identified by the "and / or" clause, other elements may optionally be present, whether related or unrelated to those specifically identified. Thus, as a non-limiting example, when used in conjunction with open language such as "comprising," a reference to "A and / or B" may refer to only A (optionally including elements other than B) in one embodiment; to only B (optionally including elements other than A) in another embodiment; to both A and B (optionally including other elements) in yet another embodiment; etc.

[0185] As used herein in the specification and claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when several items are separated in a list, "or" or "and / or" should be interpreted as inclusive, that is, including at least one element in a plurality of elements or a list of elements, but also including more than one element, and optionally additional unlisted items. Only terms with clear opposite indications, such as "only one of..." or "exactly one of..." or "consisting of..." when used in the claims will refer to including exactly one element in a plurality of elements or a list of elements. In general, when with exclusive terms, such as "any one," "one of...", "only one of..." or "exactly one of...", the term "or" as used herein should only be interpreted to indicate exclusive alternative forms (that is, "one or the other, but not both"). "Substantially consisting of..." when used in the claims, should have the general meaning as used in the field of patent law.

[0186] As used herein, unless otherwise stated or otherwise obvious from the context, the term "about" or "approximately" with respect to a numerical value is generally considered to include values ​​within a range of 5% (greater or less than) in either direction of the numerical value (unless the numerical value would exceed 100% of the possible values). Where a range is stated, unless otherwise stated or otherwise obvious from the context, the endpoints are included in the stated range.

[0187] Example

[0188] Example 1

[0189] Metabolic engineering efforts in plants, yeast, and bacteria have exploited numerous pathways across taxa for diverse applications (Heider and Wendisch, 2015; Nielsen, 2015; Sack et al., 2015). The same breadth of work has not yet been achieved in mammalian systems, with most efforts focused on biopharmaceuticals (Ceroni and Ellis, 2018; Davy et al., 2017). While this work is comparable to that in other systems, the difference in scope is significant. This disparity may be at least partially due to the lack of urgency to engineer animal cells with metabolic pathways from other taxa to date; from a bioprocessing perspective, the production of recombinant proteins, small molecules, and biofuels is cheaper in bacteria, yeast, or plant systems, and mammalian bioprocessing is preferred only when species-specific post-translational modifications are required (Davy et al., 2017; Giddings, 2001). The potential for cultured meat offers a new framework for mammalian metabolic engineering. In cultured meat production, the product is the cell itself, and therefore endogenous synthesis of additional compounds becomes purely additive, at least for those cases where it is biologically possible and does not interfere with bioprocess parameters or product value. Here, the fact that cultured meat relies solely on cell growth for survival, rather than on whole animals (an inherent limitation of animal transgenics), enables the consideration of a wider range of metabolites that may be difficult to achieve in animals but are harmless or even beneficial in cell culture.

[0190] In this example, we demonstrate the potential for producing nutritionally enhanced meat products through cell culture by engineering endogenous production of non-natural dietary carotenoids into primary bovine and immortalized murine skeletal muscle cells. While past speculation has suggested that the nutritional enhancement of cultured meat could be achieved through the addition of exogenous nutrients, endogenous production of nutrients is advantageous from a bioprocessing cost-scaling perspective and from the positive impact that endogenous nutrients can have on nutrient bioavailability or growth kinetics (Desmarchelier and Borel, 2017; Le Moal et al., 2017). We demonstrate that carotenoids are produced at levels that significantly reduce lipid oxidation, can be optimized through a range of strategies, and are substantially higher than the levels found to accumulate in beef. These compounds, with their general nutritional value and specific relevance to meat-related diseases, have the potential to counteract the effects of lipid oxidation on shelf life, color stability, and flavor. Therefore, they are compelling candidates for demonstrating how metabolic engineering can impact various meat quality metrics.

[0191] In addition, the positive effect of carotenoid synthesis on C2C12 growth shows an exciting and commensurate benefit for this approach. That is, improving cell growth can help to substantially reduce the production cost of cultured meat while producing a more nutritious product. A limitation of this study is the reliance on primary bovine satellite cells, as immortalized bovine cells will enable this possibility to be explored in cell lines more relevant to meat without the confounding effects of primary cell aging and antibiotic selection pressure. In addition, immortalized cell lines will allow the use of less efficient targeted gene insertion technologies (such as CRISPR / Cas9), which will enable the generation of homogenous cell populations that can more clearly elucidate the achievable carotenoid yields before and after optimization. Industrial cultured meat production processes will likely use targeted engineering of immortalized cells and avoid antibiotic selection, so subsequent exploration of carotenoid synthesis in one of these cell populations will be valuable future work.

[0192] The embodiments described herein demonstrate the incorporation of biosynthetic pathways for antioxidant phytonutrients (carotenoids), which are native to plants and some prokaryotes, but not animals, into mammalian cells and the production of cultured meat therefrom. These nutrients confer multiple benefits through their actions as antioxidants, provitamins, and free radical scavengers (Botella-Pavia and Rodriguez-Concepcion, 2006). Using non-viral SleepingBeauty transposon-mediated transgenesis of phytoene synthase (CrtB), phytoene desaturase (CrtI), and lycopene cyclase (CrtY) from the bacterium Pantoea ananas, we converted native geranylgeranyl pyrophosphate (GGPP) into phytoene, lycopene, and β-carotene in immortalized mouse myoblasts and primary bovine muscle stem cells (Botella-Pavia and Rodriguez-Concepcion, 2006; Izsvák et al., 2000). This work builds on previous crop engineering work and evidence of CrtB efficacy in mammalian cells (Satomi et al., 1995; Ye et al., 2000). We confirmed endogenous production of all three carotenoids and showed that cell myogenicity was maintained after modification. We then quantitatively optimized carotenoid production by increasing enzyme expression and inducing precursor accumulation, achieving yields substantially higher than those reported for beef (Simonne et al., 1996). Finally, we validated the in vitro antioxidant capacity of endogenous carotenoids, which indicates nutritional and food quality functionality. This work represents the first case of cultured meat nutritional engineering and demonstrates how cross-class transgenics can broaden the scope of metabolic engineering in mammalian cells to applications beyond the clinic.

[0193] Materials and methods

[0194] C2C12 cell culture - C2C12 mouse skeletal myoblasts (ATCC #CRL-1772, Manassas, VA, USA) were grown on tissue culture plastic in DMEM Glutamax (ThermoFisher #10566024, Waltham, MA, USA) supplemented with 10% FBS (ThermoFisher #26140079) and 1% antibiotic-antimycotic (ThermoFisher #15240062) (Yaffe and Saxel, 1977). For routine cell maintenance, cells were cultured to a maximum of 70% confluence and then passaged using 0.25% trypsin-EDTA (ThermoFisher #25200056) or frozen in FBS with 10% dimethyl sulfoxide (DMSO, Sigma #D2650, St. Louis, MO, USA). Cells were incubated at 37°C in 5% CO2.

[0195] Primary bovine satellite cell isolation and culture - Primary bovine satellite cells (BSCs) were isolated using previously described methods (Simsa et al., 2019). Briefly, a small piece of muscle (approximately 0.5 cm) was removed from the semitendinosus muscle of Simmental bulls <60 days old raised at the Tufts Cummings School of Veterinary Medicine according to methods approved by the Tufts University IACUC (protocol # G2018-36). 3 Muscle tissue was dissected from fat and connective tissue, minced into a paste, and digested in 0.2% collagenase II (Worthington Biochemical #LS004176; 275 U / mg) with regular grinding for one hour. Digestion was suspended with growth medium containing DMEM Grotama supplemented with 20% FBS, 1 ng / mL human FGF-basic (ThermoFisher #68-8785-63) and 1% Primocin (Invivogen #ant-pm-1, San Diego, CA, USA), and cells were filtered and plated at 100,000 cells / cm 2After incubation at 37°C and 5% CO2 for 24 hours, the plated suspension (containing slowly adherent satellite cells) was transferred to a flask coated with 1 μg / cm 2 New flasks containing mouse laminin (Sigma #CC095) were prepared. These flasks were left to rest for three days, at which point the growth medium was replaced, and the cells were cultured using standard practices on tissue culture plastic coated with iMatrix recombinant laminin-511 (Iwai North America #N892021, San Carlos, CA, USA). After two weeks of culture, the primoxone in the growth medium was replaced with 1% antibiotic-antimycotic. Cell passaging and cryopreservation were performed as for C2C12. To induce myogenic differentiation, cells were cultured to confluence and then incubated for one week without changing the medium.

[0196] Immunofluorescence and cell characterization - To confirm the properties of isolated primary BSCs, cells were stained for Pax7 and myosin heavy chain (MHC) before and after differentiation. These markers confirm the primary and final states of satellite cell myogenesis and are therefore used to verify the properties and myogenicity of the isolated cells. Proliferating cells and cells after one week of differentiation were fixed with 4% paraformaldehyde (ThermoFisher #AAJ61899AK) for 30 minutes, washed in PBS, permeabilized with 0.5% Triton X (Sigma #T8787) in PBS for 15 minutes, blocked with 5% goat serum (ThermoFisher #16210064) in PBS with 0.05% sodium azide (Sigma #S2002) for 45 minutes, and washed with PBS containing 0.1% Tween-20 (Sigma #P1379). Primary Pax7 antibodies (ThermoFisher #PA5-68506) were diluted 1:100 in blocking buffer and added to proliferating cells. Primary MHC antibodies (Developmental Studies Hybridoma Bank #MF-20, Iowa City, IA, USA) were diluted to 4 μg / mL in blocking buffer containing 1:100 phalloidin 594 (ThermoFisher #A12381) and added to differentiating cells. Primary antibodies were incubated overnight at 4°C. The next day, cells were washed with PBS+Tween-20, incubated with secondary antibodies for Pax7 (ThermoFisher #A-11008, 1:500) and MHC (ThermoFisher #A-11001, 1:1000) for 1 hour at room temperature, washed with PBS+tween-20, and mounted with Fluoroshield mounting medium with DAPI (Abcam #ab104139, Cambridge, UK) before imaging.

[0197] Molecular cloning and Sleeping Beauty construct design - The amino acid sequences of CrtB, CrtI, and CrtY from Pantoea ananas were obtained from UniProt (accession numbers P21683, P21685, and P21687, respectively). The gene sequences of these proteins were optimized for expression in Bos taurus using codon optimization software (IDT, Coralville, IA). A self-cleaving 2A peptide was added to the end of each gene to promote polycistronic expression, and all genes were flanked by multiple cloning sites (Szymczak et al., 2004). The final gene constructs were ordered through ThermoFisher's GeneArt gene synthesis service (Table 1). Next, three SleepingBeauty transposon vectors were constructed using the synthesized genes and based on plasmids available through Addgene: pCMV-GFP was a gift from Connie Cepko (Watertown, MA, USA) Addgene #11153), pSBbi-GP and pSBbi-Pur were a gift from Eric Kowarz (Addgene #60511 and #60523), and pCMV(CAT)T7-SB100 was a gift from Zsuzsanna Izsvak (Addgene #34879) (Kowarz et al., 2015; Mátés et al., 2009; Matsuda and Cepko, 2004). Transposon construction was performed using standard cloning techniques. Briefly, CrtB was cloned into pCMV-GFP using EcoRI-HF and XmaI restriction (NEB #R3101S and #R0180S, Ipswich, MA, USA) followed by T4 DNA ligation (NEB #M0202S) to generate pCMV-CrtB-P2A-eGFP, a plasmid for transient bicistronic expression of CrtB and green fluorescent protein (GFP) under the cytomegalovirus (CMV) promoter.

[0198] Table 1: Carotenoid synthesis genes. Gene sequences used in the constructs (upper case), followed by the 2A linker sequence (SEQ ID NO: 37) used after each gene (lower case).

[0199]

[0200]

[0201]

[0202] The CMV-CrtB-P2A-GFP portion of this plasmid was then cloned into pSBbi-Pur by Gibson assembly (SGI-DNA #GA1100, San Diego, CA, USA), simultaneously removing the backbone EF1α promoter and replacing it with the CMV promoter of the insert. This generated pSBbi-(CMV-CrtB-T2A-GFP)-pur, a Sleeping Beauty transposon vector carrying the same bicistronic CrtB and GFP expression cassettes under the CMV promoter, and a puromycin resistance gene under a synthetic promoter oriented in the reverse direction of CMV (Kowarz et al., 2015). This vector was then Gibson assembled to insert CrtI and CrtY to generate the three final Sleeping Beauty transposon carotenoid production vectors: pSBbi-(CMV-CrtB-T2A-)-pur(pCrtB), pSBbi-(CMV-CrtB-T2A-CrtI-P2A-GFP)-pur(pCrtB / I), and pSBbi-(CMV-CrtY-T2A-CrtB-T2A-CrtI-P2A-GFP)-pur(pCrtB / I / Y) Figure 1 A control SleepingBeauty transposon vector (pGFP) containing only GFP was generated by removing the carotenoid synthase and 2A sequences from pCrtB / I / Y, leaving only GFP under the CMV promoter ( Figure 1 All constructs were maintained in 5-alpha efficient chemically competent E. coli (NEB #C2988J), verified by Sanger sequencing (Genewiz, Cambridge, MA, USA), and purified by GeneJet miniprep (ThermoFisher #K0503). For Gibson assembly, polymerase chain reaction was performed using Q5 high-fidelity polymerase (NEB #M0492S), run through 1% agarose gel electrophoresis, and purified by GeneJet gel extraction (ThermoFisher #K0692).

[0203] Transfection and Selection - C2C12 and BSC were grown in 6-well plates to 80% to 90% confluence and transfected with Lipofectamine 3000 (ThermoFisher #L3000015) according to the manufacturer's protocol adapted for simultaneous transfection of two plasmids. Briefly, 2.5 μg of carotenoid-producing vector or pGFP control vector was combined with 0.25 μg of pCMV(CAT)T7-SB100 in a solution of 250 μL Opti-MEM medium (ThermoFisher #31985088), 7.5 μL of Lipofectamine 3000 reagent, and 5 μL of p3000 reagent. This mixture was incubated at room temperature for 15 minutes. During the incubation period, the cells were rinsed once with PBS and overlaid with 2 mL of Opti-MEM before adding the Lipofectamine mixture. After 4 hours at 37°C, 2 mL of growth medium was added to the wells and the cells were incubated overnight at 37°C. The next morning, the culture medium was replaced with an appropriate growth medium and the cells were cultured for two days before observing GFP expression under a fluorescence microscope. After two days, the culture medium was replaced with a growth medium containing 2.5 μg / mL puromycin to begin selection. Within one week, the cells were passaged and the culture medium was replaced as needed depending on cell death caused by the selection. Once it was observed that all cells expressed GFP, the culture was expanded and cryopreserved for subsequent use.

[0204] Growth and Development of Engineered Cells - The growth of engineered BSCs and C2C12 cells was analyzed using a dsDNA quantification kit (ThermoFisher #F2962) on days 1, 2, 4, 6, and 8 of culture. Cells were plated at a density of 1000 cells / well in 96-well plates at each time point. At each time point, the culture medium was removed from the wells and the plates were frozen at -80°C. After freezing at all time points, the plates were thawed to room temperature and 100 μL of ultrapure water (ThermoFisher #10977023) was added to the wells. The plates were incubated at 37°C for one hour, then frozen to -80°C and thawed to room temperature again. Each well was stained with 100 μL of Hoechst 33258 working solution. Fluorescence was measured using a Synergy H1 microplate reader (BioTek Instruments, Winooski, VT, USA) using excitation and emission filters centered at 360 and 460 nm, respectively. In parallel, 96-well plates were inoculated with a range of known cell densities, incubated for 12 hours, and measured using the same protocol to obtain a standard curve and convert fluorescence values ​​into cell numbers. To analyze the effect of transfection on cell phenotype, BSCs transfected with pCrtB / I / Y were differentiated and stained for Pax7 and MHC as previously described, except that red (594 nm) fluorophore-conjugated antibodies were used to detect Pax7 (ThermoFisher #A-11072) and MF20 (Abcam #ab150116), and cytoskeletal contrast staining was not performed.

[0205] Carotenoid extraction - cells at 175cm 2 The cells were cultured in flasks until confluent, harvested, and counted using a hemocytometer. The harvested cells (approximately 0.3-10 million for BSC and 10-20 million for C2C12) were washed once with PBS, resuspended in 1 mL of a 50:25:25 solution of hexane (Sigma #270504), acetone (ThermoFisher #A18-500), and ethanol (Sigma #459836), shaken for one minute, and incubated on a shaker plate at room temperature for 30 minutes. After 30 minutes, 150 μL of deionized water was added, and the suspension was shaken again for one minute. The solution was centrifuged at 3,000 g at 4°C for 5 minutes, and the upper layer containing carotenoids was collected in a Pyrex tube. Another 1 mL of the hexane:acetone:ethanol solution was added to the remaining pellet, and the extraction was repeated, pooling the two carotenoid solutions in one tube. The extracts were dried at room temperature under a stream of nitrogen, capped, and stored at -80°C prior to analysis by HPLC.

[0206] Quantitative HPLC - Carotenoids were analyzed by HPLC following published techniques on an Agilent 1200 system (Agilent Technologies, Santa Clara, CA, USA) using C 30 The stationary phase (YMC#CT99S03-1546WT, 3 μm, 4.6×150 mm, Arlington, PA, USA) and the mobile phase solvents A-methanol (ThermoFisher#A454-1) containing 1% ammonium acetate (ThermoFisher) and B-methyl-tert-butyl ether (MTBA, ThermoFisher#AC378720010) were used for analysis (Melendez-Martinez et al., 2013). Briefly, the carotenoid extract was suspended in 150 μL of ethanol, shaken, and injected (50 μL) into the HPLC system. The mobile phase solvent was pumped through the system at 1 mL / min with the following time-dependent gradient: t = 0 min, 95% A, 5% B; t = 15 min, 85% A, 15% B; t = 30-37 min, 40% A, 60% B; t = 40-55 min, 30% A, 70% B; t = 59-64 min, 90% A, 10% B; t = 70 min, 95% A, 5% B. A carotenoid standard curve was generated by dissolving (E / Z)-phytoene (Sigma #78903), lycopene (Sigma #SMB00706), and β-carotene (ThermoFisher #AAH6010603) standards in hexane at a concentration of approximately 0.5 mg / mL. The exact concentrations were determined spectrophotometrically (SpectraMax M2, Molecular Devices, San Jose, CA, USA) by measuring the absorbance of phytoene, lycopene, and β-carotene at 286, 472, and 453 nm, respectively, in a 1 cm path length quartz cell, and using A for phytoene, lycopene, and β-carotene, respectively. 1%=915, 3450 and 2592 to calculate the exact concentration. The standards were dried under nitrogen and stored at -80 ° C until the samples were analyzed after serial dilution. Because FBS can contain trace amounts of carotenoids (from animal feed), the endogenously produced carotenoid content was obtained by subtracting the area under any peak found in the extract from pGFP cells (which do not have the mechanism to produce carotenoids endogenously) (Chitchumroonchokchai et al., 2017). If the calculation returns a negative value or no peak is detected, the endogenous carotenoid content is set to zero. The final value is converted to ng / cell × 10 before normalization to cellular protein. 6 .

[0207] Protein Quantification - To normalize cellular carotenoid content on a more food-related basis than cell number, cellular protein content was measured. Briefly, engineered cells were cultured, harvested, and counted as previously described. One million cells were pelleted, washed once in PBS, and treated with 100 μL of RIPA buffer (Thermo Fisher #89900) containing EDTA-free 1% Halt protease inhibitor cocktail (ThermoFisher #78425) according to the manufacturer's instructions. The resulting cell lysates were analyzed by Pierce BCA protein assay (ThermoFisher #23225) according to the manufacturer's instructions. The absorbance at 562 nm was compared to a standard curve of known bovine serum albumin (BSA) concentrations and used to determine cellular protein / million cells (Supplementary Table 1). Figure 1 These values ​​were then used together with the carotenoid quantification / million cells (Figure 4C-4D) to obtain carotenoid content / protein mass.

[0208] Carotenoid Optimization - Explore two methods for optimizing carotenoid production in pCrtB / I / Y cells. The first method focuses on increasing gene expression by increasing puromycin selective pressure. The second method focuses on increasing the level of the carotenoid pathway precursor farnesyl pyrophosphate (FPP) by using the small molecule ketoconazole to inhibit a downstream reaction in one of the bypass metabolic pathways of FPP, namely cholesterol synthesis (Sun et al., 2007). By exploring these two methods, the possibility that a single method cannot solve the rate-limiting step in carotenoid production is reduced. Specifically, if FPP levels are completely restrictive (i.e., there are enough enzymes to completely deplete FPP levels), then increasing enzyme expression will not increase carotenoid levels. Similarly, if enzyme levels are completely restrictive, then ketoconazole treatment will not provide an increase in carotenoid production. In order to determine the appropriate puromycin concentration that increases enzyme expression, engineered cells are cultivated in the culture medium containing 2.5 μ g / mL puromycin (1 × puro), 5 μ g / mL puromycin (2 × puro) or 10 μ g / mL puromycin (4 × puro), and relative GFP expression is measured as the approximate measure of enzyme expression by flow cytometry. In brief, cells are cultivated, collected and BD FACSCalibur (BD Sciences) or Attune NxT (ThermoFisher) flow cytometer is used to analyze GFP. Use pGFP and unmodified cells as positive and negative control groups to set appropriate gate control, and measure mean fluorescence intensity. Analyze data with FlowJo software (v10). To determine the appropriate ketoconazole concentration for metabolic flux regulation, growth curves were obtained using a dsDNA quantification kit and culture medium treated with 0, 2.5, 5, 10, or 20 μg / mL ketoconazole (KTZ, ThermoFisher #455470010) dissolved in DMSO starting on day 1. Final DMSO concentration was kept constant (0.3%) under all conditions. After determining the appropriate puromycin and ketoconazole concentrations for carotenoid optimization, pCrtB / I / Y cells were cultured in culture medium containing 1×puro plus 5 μg / mL ketoconazole, 4×puro without ketoconazole, or 4×puro plus 5 μg / mL ketoconazole, and carotenoid analysis was performed as previously described.

[0209] Lipid Oxidation - To analyze the antioxidant functionality of carotenoids in cells, thiobarbituric acid reactive substances (TBARS) analysis was performed. This analysis measures malondialdehyde (MDA), a byproduct of unsaturated fatty acid oxidation, and therefore serves as a measure of lipid oxidation in cells. Because lipid oxidation is often catalyzed by processes that generate oxidative stress, such as meat cooking, TBARS analysis was performed on "raw" cells and cells that had been heated to simulate cooking. Briefly, engineered BSCs were cultured, collected, and counted as previously described. 1.5 million cells were aliquoted into tubes for heated or unheated analysis, washed once in PBS, pelleted, and the supernatant PBS removed. The collected cell pellets were stored overnight at 4°C. The next day, the samples designated for heating were incubated in a 100°C heating block for 10 minutes, cooled to room temperature, and placed on ice. All cells (heating and unheating) are suspended in 500 μ L PBS, cultivated on ice for 2 hours, and use probe sonicator (St.Louis, MO, USA) Branson) to ultrasonicate 5 × 15 second pulses on ice at 15% intensity, with 20 seconds interval between pulses.Then, follow the manufacturer's protocol, 100 μ L ultrasonicated cell lysates are carried out TBARS analysis (Ann Arbor, MI, USA) Cayman Chemical#700870), and by measuring the absorbance under 535nm and compared with the standard curve of known MDA concentration to measure MDA.The remaining cell lysates are frozen at -80 ° C until protein quantification is carried out by Bradford (Bradford) analysis (ThermoFisher#23200) following the manufacturer's protocol. Briefly, 5 μL of cell lysate was incubated with 250 μL of Coomassie reagent for 10 minutes, and the absorbance was measured at 595 nm and compared to a BSA standard curve. TBARS measurements were normalized to the protein content of each sample to obtain corrected cellular MDA (mg / g protein).

[0210] Statistical Analysis - Statistical analyses were performed using GraphPad Prism 8.0 software (San Diego, CA, USA). Carotenoid content, flow cytometry, and ketoconazole growth were analyzed by one-way ANOVA. Growth curves and TBARS analysis were analyzed by two-way ANOVA. Multiple comparisons for all analyses were performed using Tukey's HSD post-hoc test. In converting carotenoid and MDA quantification to per-protein values, error propagation was accounted for using the following: σ_(A / B)=(A / B)√((σ_(A / A)^2+(σ_(B / B)^2), where σ_A is the standard deviation of data A. P values ​​< 0.05 were considered significant. Unless otherwise stated, errors are given as ± standard deviation.

[0211] Results and Discussion

[0212] Primary bovine skeletal muscle stem cells - immunofluorescence staining of early markers of satellite cell properties and terminal markers of myogenic differentiation are used to characterize primary bovine satellite cells (BSC). Proliferating cells show universal staining (Fig. 2 A) to Pax7 (a marker of satellite cell phenotype), indicating that the cell separation protocol is successful for producing a highly consistent myogenic stem cell colony. After one week of differentiation, myosin heavy chain (MHC) staining of cells shows long multinuclear myotubes (Fig. 2 B). Actin and MHC staining of these myotubes reveal the striped architecture indicating sarcomere formation, and the spontaneous contraction in the culture observed to differentiate further supports the presence of contractile apparatus. These data indicate the separation of the highly myogenic colony of bovine skeletal muscle precursors together, and the ability of these cells to undergo stable differentiation in vitro.

[0213] Stable transgene expression in cells - BSC and C2C12 immortalized mouse precursor cells were engineered with polycistronic vectors to produce a series of protein conversations. These were green fluorescent protein (GFP) alone (pGFP), which does not produce any carotenoids; CrtB and GFP (pCrtB), which produce phytoene; CrtB, CrtI, and GFP (pCrtB / I), which produce phytoene and lycopene; or CrtB, CrtI, CrtY, and GFP (pCrtB / I / Y), which produce phytoene, lycopene, and β-carotene (Figures 2A-2B). The polycistronic nature of these vectors enables the use of GFP expression as an indicator of vector integration and gene expression. Specifically, the 2A sequence between genes allows for near-stoichiometric expression of the enzyme and GFP (Szymczak et al., 2004). After transfection and selection for one week in puromycin-containing medium, all cells stably expressed their corresponding gene cassettes, as visualized by GFP fluorescence (Figure 3A). The fluorescence intensity was uneven, likely due to the stochastic nature of transposition. No obvious morphological differences were observed between the control pGFP cells and cells expressing the carotenoid synthase.

[0214] Growth and development of engineered cells - Because antioxidant factors are known to affect muscle progenitor cell proliferation, the growth rate of cells producing all three carotenoids was analyzed over eight days (Le Moal et al., 2017). For BSCs, the size of the inserted genetic construct was negatively correlated with growth rate (Figure 3B). In contrast, C2C12 engineered with the two largest compounds (pCrtB / I and pCrtB / I / Y) showed higher growth over eight days compared to cells engineered with pGFP or pCrtB. This difference may be attributed to the effects of insertion efficiency and subsequent selection on primary cells, but not immortalized cells. That is, cells transfected with larger constructs have lower insertion efficiency and therefore require more divisions (doubling) to produce equally large engineered cell populations (Izsvák et al., 2000). In primary cells, growth slows as division increases, and eventually cells reach senescence (Ding et al., 2018). However, in immortalized cells, division does not hinder growth. Conversely, antioxidant capacity has been found to increase cell proliferation (Le Moal et al., 2017), and immortalized cells pCrtB / I and pCrtB / I / Y cells with increased antioxidant capacity showed enhanced growth compared to controls. It is possible that immortalized bovine cells will show similar relative kinetics.

[0215] To determine whether genetic modification affects myogenic potential, pCrtB / I / YBSCs were stained for Pax7 and MHC (Figure 3C). Staining showed that Pax7 expression and MHC-positive myotube formation were maintained. No striations were observed in differentiated cells, which may indicate that differentiation was less robust than in non-engineered cells. This may be due to antioxidant effects that reduce the degree of myofiber maturation; however, the ability of cells to form myotubes suggests that these cells have the potential to produce differentiated cultured meat products. These data collectively point to the ability of cells to maintain their proliferation and differentiation capacity after modification with carotenoid synthase; however, this proliferation and differentiation capacity can be reduced in primary cells.

[0216] Carotenoid Production in Engineered Cells - Quantitative HPLC confirmed the production of phytoene in pCrtB cells, phytoene and lycopene in pCrtB / I cells, and phytoene, lycopene, and β-carotene in pCrtB / I / Y cells. In all cells, carotenoids accumulated as terminal compounds, but precursors were also present (i.e., phytoene and lycopene in pCrtB / I / Y cells), indicating high, but non-exhaustive, conversion efficiency throughout the pathway (Figures 4A-4D). In pCrtB / I cells, the majority of phytoene was converted to lycopene, and total carotenoid content was highly preserved compared to cells producing only phytoene. In pCrtB / I / Y cells, carotenoids accumulated as terminal compounds (β-carotene), but the yield was significantly reduced compared to pCrtB or pCrtB / I cells. All three C2C12 constructs produced greater carotenoids than BSC. The total carotenoid content of C2C12pCrtB, pCrtB / I, and pCrtB / I / Y was 505.3, 254.8, and 63.19 μg / g protein, respectively. For BSC, these were 35.8, 31.2, and 3.7 μg / g protein, respectively. The total carotenoid content of BSC compared to C2C12, and pCrtB / I / Y cells compared to pCrtB or pCrtB / I cells, was significantly reduced, which may be attributed to the increased cellular burden of selection and protein production and / or endogenous enzymatic degradation of β-carotene (Geurts et al., 2003; Lindqvist et al., 2005).

[0217] Optimization of Carotenoid Production - Given the relatively low carotenoid production of BSC cells compared to C2C12, and pCrtB / I / Y cells compared to pCrtB or pCrtB / I cells, we hypothesized that production in these cells could be significantly improved. We explored two approaches to achieve this. In the first approach, enzyme expression was increased by increasing the selective pressure of the transgene. Puromycin was shown to induce a significant increase in GFP expression in C2C12 and BSC cells at a 4× concentration (10 μg / mL) (Figure 7A, Figures 9A-9B), so this concentration was used for optimization. In the second approach, the accumulation of carotenoid precursors was induced by inhibiting cholesterol synthesis (cholesterol competes for carotenoid precursors) using the small molecule ketoconazole (Figure 5A) (Sun et al., 2007). A ketoconazole concentration of 5 μg / mL was found to not significantly affect growth in C2C12 and BSC cells (Figure 7B), so this concentration was used.

[0218] To test how these treatments affect carotenoid production individually and synergistically, pCrtB / I / YBSCs were cultured with 1× puromycin + / - ketoconazole and 4× puromycin + / - ketoconazole. A significant increase in orange pigmentation was observed in cells cultured with 4× puromycin + ketoconazole (Figure 5B), and for these cells, quantitative HPLC showed a significant increase in β-carotene production (Figure 5C). Specifically, the optimized BSCs produced 10-fold more β-carotene compared to the unoptimized BSCs (2.08 vs. 22.6 μg / g protein, respectively). Notably, this level is approximately 7-fold higher than the literature value for β-carotene (μg / g protein) in beef from pasture-raised cattle and approximately 14-fold higher than beef from feedlot-raised cattle (Simonne et al., 1996). The treatment with the best effect (4× puromycin + ketoconazole) was then used to optimize pCrtB / I / YC2C12. The average β-carotene concentrations for unoptimized and optimized C2C12 were 35.44 and 42.43 μg / g protein, respectively, but this difference was not statistically significant. Analysis of the overall carotenoid profile of the optimized cells revealed a tendency to accumulate as the terminal compound (β-carotene) in all cases (Figures 8A-8B).

[0219] The fact that elevation of both enzymes and precursors was able to increase carotenoid production suggests that both enzymes and precursors are limiting in the system, likely due to the heterogeneous nature of enzyme expression in the cells. Specifically, in cells with high background enzyme levels, precursors are rate-limiting, and in cells with low background enzyme levels, enzyme capacity is rate-limiting. The efficacy of techniques to optimize both suggests multiple avenues of optimization that can be pursued when engineering cultured meat. While the use of ketoconazole to induce precursor accumulation was useful in the proof-of-concept, achieving the same effect in a production process for nutritionally enhanced cultured meat will likely rely on genetic strategies.

[0220] Lipid oxidation and antioxidant functionality - Lipid oxidation is a key mechanistic link between red or processed meat consumption and colorectal cancer, and a major cause of non-microbial meat quality deterioration during storage (Falowo et al., 2014; Wolk, 2017). We therefore investigated the ability of endogenous carotenoids to reduce lipid oxidation in vitro, both in "raw" unheated cells and in "cooked" heated cells, by analyzing cellular malondialdehyde (MDA) levels using the thiobarbituric acid reactive substances (TBARS) assay. Figure 6 ). In pGFP BSCs, unheated and heated samples showed 1.9 and 4.6 mg MDA / g protein, respectively, indicating a significant effect of the heating method in promoting lipid oxidation. BSCs engineered with pCrtB showed a decrease in lipid oxidation in unheated and heated samples (1.7 and 3.6 mg / g protein, respectively), but in unheated samples, this difference was not statistically significant. Cells engineered with pCrtB / I and pCrtB / I / Y showed a significant decrease in lipid oxidation in unheated and heated samples compared to the control group (1.0 and 1.1 mg / g protein for CrtB / I and CrtB / I / Y unheated samples, respectively, and 1.7 and 2.3 mg / g protein for heated samples, respectively).

[0221] Notably, cells supplemented with lycopene and / or β-carotene exhibited greater antioxidant capacity than cells supplemented with phytoene alone, despite the latter being the pCrtB cells with the highest levels of total carotenoids. This may be due to the varying antioxidant capacities of these carotenoids, with phytoene being the least potent (Martínez et al., 2014). Similarly, pCrtB / I / Y cells exhibited nearly equivalent antioxidant activity to pCrtB / I cells, despite the latter displaying approximately tenfold more total carotenoids. This may be due to the synergistic effects of carotenoids, which have been shown to occur when present simultaneously in the system (Kotíková et al., 2011). Finally, measuring lipid oxidation alone may bias the results, as cholesterol can enhance membrane antioxidant capacity (cholesterol synthesis competes with carotenoid synthesis) (López-Revuelta et al., 2006). Therefore, measuring total oxidation (including protein) is worthwhile. Nonetheless, the simplicity and ubiquity of TBARS analysis in meat science make this technique very important, and the approximately 2-fold reduction in lipid oxidation in heated and unheated samples containing endogenously produced lycopene and / or β-carotene suggests that these nutrients will have a significant impact on the nutritional and food quality of engineered cultured meat products.

[0222] References:

[0223] Banerjee,P.,Bhunia,AK,2009.Mammalian cell-based biosensors forpathogens and toxins.Trends Biotechnol.https: / / doi.org / 10.1016 / j.tibtech.2008.11.006

[0224] Botella-Pavia,P.,Rodriguez-Concepcion,M.,2006.Carotenoidbiotechnology in plants for nutritionally improved foods.Physiol.Plant.126,369-381.https: / / doi.org / 10.1111 / j.1399-3054.2006.00632.x

[0225] Ceroni,F.,Ellis,T.,2018.The challenges facing synthetic biology ineukaryotes.https: / / doi.org / 10.1038 / s41580-018-0013-2

[0226] Chitchumroonchokchai,C.,Diretto,G.,Parisi,B.,Giuliano,G.,Failla,M.L.,2017.Potential ofgolden potatoes to improve vitaminA and vitamin E status indeveloping countries.PLoS One 12,e0187102.https: / / doi.org / 10.1371 / journal.pone.0187102

[0227] Davy,A.M.,Kildegaard,H.F.,Andersen,M.R.,2017.Cell FactoryEngineering.Cell Syst.https: / / doi.org / 10.1016 / j.cels.2017.02.010

[0228] Desmarchelier,C.,Borel,P.,2017.Overview of carotenoid bioavailabilitydeterminants:From dietary factors to host genetic variations.Trends FoodSci.Technol.69,270-280.https: / / doi.org / 10.1016 / J.TIFS.2017.03.002

[0229] Ding,S.,Swennen,G.N.M.,Messmer,T.,Gagliardi,M.,Molin,D.G.M.,Li,C.,Zhou,G.,Post,M.J.,2018.Maintaining bovine satellite cells stemness throughp38 pathway.Sci.Rep.8,10808.https: / / doi.org / 10.1038 / s41598-018-28746-7

[0230] Falowo,A.B.,Fayemi,P.O.,Muchenje,V.,2014.Natural antioxidants againstlipid-protein oxidative deterioration in meat and meat products:A review.FoodRes.Int.64,171-181.https: / / doi.org / 10.1016 / J.FOODRES.2014.06.022

[0231] Geurts,A.M.,Yang,Y.,Clark,K.J.,Liu,G.,Cui,Z.,Dupuy,A.J.,Bell,J.B.,Largaespada,D.A.,Hackett,P.B.,2003.Gene transfer into genomes of human cellsby the sleeping beauty transposon system.Mol.Ther.8,108-117.https: / / doi.org / 10.1016 / S1525-0016(03)00099-6

[0232] Giddings,G.,2001.Transgenic plants as protein factories.Curr.Opin.Biotechnol.https: / / doi.org / 10.1016 / S0958-1669(00)00244-5

[0233] Heider,S.A.E.,Wendisch,V.F.,2015.Engineering microbial cellfactories:Metabolic engineering of Corynebacterium glutamicum with a focus onnon-natural products.Biotechnol.J.https: / / doi.org / 10.1002 / biot.201400590

[0234] Izsvák,Z.,Ivics,Z.,Plasterk,R.H.,2000.Sleeping Beauty,a wide host-rangetransposon vector for genetic transformation in vertebrates.J.Mol.Biol.302,93-102.https: / / doi.org / 10.1006 / JMBI.2000.4047

[0235] Keasling,J.D.,2010.Manufacturing molecules through metabolicengineering.Science(80-.).https: / / doi.org / 10.1126 / science.1193990

[0236] Kotíková,Z.,Lachman,J.,Hejtmánková,A.,Hejtmánková,K.,2011.Determinationofantioxidant activity and antioxidant content in tomato varieties andevaluation of mutual interactions between antioxidants.LWT-FoodSci.Technol.44,1703-1710.https: / / doi.org / 10.1016 / J.LWT.2011.03.015

[0237] Kowarz,E., D.,Marschalek,R.,2015.Optimized Sleeping Beautytransposons rapidly generate stable transgenic cell lines.Biotechnol.J.10,647-653.https: / / doi.org / 10.1002 / biot.201400821

[0238] Le Moal,E.,Pialoux,V.,Juban,G.,Groussard,C.,Zouhal,H.,Chazaud,B.,Mounier,R.,2017.Redox Control of Skeletal Muscle Regeneration.Antioxid.RedoxSignal.27,276-310.https: / / doi.org / 10.1089 / ars.2016.6782

[0239] Lindqvist,A.,He,YG,Andersson,S.,2005.Cell type-specific expressionofβ-carotene 9′,10′-monooxygenase in human tissues.J.Histochem.Cytochem.53,1403-1412.https: / / doi.org / 10.1369 / jhc.5A6705.2005

[0240] López-Revuelta,A.,Sánchez-Gallego,JI,Hernández-Hernández,A.,Sánchez-Yagüe,J.,Llanillo,M.,2006.Membrane cholesterol contents influence the protective effects of quercetin and rutin in erythrocytes damaged byoxidatively stress.Chem.Biol.Interact.161,79-91.https: / / doi.org / 10.1016 / j.cbi.2006.03.004

[0241] Martínez,A.,Stinco,C.M.,Meléndez-Martínez,A.J.,2014.Free radicalscavenging properties of Phytofluene and Phytoene isomers as compared toLycopene:A combined experimental and theoretical study.J.Phys.Chem.B 118,9819-9825.https: / / doi.org / 10.1021 / jp503227j

[0242] Mátés,L.,Chuah,M.K.L.,Belay,E.,Jerchow,B.,Manoj,N.,Acosta-Sanchez,A.,Grzela,D.P.,Schmitt,A.,Becker,K.,Matrai,J.,Ma,L.,Samara-Kuko,E.,Gysemans,C.,Pryputniewicz,D.,Miskey,C.,Fletcher,B.,VandenDriessche,T.,Ivics,Z.,Izsvák,Z.,2009.Molecular evolution of a novel hyperactive Sleeping Beauty transposaseenables robust stable gene transfer in vertebrates.Nat.Genet.41,753-761.https: / / doi.org / 10.1038 / ng.343

[0243] Matsuda,T.,Cepko,C.L.,2004.Electroporation and RNA interference inthe rodent retina in vivo and in vitro.Proc.Natl.Acad.Sci.101,16-22.https: / / doi.org / 10.1073 / pnas.2235688100

[0244] Mattick,C.S.,Landis,A.E.,Allenby,B.R.,Genovese,N.J.,2015.AnticipatoryLife Cycle Analysis of In Vitro Biomass Cultivation for Cultured MeatProduction in the United States.Environ.Sci.Technol.49,11941-11949.https: / / doi.org / 10.1021 / acs.est.5b01614

[0245] Melendez-Martinez,A.J.,Stinco,C.M.,Liu,C.,Wang,X.-D.,2013.A simpleHPLC method for the comprehensive analysis of cis / trans(Z / E)geometricalisomers of carotenoids for nutritional studies.Food Chem.138,1341-1350.https: / / doi.org / 10.1016 / J.FOODCHEM.2012.10.067

[0246] Mojica,F.J.M.,Montoliu,L.,2016.On the Origin of CRISPR-CasTechnology:From Prokaryotes to Mammals.Trends Microbiol.https: / / doi.org / 10.1016 / j.tim.2016.06.005

[0247] Nielsen,J.,2015.Yeast cell factories on the horizon:Metabolicengineering in yeast gets increasingly more versatile.Science(80-.).https: / / doi.org / 10.1126 / science.aad2081

[0248] Post,M.J.,2012.Cultured meat from stem cells:Challenges andprospects.Meat Sci.92,297-301.https: / / doi.org / 10.1016 / J.MEATSCI.2012.04.008

[0249] Rubio,N.R.,Fish,K.D.,Trimmer,B.A.,Kaplan,D.L.,2019.In Vitro InsectMuscle for Tissue Engineering Applications.ACS Biomater.Sci.Eng.5,1071-1082.https: / / doi.org / 10.1021 / acsbiomaterials.8b01261

[0250] Sack,M.,Rademacher,T.,Spiegel,H.,Boes,A.,Hellwig,S.,Drossard,J.,Stoger,E.,Fischer,R.,2015.From gene to harvest:Insights into upstream processdevelopment for the GMP production of a monoclonal antibody in transgenictobacco plants.Plant Biotechnol.J.https: / / doi.org / 10.1111 / pbi.12438

[0251] Satomi,Y.,Yoshida,T.,Aoki,K.,MIsAwA,N.,Masuda,M.,Murakoshi,M.,Takasuka,N.,Sugimura,T.,1995.Production of Phytoene,an Oxidative MammalianCells by Introduction of Isolated from a Bacterium Stress ProtectiveCarotenoid,in Phytoene Synthase Gene crtB Erwinia uredovora.Proc.JapanAcad71.

[0252] Schukur,L.,Fussenegger,M.,2016.Engineering of synthetic gene circuitsfor (re-)balancing physiological processes in chronic diseases.WileyInterdiscip.Rev.Syst.Biol.Med.8,402-422.https: / / doi.org / 10.1002 / wsbm.1345

[0253] Simonne,A.H.,Green,N.R.,Bransby,D.I.,1996.Consumer Acceptability andp-Carotene Content of Beef as Related to Cattle Finishing Diets.J.FoodSci.61,1254-1257.https: / / doi.org / 10.1111 / j.1365-2621.1996.tb10973.x

[0254] Simsa,R.,Yuen,J.,Stout,A.,Rubio,N.,Fogelstrand,P.,Kaplan,D.L.,2019.Extracellular Heme Proteins Influence Bovine Myosatellite CellProliferation and the Color of Cell-Based Meat.Foods 2019,Vol.8,Page 5218,521.https: / / doi.org / 10.3390 / FOODS8100521

[0255] Sun,Y.,Yuan,Q.-P.,Vriesekoop,F.,2007.Effect oftwo ergosterolbiosynthesis inhibitors on lycopene production by Blakeslea trispora.ProcessBiochem.42,1460-1464.https: / / doi.org / 10.1016 / J.PROCBIO.2007.06.006

[0256] Szymczak,A.L.,Workman,C.J.,Wang,Y.,Vignali,K.M.,Dilioglou,S.,Vanin,E.F.,Vignali,D.A.A.,2004.Correction ofmulti-gene deficiency in vivo using asingle“self-cleaving”2A peptide-basedretroviral vector.Nat.Biotechnol.22,589-594.https: / / doi.org / 10.1038 / nbt957

[0257] Wang,Z.,Li,H.,Guo,R.,Wang,Q.,Zhang,D.,2016.Antioxidants inhibitadvanced glycosylation end-product-induced apoptosis by downregulation ofmiR-223 in human adipose tissue-derived stem cells.Sci.Rep.6.https: / / doi.org / 10.1038 / srep23021

[0258] Wolk,A.,2017.Potential health hazards of eating red meat.J.Intern.Med.281,106-122.https: / / doi.org / 10.1111 / joim.12543

[0259] Yaffe,D.,Saxel,O.,1977.Serial passaging and differentiation ofmyogenic cells isolated from dystrophic mouse muscle.Nature 270,725-727.https: / / doi.org / 10.1038 / 270725a0

[0260] Ye,X.,Al-Babili,S., A.,Zhang,J.,Lucca,P.,Beyer,P.,Potrykus,I.,2000.Engineering the provitamin A(beta-carotene)biosynthetic pathway into(carotenoid-free)rice endosperm.Science 287,303-5.https: / / doi.org / 10.1126 / SCIENCE.287.5451.303

[0261] Zhang,F.,Wang,LP,Boyden,ES,Deisseroth,K.,2006.Channelrhodopsin-2and optical control of excitable cells.Nat.Methods 3,785-792.https: / / doi.org / 10.1038 / nmeth936

[0262] Zhang, L., Xia, H., Han, Q., Chen, B., 2014. Effects of antioxidant genetherapy on the development of diabetic retinopathy and the metabolic memory phenomenonon. Graefe's Arch.

[0263] Example 2

[0264] Meat is a key source of nutrition for many groups due to its ability to provide valuable nutrients in high density. Meat provides a substantial protein content (approximately 30% by weight when cooked), an amino acid profile well-proportioned for human health, a range of essential fatty acids, vitamins A, B, D and E, and key minerals in highly bioavailable forms. 5-9 The impact of these characteristics on human health is amplified by the current and projected prevalence of meat in the global diet. Indeed, in some Western diets, meat constitutes as much as 40% of daily protein intake, and a recent report from the Food and Agriculture Organization of the United Nations (FAO) indicates that global meat production is projected to increase by 76% from 2012 to 2050, reaching 455 million tons. 5,10 .

[0265] However, despite this value, a growing body of research highlights the fact that the global impact of meat as a source of nutrition and a commodity goes beyond its nutritional value. From a health perspective, high intakes of red and processed meat are associated with an increased risk of numerous conditions, including type 2 diabetes, cardiovascular disease, and colorectal cancer. 11-16 While the epidemiological studies behind these associations make it difficult to provide firm dietary recommendations (and are therefore often controversial), for colorectal cancer there is sufficient meta-analytical evidence to be very convincing to most nutritionists, and the World Health Organization's International Agency for Research on Cancer (IARC) has deemed red meat and processed meat to be 'probably carcinogenic' and 'carcinogenic', respectively. 17,18 From a production perspective, livestock farming contributes significantly to natural resource use, greenhouse gas emissions, and environmental degradation. Specifically, it is estimated that livestock farming produces approximately 15% of all anthropogenic greenhouse gases (CO2 equivalent), accounts for approximately 29% of the global human water footprint, contributes to approximately 71% of deforestation in some regions, and is a major source of eutrophication. 10,19 At the same time, concentrated livestock farming raises concerns about animal welfare and antibiotic resistance. 10 With meat production projected to rise sharply by 2050, these problems are likely to intensify.

[0266] Recently, the possibility of producing meat from cell cultures (called "cultured meat") has been proposed as a solution to the environmental and ethical problems of animal husbandry. 20 Producing cultured meat involves expanding muscle and fat cells from relevant species in vitro and seeding them onto edible scaffolds to form 3D tissue. 21 By producing meat without the competing energy demands present in whole animals, cultured meat is expected to significantly reduce meat's land use, water use, and greenhouse gas emissions. 22 Cultured meat is also expected to reduce the animal welfare and antibiotic resistance issues of conventional meat.

[0267] However, despite these predicted benefits, it is still unclear how exactly cultured meat reproduces the nutritional characteristics of meat, and what its nutritional advantages or disadvantages might be. On the one hand, due to the often immature nature of skeletal muscle fibers cultured in vitro and the importance of sarcomeric proteins to the nutritional value of meat, cultured meat may offer a poorer protein profile than conventional meat. 23 In addition, many nutrients, such as minerals and some vitamins, are not synthesized endogenously by muscle tissue, including essential vitamins such as B 12 The content of will be entirely dependent on the uptake of the culture medium components by the cells and is therefore likely to be reduced or absent in bioprocesses where culture medium costs are strictly constrained. 24On the other hand, some harmful nutrients that exist in muscle tissue but are not endogenously synthesized, such as trans-saturated fatty acids, will be easily excluded from cultured meat products. 25 .

[0268] Along with the inherent variability, the cellular-level control inherent to cultured meat provides the opportunity to modulate composition for a variety of goals. This could be to adjust naturally occurring nutrients, such as the amino acid or lipid profile, or to add compounds not endogenously synthesized in meat tissue, such as vitamins or other phytochemicals. These modifications could be aimed at addressing potential nutritional deficiencies in cultured meat, enhancing its nutritional advantages, or adding entirely new nutritional functionalities. Beyond nutrition, composition could also potentially be modulated for: sensory and food functional goals, such as flavor, aroma, color, or storage stability; or therapeutic activity, allowing for the production of 'therapeutic foods' with beneficial bioactivity upon ingestion.

[0269] One promising technology for influencing the composition of cultured meat in this way is through metabolic engineering, or the genetic and regulatory control of cellular metabolism, directed at various targets. Metabolic engineering efforts in plants, yeast, and bacteria have targeted applications ranging from medicine and cosmetics to energy and agriculture, utilizing numerous pathways from diverse taxa. 26-28 The same breadth has not yet been achieved in mammalian systems, with most work focused on biopharmaceuticals. 29-31 While this work is not inferior to that in other systems, the difference in scope is significant. To date, this difference may be at least partially due to the lack of urgency to engineer animal cells with metabolic pathways from other taxa; from a bioprocessing perspective, the production of recombinant proteins, small molecules, and biofuels is cheaper in bacteria, yeast, or plant systems, and mammalian bioprocessing is preferred only when species-specific post-translational modifications are required. 29,32 The possibility of cultured meat offers a new framework in which the product is the cell itself, and thus endogenous synthesis of additional compounds becomes a purely accessory task, at least for those cases where it is biologically possible and does not hinder the bioprocess or product value. Here, the fact that cultured meat relies solely on cell growth for survival, rather than on whole animals (a limitation inherent in animal transgenics), enables consideration of a wider range of metabolites that may be difficult to achieve in animals but are harmless or even beneficial in cell culture. Attractive functionalities that can be explored include nutritional, bioactive and food functional, flavor or therapeutic activities.

[0270] Example 1 demonstrates mammalian cells engineered with metabolic pathways for carotenoid synthesis that are native to many plants and some prokaryotes, but not to animals. Specifically, using the non-viral SleepingBeauty transgene, we engineered the production of phytoene, lycopene, and beta-carotene from natural precursors in primary bovine and immortalized C2C12 mouse muscle cells. These nutrients are attractive targets for several reasons. First, they each offer unique nutritional value; phytoene is suggested to act as a UV photoprotectant, lycopene has been shown to reduce hepatocellular carcinoma and fatty liver disease, and beta-carotene is an essential vitamin A precursor in the human diet. 33-35 Second, all three compounds are antioxidant factors 36 This is particularly relevant for red meat, as the key mechanistic link between red or processed meat intake and colorectal cancer is lipid oxidation. 17 The antioxidant properties of these compounds also offer value in extending the shelf life of meat, as lipid oxidation is the main cause of non-microbiological deterioration over time. 37 Finally, these compounds are red pigments, and their synthesis could therefore influence the color of cultured meat products. We demonstrate the successful synthesis of all three dietary carotenoids, the phenotypic integrity of the modified cells, and the ability to modulate carotenoid yields through multiple strategies.

[0271] A single metabolite may have diverse effects on cultured meat products, such as antioxidants that confer both quality and nutritional benefits to cultured meat, a common feature of many potential targets. In addition to the aforementioned meat quality effects, antioxidants can also affect cell proliferation, where unregulated levels of reactive oxygen species induce cell cycle arrest and inhibit proliferation. 38-40 Indeed, in our previous study, C2C12, a synthetic carotenoid with increased antioxidant capacity, showed increased proliferation compared to controls, but this was not observed in engineered primary cells. Other interesting cases of pro-proliferative effects from phytochemicals include those of vitamin C in teleost myoblasts, cyanidin (a polyphenolic nutrient) in C2C12, and D-limonene (a flavor and aroma compound found in citrus) in lymphocytes. 41,42 In contrast, phytonutrients such as the polyphenol resveratrol have been shown to have anti-proliferative but pro-differentiating effects in myoblasts, suggesting their potential applicability during the differentiation phase of cultured meat production. 43 Similarly, there is evidence that cannabinoid receptor 1 (CB1) antagonists, such as cannabidiol, a therapeutic phytochemical, can enhance the differentiation of C2C12 and primary human myoblasts in vitro. 44 Depending on the dose, some phytochemicals, such as the nutrient curcumin, can exhibit pro-proliferative and pro-differentiation effects on primary myoblasts.45 Given these effects, it is interesting to consider how engineering targets can enhance both cultured meat products and processes.

[0272] The implementation described in this example demonstrates (1) background nutritional analysis of in vitro cultured bovine skeletal muscle cells (both proliferating and differentiating cells will be analyzed) to better understand the inherent nutritional differences between cultured meat and conventional meat, (2) testing various engineering targets to enhance nutrition, food quality, or bioactivity to outline the range of possibilities for compositional modulation of cultured meat, and (3) analysis of the effects of modifications on food functionality, such as oxidation and nutrient bioavailability, and on bioprocessing parameters, such as cell growth and differentiation. This work will help elucidate the inherent nutritional characteristics of cultured meat and establish the basis for the broad use of metabolic engineering to modulate compositional and bioprocessing parameters.

[0273] Cell Isolation and Culture - Bovine satellite cells (BSCs) were isolated from live animal biopsies collected at Tufts University Cummings School of Veterinary Medicine using methods previously reported by our group. 46 Briefly, a small piece of tissue (approximately 0.25 cm) was removed from the semitendinosus muscle of Simmental bulls <30 days old. 3 ), minced and digested in DMEM Grotama (Gibco) with 0.2% collagenase II (Worthington). The resulting cell suspension was diluted in growth medium containing DMEM Grotama with 20% fetal bovine serum (FBS), 1% primoxone (Sigma) and 1 ng / mL FGF-2 (Thermo Fisher), filtered and plated onto tissue culture flasks. After 24 hours, unattached cells were moved to new tissue culture flasks coated with 0.25 μg / cm2 recombinant laminin-511 (Iwai) and left to stand for three days. This pre-coating separated the slowly attaching BSCs from the rapidly attaching fibroblasts. After three days, the BSCs were supplemented with growth medium every 2-3 days and passaged onto laminin-coated flasks when 70% confluent. Two weeks later, 1% antibiotic-antimycotic (Thermo Fisher) replaced the primoxone in the culture medium. For BSC differentiation, cells were cultured to confluence and then cultured for one week without medium change. To confirm BSC nature, immunocytochemistry was performed for the satellite cell marker Pax7 (during proliferation) and the myogenic marker myosin heavy chain (MHC; after differentiation).

[0274] Protein analysis - Cells were harvested before and after differentiation in standard medium, medium with 1×, 2×, and 4× levels of essential amino acids, and medium formulated for an amino acid profile that closely matches human nutritional requirements 1 Bulk protein was quantified using the Pierce BCA protein assay kit (Thermo Fisher) according to the manufacturer's instructions. Amino acid composition was quantified by HPLC as previously described. 47,48 . Briefly, cells were homogenized by sonication, spiked with known concentrations of the internal standard norvaline, hydrolyzed with HCl, and quantified by HPLC relative to amino acid standards (also spiked with norvaline) after pre-column derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate. Samples were separated on a Nova-Pak C18 (Waters) column and analyzed using fluorescence detection with excitation at 250 nm and emission at 395 nm. Bulk protein and amino acid composition were correlated with DNA content (CyQuant analysis; Thermo Fisher) to compare undifferentiated and differentiated cells. Conventional meat samples were analyzed and compared with cultured cells.

[0275] Lipid analysis - Lipid analysis was performed using liquid chromatography-mass spectrometry (LC-MS) as previously described. 49 . Briefly, undifferentiated and differentiated BSCs were homogenized by ultrasonication, and an internal lipid standard was added to the homogenate (a mixture of phosphatidylcholine (PC), phosphatidylethanolamine (PE), ceramide (Cer), phosphatidylserine (PS), phosphatidic acid (PA), and a defined composition of monoacylglycerol, diacylglycerol, and triacylglycerol (MG, DG, and TG)). Cellular lipids were extracted with a solution of chloroform and methanol (2:1, v / v), centrifuged, and the lower phase was collected and combined with an external standard (comprising isotope-labeled TG and PC). Samples were separated by LC-MS in a BEH C18 column (Waters) relative to lipid standards, followed by quadrupole-time-of-flight detection for quantification. Fatty acid profiles were standardized using internal and external standards and relative to DNA and protein quantification. Again, samples were analyzed at different levels of differentiation and compared with store-bought products.

[0276] The bulk protein in bovine cells is expected to be similar to that found in store-bought beef. Specifically, for bulk protein in mammalian muscle cells, previous reports have suggested an expected value of approximately 20% protein by wet cell weight, which is similar to the concentration found in beef. 9At the same time, reduced extracellular protein accumulation and myotube maturation can lead to reduced protein levels. The expected amino acid profile is a combination of the amino acid profile of the cell growth medium (i.e., input profile) and the amino acid profile of the commercially available product (i.e., intrinsic tissue profile). A significant, but non-stoichiometric, increase in cellular amino acids following culture medium supplementation with essential amino acids is expected.

[0277] Lipids make up approximately 10% of the dry mass of cultured myoblasts, or approximately 2-5% of the wet mass (a rough estimate based on 70% water). 50 . This corresponds to 20 to 50 mg / g protein. Because store-bought samples will contain skeletal muscle cells, extracellular matrix, and intramuscular adipocytes, it is difficult to predict how the lipid content will compare. On the one hand, the higher protein content of the store-bought sample may result in relatively less lipid per protein; however, intramuscular adipocytes may produce relatively more lipid per protein. Nonetheless, store-bought meat presents about 4 mass% lipid and about 20 mass% protein (wet), and the cellular lipid content is expected to be similar to conventional meat 9 It is expected that the specific lipid ratios will represent a combination of endogenously produced fatty acids and lipids present in the culture medium. Because the culture medium lipids will be provided by fetal bovine serum and the cells are bovine in nature, it is expected that these ratios will closely match those of store-bought beef samples. Lipidomic analysis can also be performed on bovine adipocytes instead of, or in addition to, BSCs.

[0278] Genetic modification - Genetic modification of the cellular approach will be achieved through two mechanisms: transposon-mediated transgenesis or CRISPR-dCas9 gene activation. For constitutive expression, transposon-mediated gene insertion will be used due to its non-viral nature, high efficiency, and demonstrated utility in previous carotenoid work. Specifically, SleepingBeauty, PiggyBac, or Tol2 transposon systems will be considered, depending on the insert size, the requirement for multiple insertions, and ease of cloning. 54-56 For gene activation, the CRISPR-dCas9 system will be used due to its high specificity, efficiency, and ease of use. 57 In this approach, a guide RNA targeting a specific gene is introduced into cells along with a plasmid encoding a deactivated Cas9 (dCas9) protein linked to an activation domain. This triggers transcription, thereby activating the native gene.

[0279] Molecular cloning will be carried out using standard techniques. For gene insertion, the transposable element will contain the gene of interest and the gene to which antibiotics (such as puromycin) are selected to be resistant so that the cells of successful transfection can be selected. Cell transfection will be carried out using lipofectamine 3000 reagent (Thermo Fisher). In brief, cells are cultured to 85% confluence, washed with OptiMEM culture medium, and cultivated together with the transfection reagent containing the purified plasmid. After 6 hours, growth medium will be added to the cells, and after 42 hours, selection pressure (such as puromycin) will be added to the culture medium. Cells will be cultivated under selective pressure for one week, and thereafter will be expressed by immunocytochemistry, using fluorescent tags or polymerase chain reaction (PCR). When polycistronic expression is needed, the gene will be connected by 2A peptide sequences to allow translation of multiple proteins from the RNA single strand encoding multiple genes. 58 In most cases, the 2A sequence will link the green fluorescent protein (GFP) to the expression cassette, allowing expression to be screened by simple fluorescence microscopy. Throughout these studies, cell health and myogenic potential will be verified by observing cell proliferation and differentiation.

[0280] Vitamin C: The genes for vitamin C synthesis are present in bovine muscle cells but are silenced. From a readily available precursor (UDP-glucose) in BSCs, this pathway involves five enzymes ( Figure 1 ): UDP-glucose 6-dehydrogenase (UGDH), UDP glucuronosyltransferase 1 (UGT1A1), aldo-keto reductase family 1 (AKR1A1), calmodulin (RGN), and L-gulono-γ-lactone oxidase (GULO) 59-61 RNA sequencing data from steer muscle showed that UGT1A1 expression was the lowest among these, two orders of magnitude lower. 62 Therefore, UGT1A1 will be the first target. The second least expressed enzyme is GULO, followed by RGN, and therefore these enzymes will be targeted if UGT1A1 engineering proves ineffective. It should be noted that this transcriptomic approach to target selection has a disadvantage, as RNA production does not necessarily correlate with protein production or enzyme activity. This limitation should be kept in mind throughout the process.

[0281] Methods for engineering UGT1A1, RGN, and GULO expression in two cell lines will be explored. In the first approach, CRISPR-dCas9 gene activation will be performed. Transposon-mediated insertion and constitutive expression of these genes can also be performed as previously described for carotenoids. Genetic modification will be performed using Lipofectamine 3000, and vitamin C levels will be analyzed by enzymatic assay (Abcam) according to the manufacturer's instructions.

[0282] Alternative biosynthetic pathways are also relevant for the production of vitamin C. For example, D-threonose 1-dehydrogenase (CDS) and L-galactono-1,4-lactone dehydrogenase (GLDH), which are native to bacteria and synthesize vitamin C from L-galactose, can be expressed in mammalian cells to increase vitamin C production. 59 CDS and GLDH enzymes can be constitutively expressed in cells as a bypass for endogenous vitamin C production.

[0283] Curcumin: From a readily available precursor (tyrosine) in mammalian cells, curcumin synthesis involves four enzymes ( Figure 10 ): tyrosine ammonia lyase (PTAL), 4-coumarate-CoA ligase (4CL), phenylpropionyl-diketolyase-CoA synthetase (DCS), and curcumin synthase (CURS3) 63,64 These genes will be codon optimized, synthesized, and cloned into a polycistronic tetracycline-responsive expression vector. This expression vector will be stably inserted into BSCs by lipofectamine 3000 transfection as previously mentioned. Cells will be cultured and treated with tetracycline during proliferation or after differentiation initiation. Curcumin will be detected by HPLC based on previously reported methods. 65-67 . Briefly, cells will be collected and homogenized by ultrasonic treatment. Berberine will be added to the homogenate as an internal standard, and the solution will be acidified with 6N HCl. Curcumin and berberine will be extracted with ethyl acetate: propanol (9: 1, v / v), centrifuged, and the top layer will be collected for HPLC analysis by Zorbax Eclipse XDB-C18 column (Agilent) separation and 420nm detection. Standard curves of pure curcumin and berberine will be used to accurately quantify sample curcumin levels, which will then be standardized relative to cellular protein. In order to increase cellular curcumin levels, cells can be cultured in medium containing higher levels of tyrosine.

[0284] An alternative pathway using caffeoyl-CoA and feruloyl-CoA as intermediates can be used for endogenous curcumin production in mammalian cells. Similarly, phenylalanine can be used as a precursor for p-coumaroyl-CoA instead of tyrosine.

[0285] Cannabidiol: From a readily available precursor (malonyl-CoA) in mammalian cells, cannabidiol synthesis involves four enzymes ( Figure 10 ): 3,5,7-trioxododecyl-CoA synthase (OLS), oleuronate cyclase (OAC), cannabigerolic acid synthase (CPGAS), and cannabidiolic acid synthase (CBDAS) 68In some embodiments, CPGAS can be replaced by the prenyltransferase NphB, which will have the same activity but improved expression. These genes will be cloned into polycistronic expression vectors and inserted into BSCs as with other vectors. Cells will be cultured, harvested, and homogenized as with curcumin and vitamin C, and cannabidiol will be analyzed by HPLC as previously described. 69 Briefly, the homogenate will be spiked with a known concentration of the internal standard 4,4-dichlorodiphenyltrichloroethane (DDT), the protein will be precipitated with cold acetonitrile, and the organic components will be isolated with n-hexane. The solution will be centrifuged, the upper layer will be separated, dried under nitrogen, and resuspended in acetonitrile. Cannabidiol and DDT will be separated on a C18-PFP HPLC column (ACE) and detected at 220 nm. As with other nutrients, the readings will be normalized to the standard curve, the internal standard, and the cellular protein content.

[0286] Additional targets of interest include D-limonene (a flavor compound that requires only enzymes and has been shown to increase cell proliferation in some cell types), vitamin B 12 , flavor compounds (such as limonene or cinnamaldehyde) and other therapeutic compounds, such as antibiotics.

[0287] Previous carotenoid data showed approximately 35 μg / g protein in BSC. At least this level of vitamin C (which is natural for mammalian cells) is expected in vitro, as are similar levels of curcumin or cannabidiol. Carotenoid production in immortalized mouse muscle cells C2C12 (work performed in conjunction with BSC) reaches up to 500 μg / g protein, and therefore it is expected that appropriate optimization could potentially increase nutrient levels by an order of magnitude.

[0288] Beef liver exhibits approximately 0.3 mg / 100 g of vitamin C (and is approximately 20 wt% protein), so it is expected that protein levels of at least about 15 μg / g in BSC will not provide drawbacks of cytotoxicity or negative cellular effects. 9 Although data do not exist to predict the potential cytotoxicity of curcumin or cannabidiol synthesis in BSCs, previous studies have shown that curcumin in the range of approximately 0.005 to approximately 1 μg / mL in culture medium has no negative effects on myoblasts in vitro. 45 Similarly, studies using a range of cell types have explored cannabidiol treatment in the range of 1–50 μM (0.313–15.65 μg / mL) without mentioning excessive cell death. 70 These correspond to significantly lower levels than those produced for carotenoids, and therefore it is likely that control of curcumin and cannabidiol synthesis in vitro will be required. However, these results do not definitively indicate cytotoxicity of endogenous nutrients, and therefore higher levels are feasible.

[0289] Growth and differentiation of engineered cells: To understand how metabolic engineering affects growth kinetics, cell growth curves will be generated for engineered and control cells and cells treated with pure compounds (i.e., vitamin C, curcumin, and cannabidiol) using dsDNA-based fluorometric analysis (Molecular Probes). In addition, cell cycle analysis will be performed on an NC-3000 image cytometer (ChemoMetec). To explore cellular aging in engineered cells, quantitative PCR will be performed for Pax7, a marker of BSC stemness, throughout the culture of engineered, control, and compound-treated cells. 73 To understand the effect on cell differentiation, cells (engineered cells, control cells, and cells treated with pure compounds) will be differentiated as described above and stained for myosin heavy chain (MHC). For further analysis, quantitative PCR will be performed for the intermediate and terminal myogenic markers myogenic protein and MHC.

[0290] Bioavailability: Nutrient bioavailability depends on the surrounding food matrix 4,74 Therefore, bioavailability analysis of raw and cooked samples of all engineered cells (including carotenoid-producing cells) will be performed by in vitro digestion followed by enterocyte absorption analysis. 4,75 . Briefly, the cells producing nutrients will be cultured, collected, and the cell pellets will be kept "raw" or "cooked" by heating the cell pellets to 100°C for ten minutes. The samples will be added to a saline solution containing 140mM NaCl, 5mM KCl, and 150μM butylated hydroxytoluene. To simulate gastric digestion, HCl will be added to a final pH of 2.0, the sample will be mixed with a solution of 4% w / v pepsin in 0.1M HCl 36:1, and the sample will be incubated in a shaking water bath at 37°C for one hour. The pH of the digest will be raised to 6.9 with NaHCO3, and further intestinal digestion will be performed by mixing the sample with a pancreatin-bile solution (1.2w / v bile extract and 0.2% pancreatin in 0.1M NaHCO3) 7.4:1 and incubating the sample in a shaking water bath at 37°C for two hours.

[0291] Caco-2 intestinal cells (ATCC) will be maintained in a growth medium of DMEM Grotama, 5% FBS and 1% antibiotic-antimycotic, and the cells will be passaged at 70% confluence. To analyze the bioavailability of nutrients in the digest, Caco-2 cells will be cultured in a well plate until confluence. The digest solution will be centrifuged, the supernatant will be diluted 1:4 in Williams' Medium E (Gibco), and the resulting solution will be added to the Caco-2 cell culture after rinsing with PBS. The cells will be cultivated at 37°C for 12 hours, after which the cells will be washed 3 times with PBS, and the Caco-2 cells will be subjected to nutrient analysis as described above, and the nutrients in question will be analyzed as needed. Similar bioavailability analysis will be performed for control cells in DMSO and pure compounds added to Williams' Medium E.

[0292] Lipid oxidation: Vitamin C, curcumin, and cannabidiol have all been reported to provide antioxidant activity 76-78 Because lipid peroxidation is a significant contributor to the deterioration of meat quality during storage, the antioxidant capacity of the supplement may be of particular relevance to the food quality of cultured meat. 79 Therefore, lipid peroxidation analysis will be performed using the thiobarbituric acid reactive substances (TBARS) assay (Cayman Chemical) according to the manufacturer's instructions before and after storage for one week at 4°C and as for the bioavailability analysis before and after "cooking".

[0293] Previous studies have shown that many phytochemicals are more bioavailable when derived from non-plant sources because the compounds are not trapped in the cellulose network. 80 Therefore, high bioavailability of endogenously expressed nutrients, including carotenoids, vitamin C, curcumin, and cannabidiol, is expected. Increased iron bioavailability in vitamin C-producing cells is expected. 81 Decreased lipid oxidation in all cell samples expected to produce vitamin C, curcumin, and cannabidiol 76-78 .

[0294] References:

[0295] 1. Elango, R., Ball, RO & Pencharz, PBRecent advances in determining protein and amino acid requirements in humans. British Journal of Nutrition 108, S22-S30 (2012).

[0296] 2.Matsui,T.Vitamin C nutrition in cattle.Asian-Australasian journalof animal sciences 25,597-605(2012).

[0297] 3.Chang-Shu Liu, Raymond P.Glahn,§and&Rui Hai Liu*, #.Assessment ofCarotenoid Bioavailability of Whole Foods Using a Caco-2 Cell Culture ModelCoupled with an in Vitro Digestion.(2004).doi:10.1021 / JF040028K

[0298] 4.Yun,S.,Habicht,J.-P.,Miller,D.D.&Glahn,R.P.An In Vitro Digestion / Caco-2 Cell Culture System Accurately Predicts the Effects of Ascorbic Acidand Polyphenolic Compounds on Iron Bioavailability in Humans.The Journal ofNutrition 134,2717-2721(2004).

[0299] 5.Wyness,L.,Weichselbaum,E.,O'Connor,A.,Williams,E.B.,Benelam,B.,Riley,H.&Stanner,S.Red meat in the diet:an update.Nutrition Bulletin 36,34-77(2011).

[0300] 6.Purchas,R.W.,Wilkinson,B.H.P.,Carruthers,F.&Jackson,F.A comparisonof the nutrient content of uncooked and cooked lean from New Zealand beef andlamb.Journal of Food Composition and Analysis 35,75-82(2014).

[0301] 7. D.,Barański,M.,Seal,C.,Sanderson,R.,Benbrook,C.,Steinshamn,H.,Gromadzka-Ostrowska,J., E., K.,Eyre,M.,Cozzi,G.,Krogh Larsen,M.,Jordon,T.,Niggli,U.,Sakowski,T.,Calder,P.C.,Burdge,G.C.,Sotiraki,S.,Stefanakis,A.,et al.Composition differences between organicand conventional meat:a systematic literature review and meta-analysis.British Journal of Nutrition 115,994-1011(2016).

[0302] 8.Rizzo,G.,Laganà,A.,Rapisarda,A.,La Ferrera,G.,Buscema,M.,Rossetti,P.,Nigro,A.,Muscia,V.,Valenti,G.,Sapia,F.,Sarpietro,G.,Zigarelli,M.,Vitale,S.,Rizzo,G.,Laganà,A.S.,Rapisarda,A.M.C.,La Ferrera,G.M.G.,Buscema,M.,Rossetti,P.,et al.Vitamin B12 among Vegetarians:Status,Assessment andSupplementation.Nutrients 8,767(2016).

[0303] 9.Wood,J.D.Meat Composition and Nutritional Value.Lawrie′s MeatScience 635-659(2017).doi:10.1016 / B978-0-08-100694-8.00020-0

[0304] 10.Godfray,H.C.J.,Aveyard,P.,Garnett,T.,Hall,J.W.,Key,T.J.,Lorimer,J.,Pierrehumbert,R.T.,Scarborough,P.,Springmann,M.&Jebb,S.A.Meat consumption,health,and the environment.Science(New York,N.Y.)361,eaam5324(2018).

[0305] 11.Feskens,E.J.M.,Sluik,D.&van Woudenbergh,G.J.Meat Consumption,Diabetes,and Its Complications.Current Diabetes Reports 13,298-306(2013).

[0306] 12.Schwingshackl,L.,Hoffmann,G.,Lampousi,A.-M.,Knüppel,S.,Iqbal,K.,Schwedhelm,C.,Bechthold,A.,Schlesinger,S.&Boeing,H.Food groups and risk oftype 2 diabetes mellitus:a systematic review and meta-analysis of prospectivestudies.European Journal of Epidemiology 32,363-375(2017).

[0307] 13.Alshahrani,S.,Fraser,G.,Sabaté,J.,Knutsen,R.,Shavlik,D.,Mashchak,A.,Lloren,J.,Orlich,M.,Alshahrani,S.M.,Fraser,G.E.,Sabaté,J.,Knutsen,R.,Shavlik,D.,Mashchak,A.,Lloren,J.I.&Orlich,M.J.Red and Processed Meat andMortality in a Low Meat Intake Population.Nutrients 11,622(2019).

[0308] 14.Abete,I.,Romaguera,D.,Vieira,A.R.,Lopez de Munain,A.&Norat,T.Association between total,processed,red and white meat consumption and all-cause,CVD and IHD mortality:a meta-analysis ofcohort studies.British JournalofNutrition 112,762-775(2014).

[0309] 15.Chan,D.S.M.,Lau,R.,Aune,D.,Vieira,R.,Greenwood,D.C.,Kampman,E.&Norat,T.Red and Processed Meat and Colorectal Cancer Incidence:Meta-Analysisof Prospective Studies.PLoS ONE 6,e20456(2011).

[0310] 16.Wang,X.,Lin,X.,Ouyang,Y.Y.,Liu,J.,Zhao,G.,Pan,A.&Hu,F.B.Red andprocessed meat consumption and mortality:dose-response meta-analysis ofprospective cohort studies.Public Health Nutrition 19,893-905(2016).

[0311] 17.Wolk,A.Potential health hazards of eating red meat.Journal ofInternal Medicine 281,106-122(2017).

[0312] 18.Klurfeld,D.M.Research gaps in evaluating the relationship of meatand health.Meat Science 109,86-95(2015).

[0313] 19.Hoekstra,A.Y.&Mekonnen,M.M.The water footprint ofhumanity.Proceedings of the National Academy of Sciences of the United Statesof America 109,3232-7(2012).

[0314] 20.Datar,I.&Betti,M.Possibilities for an in vitro meat productionsystem.Innovative Food Science&Emerging Technologies 11,13-22(2010).

[0315] 21.Post,M.J.Cultured meat from stem cells:Challenges andprospects.Meat Science 92,297-301(2012).

[0316] 22.Mattick,C.S.,Landis,A.E.,Allenby,B.R.&Genovese,N.J.AnticipatoryLife Cycle Analysis of In Vitro Biomass Cultivation for Cultured MeatProduction in the United States.Environmental Science&Technology 49,11941-11949(2015).

[0317] 23.Thorrez,L.&Vandenburgh,H.Challenges in the quest for‘clean meat’.Nature Biotechnology 37,215-216(2019).

[0318] 24.Kon,S.K.&Porter,J.W.G.The Intestinal Synthesis of Vitamins in theRuminant.Vitamins and Hormones 12,53-68(1954).

[0319] 25.Mosley,E.E.,Powell,G.L.,Riley,M.B.&Jenkins,T.C.Microbialbiohydrogenation of oleic acid to trans isomers in vitro.Journal of LipidResearch 43,290-296(2002).

[0320] 26.Nielsen,J.Yeast cell factories on the horizon:Metabolicengineering in yeast gets increasingly more versatile.Science 349,1050-1051(2015).

[0321] 27.Heider,S.A.E.&Wendisch,V.F.Engineering microbial cell factories:Metabolic engineering of Corynebacterium glutamicum with a focus on non-natural products.Biotechnology Journal 10,1170-1184(2015).

[0322] 28.Sack,M.,Rademacher,T.,Spiegel,H.,Boes,A.,Hellwig,S.,Drossard,J.,Stoger,E.&Fischer,R.From gene to harvest:Insights into upstream processdevelopment for the GMP production of a monoclonal antibody in transgenictobacco plants.Plant Biotechnology Journal 13,1094-1105(2015).

[0323] 29.Davy,A.M.,Kildegaard,H.F.&Andersen,M.R.Cell FactoryEngineering.Cell Systems 4,262-275(2017).

[0324] 30.Ceroni,F.&Ellis,T.The challenges facing synthetic biology ineukaryotes.(2018).doi:10.1038 / s41580-018-0013-2

[0325] 31.Walsh,G.Biopharmaceutical benchmarks 2018.Nature Publishing Group36,(2018).

[0326] 32.Giddings,G.Transgenic plants as protein factories.Current Opinionin Biotechnology 12,450-454(2001).

[0327] 33.Stice,C.P.,Xia,H.&Wang,X.-D.Tomato lycopene prevention of alcoholicfatty liver disease and hepatocellular carcinoma development.Chronic Diseasesand Translational Medicine 4,211-224(2018).

[0328] 34.Meléndez-Martínez,A.J.,Mapelli-Brahm,P.&Stinco,C.M.The colourlesscarotenoids phytoene and phytofluene:From dietary sources to their usefulnessfor the functional foods and nutricosmetics industries.Journal of FoodComposition and Analysis 67,91-103(2018).

[0329] 35.Kim,S.-W.,Kim,J.-B.,Jung,W.-H.,Kim,J.-H.&Jung,J.-K.Over-productionofβ-carotene from metabolically engineered Escherichia coli.BiotechnologyLetters 28,897-904(2006).

[0330] 36.Fiedor,J.&Burda,K.Potential role of carotenoids as antioxidants inhuman health and disease.Nutrients 6,466-88(2014).

[0331] 37.Falowo,A.B.,Fayemi,P.O.&Muchenje,V.Natural antioxidants againstlipid-protein oxidative deterioration in meat and meat products:A review.FoodResearch International 64,171-181(2014).

[0332] 38.Sart,S.,Song,L.&Li,Y.Controlling redox status for stem cellsurvival,expansion,and differentiation.Oxidative Medicine and CellularLongevity 2015,(2015).

[0333] 39.Intlekofer,A.M.&Finley,L.W.S.Metabolic signatures of cancer cellsand stem cells.Nature Metabolism 1,177-188(2019).

[0334] 40.Kornienko,J.S.,Smirnova,I.S.,Pugovkina,N.A.,Ivanova,J.S.,Shilina,M.A.,Grinchuk,T.M.,Shatrova,A.N.,Aksenov,N.D.,Zenin,V.V.,Nikolsky,N.N.&Lyublinskaya,O.G.High doses of synthetic antioxidants induce prematuresenescence in cultivated mesenchymal stem cells.Scientific Reports 9,(2019).

[0335] 41.Duran,B.O.S.,Góes,G.A.,Zanella,B.T.T.,Freire,P.P.,Valente,J.S., R.A.S.,Fernandes,A.,Mareco,E.A.,Carvalho,R.F.&Dal-Pai-Silva,M.Ascorbic acid stimulates the in vitro myoblast proliferation and migrationof pacu(Piaractus mesopotamicus).Scientific Reports 9,(2019).

[0336] 42.Roberto,D.,Micucci,P.,Sebastian,T.,Graciela,F.&Anesini,C.AntioxidantActivity of Limonene on Normal Murine Lymphocytes:Relation to H2O2 Modulation and Cell Proliferation.Basic&Clinical Pharmacology&Toxicology(2009).doi:10.1111 / j.1742-7843.2009.00467.x

[0337] 43.Kaminski,J., A.,Aires,V.,Limagne,E.,Tili,E.,Michaille,J.J.&Latruffe,N.Resveratrol initiates differentiation of mouse skeletal muscle-derived C2C12 myoblasts.Biochemical Pharmacology 84,1251-1259(2012).

[0338] 44.Iannotti,F.A.,Silvestri,C.,Mazzarella,E.,Martella,A.,Calvigioni,D.,Piscitelli,F.,Ambrosino,P.,Petrosino,S.,Czifra,G., T.,Harkany,T.,Taglialatela,M.&Di Marzo,V.The endocannabinoid 2-AG controls skeletal musclecell differentiation via CB1 receptor-dependent inhibition of Kv7channels.Proceedings of the National Academy of Sciences of the United Statesof America 111,(2014).

[0339] 45.Thaloor,D.,Miller,K.J.,Gephart,J.,Mitchell,P.O.&Pavlath,G.K.Systemic administration of the NF-κB inhibitor curcumin stimulates muscleregeneration after traumatic injury.American Journal of Physiology-CellPhysiology 277,(1999).

[0340] 46.Simsa,R.,Yuen,J.,Stout,A.,Rubio,N.,Fogelstrand,P.&Kaplan,D.L.Extracellular Heme Proteins Influence Bovine Myosatellite CellProliferation and the Color of Cell-Based Meat.Foods 2019,Vol.8,Page 521 8,521(2019).

[0341] 47.Sengupta,S.,Park,S.-H.,Patel,A.,Carn,J.,Lee,K.&Kaplan,D.L.Hypoxiaand Amino Acid Supplementation Synergistically Promote the Osteogenesis ofHuman Mesenchymal Stem Cells on Silk Protein Scaffolds.Tissue EngineeringPart A 16,3623-3634(2010).

[0342] 48.Cohen,S.A.Amino Acid Analysis Using Precolumn Derivatization with6-Aminoquinolyl-NHydroxysuccinimidyl Carbamate.in Amino Acid AnalysisProtocols 039-047(Humana Press).doi:10.1385 / 1-59259-047-0:039

[0343] 49.Nygren,H., T.,Castillo,S., T.& M.Liquid Chromatography-Mass Spectrometry(LC-MS)-Based Lipidomics for Studiesof Body Fluids and Tissues.in 247-257(Humana Press,2011).doi:10.1007 / 978-1-61737-985-7_15

[0344] 50.Blondelle,J.,de Barros,J.P.P.,Pilot-Storck,F.&Tiret,L.Targetedlipidomic analysis of myoblasts by GC-MS and LC-MS / MS.in Methods in MolecularBiology 1668,39-60(Humana Press Inc.,2017).

[0345] 51.Krumpochova,P.,Bruyneel,B.,Molenaar,D.,Koukou,A.,Wuhrer,M.,Niessen,W.M.A.&Giera,M.Amino acid analysis using chromatography-massspectrometry:An inter platform comparison study.Journal of Pharmaceutical andBiomedical Analysis 114,398-407(2015).

[0346] 52. M.,Liebisch,G.&Ekroos,K.Lipidomic Analysis.AnalyticalChemistry 90,4249-4257(2018).

[0347] 53.Abraham,A.,Dillwith,J.W.,Mafi,G.G.,VanOverbeke,D.L.&Ramanathan,R.Metabolite Profile Differences between Beef Longissimus and Psoas Musclesduring Display.Meat and Muscle Biology 1,18(2017).

[0348] 54.Kowarz,E., D.&Marschalek,R.Optimized Sleeping Beautytransposons rapidly generate stable transgenic cell lines.BiotechnologyJournal 10,647-653(2015).

[0349] 55.Alessio,A.P.,Fili,A.E.,Garrels,W.,Forcato,D.O.,Olmos Nicotra,M.F.,Liaudat,A.C.,Bevacqua,R.J.,Savy,V.,Hiriart,M.I.,Talluri,T.R.,Owens,J.B.,Ivics,Z.,Salamone,D.F.,Moisyadi,S.,Kues,W.A.&Bosch,P.Establishment of cell-based transposon-mediated transgenesis in cattle.Theriogenology 85,1297-1311.e2(2016).

[0350] 56.Kawakami,K.Tol2:a versatile gene transfer vector invertebrates.Genome Biology 8,S7(2007).

[0351] 57.Sander,J.D.&Joung,J.K.CRISPR-Cas systems for editing,regulatingand targeting genomes.Nature Biotechnology 32,347-355(2014).

[0352] 58.Szymczak,A.L.&Vignali,D.A.Development of 2A peptide-basedstrategies in the design of multicistronic vectors.Expert Opinion onBiological Therapy 5,627-638(2005).

[0353] 59.Kanehisa,M.&Goto,S.KEGG:Kyoto Encyclopedia of Genes andGenomes.Nucleic Acids Research 28,27-30(2000).

[0354] 60.Reynolds,T.H.,Pak,Y.,Harris,T.E.,Manchester,J.,Barrett,E.J.&Lawrence,J.C.Effects of Insulin and Transgenic Overexpression of UDP-glucosePyrophosphorylase on UDP-glucose and Glycogen Accumulation in Skeletal MuscleFibers.Journal of Biological Chemistry 280,5510-5515(2005).

[0355] 61.Oikari,S., T.&Tammi,M.Borate-aided anion exchange high-performance liquid chromatography of uridine diphosphate-sugars in brain,heart,adipose and liver tissues.Journal of ChromatographyA 1323,82-86(2014).

[0356] 62.Lee,H.-J.,Jang,M.,Kim,H.,Kwak,W.,Park,W.,Hwang,J.Y.,Lee,C.-K.,Jang,G.W.,Park,M.N.,Kim,H.-C.,Jeong,J.Y.,Seo,K.S.,Kim,H.,Cho,S.&Lee,B.-Y.Comparative Transcriptome Analysis of Adipose Tissues Reveals that ECM-Receptor Interaction Is Involved in the Depot-Specific Adipogenesis inCattle.PLoS ONE 8,e66267(2013).

[0357] 63.Oyarce,P.,De Meester,B.,Fonseca,F.,de Vries,L.,Goeminne,G.,Pallidis,A.,De Rycke,R.,Tsuji,Y.,Li,Y.,Van den Bosch,S.,Sels,B.,Ralph,J.,Vanholme,R.&Boerjan,W.Introducing curcumin biosynthesis in Arabidopsisenhances lignocellulosic biomass processing.Nature Plants 5,225-237(2019).

[0358] 64.Katsuyama,Y.,Kita,T.&Horinouchi,S.Identification andcharacterization of multiple curcumin synthases from the herb Curcumalonga.FEBSLetters 583,2799-2803(2009).

[0359] 65.Ireson,C.,Orr,S.,Jones,D.J.L.,Verschoyle,R.,Lim,C.K.,Luo,J.L.,Howells,L.,Plummer,S.,Jukes,R.,Williams,M.,Steward,W.P.&Gescher,A.Characterization of metabolites of the chemopreventive agent curcumin inhuman and rat hepatocytes and in the rat in vivo,and evaluation of theirability to inhibit phorbol ester-induced prostaglandinE2production.CancerResearch 61,1058-1064(2001).

[0360] 66.Gugulothu,D.,Desai,P.&Patravale,V.A versatile liquidchromatographic technique for pharmacokinetic estimation of curcumin in humanplasma.Journal of Chromatographic Science 52,872-879(2014).

[0361] 67.Pan,M.-H.,Huang,T.-M.&Lin,J.-K.Biotransformation of CurcuminThrough Reduction and Glucuronidation in Mice.Drug Metabolism and Disposition27,(1999).

[0362] 68.Carvalho, Hansen,E.H.,Kayser,O.,Carlsen,S.&Stehle,F.Designingmicroorganisms for heterologous biosynthesis of cannabinoids.FEMS YeastResearch 17,(2017).

[0363] 69.Zgair,A.,Wong,J.C.M.,Sabri,A.,Fischer,P.M.,Barrett,D.A.,Constantinescu,C.S.&Gershkovich,P.Development of a simple and sensitive HPLC-UV method for the simultaneous determination of cannabidiol andδ9-tetrahydrocannabinol in rat plasma.Journal of Pharmaceutical and BiomedicalAnalysis 114,145-151(2015).

[0364] 70.Burstein,S.Cannabidiol(CBD)and its analogs:a review of theireffects on inflammation.Bioorganic&Medicinal Chemistry 23,1377-1385(2015).

[0365] 71.Carvalho, Hansen,E.H.,Kayser,O.,Carlsen,S.&Stehle,F.Designingmicroorganisms for heterologous biosynthesis of cannabinoids.FEMSyeastresearch 17,(2017).

[0366] 72.Ko,Y.,Ashok,S.,Ainala,S.K.,Sankaranarayanan,M.,Chun,A.Y.,Jung,G.Y.&Park,S.Coenzyme B 12 can be produced by engineered Escherichia coli underboth anaerobic and aerobic conditions.Biotechnology Journal 9,1526-1535(2014).

[0367] 73.Ding,S.,Swennen,G.N.M.,Messmer,T.,Gagliardi,M.,Molin,D.G.M.,Li,C.,Zhou,G.&Post,M.J.Maintaining bovine satellite cells stemness through p38pathway.Scientific Reports 8,10808(2018).

[0368] 74.Etcheverry,P.,Grusak,M.A.&Fleige,L.E.Application ofin vitrobioaccessibility and bioavailability methods for calcium,carotenoids,folate,iron,magnesium,polyphenols,zinc,and vitamins B6,B12,D,and E.Frontiers inPhysiology 3,317(2012).

[0369] 75.Liu,C.-S.,Glahn,R.P.,Rui,A.&Liu,H.Assessment of CarotenoidBioavailability of Whole Foods Using a Caco-2 Cell Culture Model Coupled withan in Vitro Digestion.(2004).doi:10.1021 / jf040028k

[0370] 76.Jayaprakasha,G.K.,Jaganmohan Rao,L.&Sakariah,K.K.Antioxidantactivities of curcumin,demethoxycurcumin and bisdemethoxycurcumin.FoodChemistry 98,720-724(2006).

[0371] 77.Padayatty,S.J.,Katz,A.,Wang,Y.,Eck,P.,Kwon,O.,Lee,J.-H.,Chen,S.,Corpe,C.,Dutta,A.,Dutta,S.K.&Levine,M.Vitamin C as an Antioxidant:Evaluationof Its Role in Disease Prevention.Journal of the American College ofNutrition 22,18-35(2003).

[0372] 78.Borges,R.,Batista,J.,Viana,R.,Baetas,A.,Orestes,E.,Andrade,M.,Honório,K.&da Silva,A.Understanding the Molecular Aspects of Tetrahydrocannabinoland Cannabidiol as Antioxidants.Molecules 18,12663-12674(2013).

[0373] 79.Jiang,J.&Xiong,Y.L.Natural antioxidants as food and feed additivesto promote health benefits and quality of meat products:Areview.Meat Science120,107-117(2016).

[0374] 80.Desmarchelier,C.&Borel,P.Overview of carotenoid bioavailabilitydeterminants:From dietary factors to host genetic variations.Trends in FoodScience&Technology 69,270-280(2017).

[0375] 81.Lynch,S.R.&Cook,J.D.Interaction of Vitamin C and Iron.Annals ofthe New York Academy of Sciences 355,32-44(1980).

[0376] 82.Huri,P.Y.,Wang,A.,Spector,A.A.&Grayson,W.L.Multistage Adipose-Derived Stem Cell Myogenesis:An Experimental and Modeling Study.Cellular andMolecular Bioengineering 7,497-509(2014).

[0377] 83.Devasagayam,T.P.A.,Boloor,K.K.&Ramasarma,T.Minireview Methods forestimating lipid peroxidation:An analysis of merits and demerits.IndianJournal of Biochemistry&Biophysics 40,(2003).

[0378] 84.DeCicco RePass,M.A.,Chen,Y.,Lin,Y.,Zhou,W.,Kaplan,D.L.&Ward,H.D.Novel Bioengineered Three-Dimensional Human Intestinal Model for Long-Term Infection of Cryptosporidium parvum.Infection and immunity 85,e00731-16(2017).

[0379] 85.Ma,J.,Huang,H.,Xie,Y.,Liu,Z.,Zhao,J.,Zhang,C.,Jia,Y.,Zhang,Y.,Zhang,H.,Zhang,T.&Ju,J.Biosynthesis of ilamycins featuring unusual buildingblocks and engineered production of enhanced anti-tuberculosis agents.NatureCommunications 8,(2017).

[0380] 86.Wang,Z.,Li,H.,Guo,R.,Wang,Q.&Zhang,D.Antioxidants inhibit advancedglycosylation end-product-induced apoptosis by downregulation of miR-223 inhuman adipose tissue-derived stem cells.Scientific Reports 6,(2016).

[0381] 87.Zhang,L.,Xia,H.,Han,Q.&Chen,B.Effects of antioxidant gene therapyon the development of diabetic retinopathy and the metabolic memoryphenomenon.Graefe's Archive for Clinical and Experimental Ophthalmology 253,249-259(2014).

[0382] 88. Quan, M., Cai, C., Valencia, G., Aranda, J. & Beharry, K. MnTBAP or CatalaseIs More Protective against Oxidative Stress in Human Retinal Endothelial Cells Exposed to Intermittent Hypoxia than Their Co-Administration (EUK-134). Reactive Oxygen Species(2017).doi:10.20455 / ros.2017.801

[0383] Example 3

[0384] Oral administration is an ideal form of drug delivery due to its convenience, non-invasiveness, and safety. However, oral delivery, especially of protein therapeutics, presents significant challenges in terms of drug stability, release kinetics, and permeability. 1 To address these challenges, highly engineered, complex pharmaceutical formulations have been designed, but these formulations are expensive to develop and manufacture, and still have efficacy issues. To address these issues, the embodiments described in this example show an approach based on recent advances in mammalian cell engineering and the use of in vitro tissue engineered muscle and fat to produce food for human consumption (referred to as "cultured meat"). Specifically, the cellular level control available in cultured meat production offers the potential to tailor food composition to achieve diverse outcomes, from personalized nutrition and improved public health, to personalized medicine and drug delivery. We have recently demonstrated this possibility by engineering the endogenous synthesis of antioxidant phytonutrients (carotenoids) in bovine muscle stem cells to impart novel micronutrient and functional values ​​to cell cultured foods. 2 . See Example 1. This example describes engineering animal muscle cells to synthesize therapeutic agents in disease-responsive edible formulations. These "therapeutic foods" will provide a novel form of oral (food-based) drug delivery that can provide improved drug absorption, patient compliance, drug activity, and cost savings. Therapeutic foods can provide significant benefits in terms of patient compliance, reduced drug costs, and improved pharmacokinetic / pharmacodynamic outcomes.

[0385] Cell Engineering. (a) Drug Production in Mammalian Cells: We will engineer bovine muscle cells grown in defined serum-free medium to synthesize three drug types to demonstrate a broad approach. These will be: 1) a physiochemically stable anti-TNFα nanobody, V565, which targets IBD, and 2) a proteolytically stable antimicrobial peptide (AMP), here called AMP16, which is effective against Salmonella infection. 3,4 . The cells will be engineered using the methods described herein and molecular biology techniques known in the art. The yield, stability, and activity / bioavailability of cell-encapsulated drugs with or without heat treatment (e.g., cooking) will be analyzed. The result will be the production of therapeutic compounds in mammalian cells. (b) Optimizing cell-encapsulated therapeutics: Drug yield will be adjusted through metabolic engineering. To optimize delivery, cells will be engineered to produce adjuvants for increasing the stability of protein drugs. Specifically, recombinase-mediated cassette exchange (RMCE) will be used to engineer the production of the silk enzyme inhibitor pepstatin into the drug-producing cells to mitigate drug breakdown in the gastric environment. 22 The result would be controlled levels of drug synthesis and improved pharmacokinetic profiles.

[0386] Engineering disease-responsive drug formulations: Drug activity will be disease-responsive by exploiting the elevated levels of specific digestive enzymes present during disease. 5,6 Specifically, for V565, a previously reported “antibody masking” technique will be employed, in which V565 will be linked to its epitope via a flexible peptide linker rich in trypsin cleavage sites, lysine and arginine. 7 Upon exposure to a trypsin-rich gut (a hallmark of IBD), the linker will be cleaved and V565 will be activated; however, in a non-inflamed gut, drug activity will be reduced. Unmasked efficacy will be analyzed by in vitro digestion in a trypsin-rich condition nanobody binding affinity assay. 7 For AMP16, a similar approach would be to express a peptide as a long chain containing AMP16 repeats linked by an elastase-cleavable domain, NPV. 8. When exposed to increased levels of elastase, a characteristic of Salmonella enterica infection, increased linker cleavage will release more AMP16, thereby increasing activity. The cleavability and antibiotic effect of the linked AMP16 peptide will be analyzed by in vitro digestion in elastase-rich conditions and application to Salmonella enterica cultures. To explore the possibility of a single therapeutic food acting on multiple lesions in a disease-responsive manner, cells will be engineered to produce two disease-responsive drugs. In vitro digestion will be performed in an enzyme-rich environment, and the activity of the two drugs will be tested to determine the specificity of the engineered disease-responsive system. The result will be a multi-drug disease-responsive formulation that can respond to multiple lesions and demonstrates the flexibility of these systems.

[0387] In vitro evaluation of drug bioactivity: Drug bioactivity will be analyzed using a previously described 3D intestinal tissue model that was engineered to mimic inflammatory disease (i.e., IBD) and allows for the incorporation of gut-colonizing bacteria (i.e., Salmonella enterica) and immune cells (i.e., macrophages, the proposed target of V565). 9-12 Thus, the effects of anti-inflammatory and antibiotic drugs will be evaluated using this system. Trypsin and elastase levels will be modulated to mimic the protease profiles of IBD and Salmonella enterica gastroenteritis, respectively, and drug activity will be analyzed in an inflamed tissue model and in a model inoculated with Salmonella enterica compared to a standard oral formulation as a control. The relative effects of individual and combined engineering strategies will be evaluated.

[0388] Oral administration of therapeutics offers significant advantages over alternatives (e.g., parenteral delivery) in terms of patient compliance, comfort, safety, and convenience. Consequently, it is the preferred method of drug delivery and, in fact, represents more than half of the new drugs recently approved by the FDA. 13 However, significant challenges in oral drug delivery of biological (e.g., protein or peptide) therapeutics mean that fewer than 5% of FDA-approved peptide therapeutics are deliverable by the oral route, despite growing interest in their potential. 14,15 These challenges include a harsh gastrointestinal environment and limited intestinal absorption, resulting in limited bioavailability (<1%). 13 In order to reconcile the promise of therapeutic biologics with the challenges of their oral delivery, novel drug formulations are needed. In addition to drug stability, bioavailability of biologics and small molecule therapeutics can be significantly affected by concomitant food ingestion, which can also complicate clinical formulations. 16Thus, drug formulations incorporated into defined food matrices may provide increased pharmacological consistency and predictability, thereby improving patient outcomes. Finally, the promising possibility of disease-responsive “smart” drug delivery systems that can selectively target active disease has garnered interest in recent years17 ,18 These drugs will become active only when needed (i.e., when presented to the diseased environment) and can therefore improve pharmacological outcomes by reducing off-target effects, avoiding excessive drug exposure, and regulating release to steady-state levels. The edible therapeutic system described herein will explore the potential of therapeutic cell-based foods to target all three of these drug targets, with improved bioavailability and disease specificity of biological and small molecule therapeutics.

[0389] Scientific Premise - The bioavailability of many oral drugs is significantly affected by concomitant food intake 19-21 This leads to considerable pharmacokinetic uncertainty. 22 The possibility of delivering drugs as part of a defined food matrix provides tight control over food-drug interactions and, therefore, drug delivery. Secondly, the ability of mammalian cells to synthesize a wide variety of proteins and metabolites allows for complex formulations that address obstacles associated with oral delivery while also eliminating expensive purification steps for extraction, stabilization, and formulation of oral therapeutics. 23 For example, through metabolic engineering, food-based delivery systems can utilize the simultaneous synthesis of drug formulations that stabilize drug delivery within mammalian cells, digestive enzyme inhibitors (to improve intestinal stability of ingested drugs), and permeation enhancers to improve absorption. 3 At the same time, the "natural liposome" of the cell lipid bilayer provides further control of stability and delivery 24 Finally, when engineered into environmentally responsive systems, these therapeutic foods can provide high specificity for disease. 5 For example, many pathologies induce alterations in the intestinal enzyme profile, and thus protease-triggered drug activity can enhance drug release / bioavailability to achieve disease-responsive activity against a range of pathologies. 5,6 .

[0390] Therapeutic Foods - In addition to the aforementioned benefits, edible cultured meat-based therapeutic formulations will also provide an entirely new class of drug delivery systems that could be of significant use to patients and clinicians alike. For example, the most common form of medication non-compliance in the elderly is under-dosing, primarily due to forgetfulness and polypharmacy. 25,26The possibility of directly combining medicine and diet, which are inseparable, into a more ingrained and enjoyable daily ritual would help alleviate these problems. Additionally, the possibility of formulating foods with complex combinations of disease-responsive medications could alleviate the problems presented by polypharmacy. Finally, dysphagia with solid oral medications exists across age groups, and temporary oral medication modifications (i.e., crushing, cutting, dispersing in liquids, etc.) can increase variability and pose risks to patients. 27 Edible formulations would help alleviate these issues by making drug ingestion a simple matter of chewing food. Cultured meat is a promising emerging technology that has the potential to reduce the environmental, ethical, and public health issues associated with meat production. Specifically, speculative life cycle analyses estimate that cultured meat could emit 78-96% less greenhouse gases, use 99% less land, use 82-96% less water, and use 7-45% less energy than a range of livestock species. 28 .

[0391] Recently, drug production in plants has been proposed as a means of producing edible therapeutics, including antibodies or vaccines. 23,32 For example, vaccines against hepatitis B, Norwalk virus, rabies, and HIV have been expressed in tobacco plants, potatoes, lettuce, tomatoes, and corn, and human clinical trials have demonstrated the efficacy of edible vaccines in genetically modified potatoes. 33,34 The proposed benefits of these products largely center around reducing costs by eliminating purification steps and leveraging the massive scale of agricultural production. However, despite promising early results across multiple drug types, variability in drug concentrations and differences in glycosylation patterns in plants relative to humans have limited further development. 32 Edible therapeutics based on mammalian cells offer a potential way to overcome these obstacles. Specifically, the high degree of control that will exist in cultured meat production can circumvent this variability because the cells will be grown in a controlled culture environment without variables that affect crops (such as weather patterns). Furthermore, the use of animal cells will facilitate correct glycosylation. Finally, encapsulating and delivering therapeutics in whole animal cells is an unexplored idea with vast white space and the potential for innovation in both targets and applications.

[0392] The cellular level control inherent in cultured meat (at the gene, transcript, protein, and metabolic levels) provides the opportunity to modulate composition for a variety of targets, enabling the creation of entirely novel food products with modulated meat quality and added functionality. To demonstrate this, we recently engineered mammalian cells with metabolic pathways for the synthesis of three different carotenoids, essential micronutrients naturally occurring in many plants and some prokaryotes, but not in animals. 2Ultimately, novel food functionality in cultured meat products could have applications in nutrition (general and personalized), food quality (i.e., flavor, texture, and other sensory properties), diet-related diseases (e.g., diabetes or colorectal cancer), therapeutics (as explored in this proposal), edible vaccines, or other enhancements not contemplated here.

[0393] Bovine muscle and adipocyte culture - To date, our group has explored several topics directly related to this proposal. From a culture system perspective, we have established protocols for generating populations of primary bovine satellite cells (BSCs) that are pure (ubiquitous expression of the satellite cell marker paired-box seven (Pax7) in imaging cells) (Figure 13A) and myogenic, capable of generating long multinucleated myotubes that express myosin heavy chain (MHC) and form the actin / myosin contractile apparatus (Figure 13B). 42,43 In addition, we have confirmed a serum-free, growth factor-based medium formulation for BSC culture (B8) based on a previously reported formulation. 44 , and superior BSC growth was observed in B8 medium compared to serum-containing growth medium (GM) (Figure 13C). We have also established a method for adipogenic transdifferentiation of myogenic BSCs into lipid-accumulating adipocytes by treating the cells with a mixture of free fatty acids (FFA) (Figure 13D). We have demonstrated robust and regulated lipid accumulation using this method (Figure 13E), indicating that a single cell population (i.e., bovine satellite cells) can be used to generate muscle and fat for cultured meat, which can significantly simplify the industrial production process. 45 This work demonstrates extensive experience in the culture of relevant bovine muscle precursor cells.

[0394] Metabolic Engineering of Bovine Satellite Cells - From the perspective of synthetic biology and metabolic engineering, we engineered BSCs to endogenously synthesize the carotenoids phytoene, lycopene, and β-carotene 2 These nutrients are attractive targets for several reasons. First, they each offer unique nutritional value; phytoene has been proposed to act as a UV photoprotectant, lycopene has been shown to reduce hepatocellular carcinoma and fatty liver disease, and beta-carotene is an essential vitamin A precursor in the human diet. 46-48 Second, all three compounds are antioxidant factors 49 This is particularly relevant for red meat, as the key mechanistic link between red or processed meat intake and colorectal cancer is lipid oxidation. 50 The antioxidant properties of these compounds also offer value in extending the shelf life of meat, as lipid oxidation is the main cause of non-microbiological deterioration over time. 51 .

[0395] The cells were engineered using Sleeping Beauty transposon-mediated transgenesis to express green fluorescent protein (GFP) alone without producing any carotenoids (pGFP), CrtB and GFP (pCrtB) that produce phytoene, CrtB, CrtI, and GFP (pCrtB / I) that produce phytoene and lycopene, or CrtB, CrtI, CrtY, and GFP (pCrtB / I / Y) that produce phytoene, lycopene, and β-carotene. The polycistronic nature of these vectors enabled the use of GFP expression as a marker for vector integration and gene expression. All cells also expressed a puromycin resistance gene to enable selection of engineered cells. We first confirmed the successful synthesis of all three carotenoids in the cells (Figure 14A). Next, we showed that carotenoid levels can be modulated by increasing puromycin concentration (i.e., increasing the selection pressure to select cells in which the transgene is located in a more transcriptionally active locus) or by adding ketoconazole (a small molecule that inhibits cholesterol synthesis and competes with carotenoids for shared precursor metabolic pathways) to the culture medium (Figure 14B). We showed that the food functionality reduced lipid oxidation in vitro (Figure 14C). Together with the previous carotenoid work, we have engineered cells to express enzymes involved in the synthesis of cannabidiol, a small molecule anti-inflammatory and pain-mediating therapeutic agent. 52,53 BSCs were genetically engineered by SleepingBeauty to express 3,5,7-trioxododecyl-CoA synthase (OLS), oleuronate cyclase (OAC), cannabigerolic acid synthase (CPGAS), cannabidiolic acid synthase (CBDAS), and GFP (plasmid name pCBD) to convert malonyl-CoA to CBD. 54 The cells showed successful gene expression (Figure 14D).

[0396] 3D intestinal disease model - this model is by casting silk fibroin around the central wire in order to produce the hollow lumen of geometrical engineering in polydimethylsiloxane (PDMS) mold, and inducing β fold formation to form (Figure 15 A-Figure 15 B) subsequently. We have shown that these scaffolds show stable cell development when inoculating human intestinal cells (for example, organoids), including producing microvilli, expressing intestinal cell markers and producing mucus layer (Figure 15 C, 15D and 15I). When inoculating macrophages in addition and with Escherichia coli O111:B4 lipopolysaccharide (LPS) and interferon gamma (IFNγ) processing, culture can simulate enteritis, showing the secretion of proinflammatory cytokines (that is, CXCL10, IL-1β, IL-6, MCP-2 and MIP-1β) related to IBD increases 55When inoculated with oocysts of the intestinal apicomplexan parasite Cryptosporidium parvum, the 3D model demonstrated the ability to support infection for over two weeks. Furthermore, the parasites displayed physiological development, progression, and pathological effects in vitro, demonstrating the ability of this system to accurately mimic intestinal infection. 56 Finally, our preliminary data support the use of this model for in vitro testing of a range of drug activities against inflammatory and infectious diseases. The use of human cells makes the model particularly relevant for proof-of-principle studies of edible therapeutics.

[0397] Drug production and optimization in mammalian cells - Because drug bioavailability can vary significantly with the composition of the surrounding food matrix, and because muscle cells undergo considerable compositional changes during differentiation, drug delivery in both undifferentiated and differentiated muscle tissue contexts will be explored 58 Specifically, we explore drug production in undifferentiated bovine satellite cells (BSCs) and BSCs that have differentiated into multinucleated myotubes (Figure 13A). Non-viral transposon-mediated gene editing technology will be used due to its non-viral nature, high efficiency, and demonstrated utility in previous work. 59,60

[0398] Drug production in mammalian cells

[0399] Bovine satellite cell isolation and culture -Bovine satellite cells (BSCs) will be isolated from the Tufts Cummings School of Veterinary Medicine using a protocol approved by the Tufts University Institutional Animal Care and Use Committee (IACUC protocol number G2018-36) and reported by our laboratory 43 Briefly, approximately 0.5 cm of the semitendinosus muscle was cut from Simmental bulls < 60 days old. 3 Muscles were harvested and transferred to a tissue culture laboratory in DMEM + Grotama with 1× penicillin / streptomycin. The tissue was minced and digested in a 0.2% collagenase II solution for one hour with regular grinding. The digestion was suspended with growth medium containing DMEM Grotama supplemented with 20% fetal bovine serum (FBS), 1% Primoxan, and 1 ng / mL human FGF-2, and the cells were filtered and plated at 100,000 cells / cm 2 After 24 hours of incubation at 37°C with 5% CO2, the unattached cells (including slowly adherent satellite cells) were moved to the culture flasks coated with 0.375 μg / cm 2New tissue culture flasks with recombinant laminin-511. Satellite cells will be left to rest for three days, after which the cells will be replenished with growth medium every 2-3 days and passaged at 70% confluence. The culture medium will be supplemented with primoxone only during the first two weeks of culture. Due to the importance of using serum-free culture medium in cultured meat production, experiments will be performed in serum-free growth medium using a previously reported culture medium (B8), which contains DMEM:F12 (1:1) supplemented with L-ascorbic acid 2-phosphate (200 μg / mL), insulin (20 μg / mL), transferrin (20 μg / mL), sodium selenite (20 ng / mL), FGF-2 (10 ng / mL), neuregulin 1 (NRG-1; 0.1 ng / mL), and TGFβ-3 (0.1 ng / μL) (Figures 13A-13E) 44 To verify the cell nature, immunocytochemistry for satellite cell markers will be performed. Cells will be fixed with 4% paraformaldehyde, permeabilized with Triton-X solution, blocked, and stained for paired box 7 (Pax7). Positive staining for these markers will be considered to confirm the BSC phenotype as previously reported and as can be seen in Figure 2 43 .

[0400] Myogenic differentiation To differentiate satellite cells into myotubes (in serum-free conditions), cells were cultured to confluence in B8 and the medium was changed to the previously reported differentiation medium, which consisted of Neurobasal / L15 (1:1) basal medium supplemented with epidermal growth factor (EGF; 0.5 ng / mL), insulin-like growth factor 1 (IGF-1; 0.05 ng / mL), and 1% antibiotic-antimycotic. 61 Cells were differentiated for 1 to 2 weeks, fixed as described above, and stained for myosin heavy chain (MHC) as previously shown (Figure 2). 43 .

[0401] Gene modification technology - Molecular cloning will be performed using standard techniques. For gene insertion, the transposable element will contain the gene of interest (controlled by a CMV promoter) and a gene confers resistance to a selective antibiotic (puromycin) to enable selection of successfully transfected cells. Additionally, to simplify future engineering efforts, the puromycin resistance cassette will be engineered with a flip-recombinase target (FRT) sequence between them to allow future gene insertion via recombinase-mediated cassette exchange (RMCE). 62,63. Cell transfection will be performed using Lipofectamine 3000 reagent (Thermo Fisher). Briefly, cells will be cultured to 85% confluence, washed with OptiMEM medium, and incubated with a transfection reagent containing the purified plasmid. After 6 hours, growth medium will be added to the cells, and after 42 hours, a selective pressure (e.g., puromycin) will be added to the culture medium. The cells will be cultured under selective pressure for one week, after which expression will be verified by immunocytochemistry, using fluorescent tags, or polymerase chain reaction (PCR). When polycistronic expression is desired, the genes will be linked by 2A peptide sequences to allow translation of multiple proteins from a single strand of RNA encoding multiple genes. 64 In most cases, the 2A sequence will link the green fluorescent protein (GFP) to the expression cassette, allowing expression to be screened by simple fluorescence microscopy. Throughout these studies, cell health and myogenic potential will be verified by observing cell proliferation and differentiation.

[0402] V565 production and activity -V565 amino acid sequence (DVQLVESGGGLVQPGGSLKLSCAASGFDFSSHWMYWVRQAPGKELEWLSEINTNGLITHYGDSVKGRFTVSRNNAANKMYLELTRLEPEDTALYYCARNQHGLNKGQGTQVTVSS; SEQ ID NO: 7) 3,65 Will be codon optimized for cattle expression, modified with 6xHis-tag sequence to quantify, and cloned into the polycistronic expression vector of V565 and GFP as described above.Cell will be transfected, selected and verified gene expression by fluorescence imaging.Cells will be cultured, cells (10 million cells, as propagation BSC or differentiation myotubes), and will be quantitatively measured by competitive His-tag ELISA on cell lysate for V565 output.As the orthogonal measure of gene expression, GFP will be quantitatively measured from cell lysate with GFP quantitative test kit (abcam#ab235672).Described 2A sequence allows the stoichiometric expression of multiple proteins, should allow GFP to quantitatively serve as the accurate representative of V565 level. 66 Readings will be normalized to a standard curve, cell counts, and cellular protein content (determined by Bradford assay).

[0403] To analyze V565 in an edible form, cells (10 million cells) will be harvested and kept "raw" or "cooked" by heating the cell pellet to 100°C for 1 to 10 minutes. Samples will be lysed using standard cell lysis buffer or by in vitro digestion based on previously reported methods. 67,68. Briefly, samples were added to a saline solution containing 140 mM NaCl, 5 mM KCl, and 150 μM butylated hydroxytoluene. To simulate gastric digestion, HCl was added to a final pH of 2.0, the samples were mixed 36:1 with a solution of 4% w / v pepsin in 0.1 M HCl, and the samples were incubated in a shaking water bath at 37°C for one hour. The pH of the digest will be raised to 6.9 with NaHCO3, and further intestinal digestion will be performed by mixing the samples with a pancreatin-bile solution (1.2 w / v bile extract and 0.2% pancreatin with 550 U / mL trypsin and 3.3 U / mL chymotrypsin in 0.1 M NaHCO3) 7.4:1 and incubating the samples in a shaking water bath at 37°C for two hours. Following in vitro digestion, samples will be quantified by His-tag and analyzed by competitive ELISA to determine binding activity as previously described. 69 Briefly, plates will be coated with TNFα, washed, blocked, and treated with the digest. Anti-His secondary antibody and horseradish peroxidase (HRP)-conjugated tertiary antibody will be added, followed by treatment with 3,3′,5,5′-tetramethylbenzidine (TMB). Absorbance at 450 nm will be used to quantify binding. Results will be compared between cooked, uncooked, digested, and undigested samples.

[0404] AMP16 production and activity -AMP16 peptide amino acid sequence (IRPI IRPI IRPI IRPI IRPI IRPI IRPI; SEQ ID NO: 8) 4 The expression of the peptide of the present invention is carried out by codon optimization, and is cloned into two polycistronic expression vectors that comprise or do not comprise 6xHis-tag of AMP16 and GFP.Cell will be transfected, selected and verified gene expression by fluorescence imaging.As with V565, cell will be cultivated, differentiated into muscle and fat, collected (10,000,000 cells), and will use His-tag quantitative and GFP quantitative analysis expression level.The use of two kinds of methods will allow quantitative unlabeled peptide, because 6xHis-tag can finally confuse (confound) peptide activity.As other medicines, reading will be with respect to standard curve, cell count and cell protein content standardization.

[0405] To analyze AMP16 antimicrobial activity in an edible format, cells were harvested (10 million cells), processed, and "digested" like V565 cells. Following in vitro digestion, paper discs were soaked in the digestate and placed on agar plates previously inoculated with Salmonella enterica and incubated at 37°C. After incubation for 1 to 24 hours, the inhibition zone between samples was measured and compared.

[0406] It has been previously shown that while V565 is largely stable in the gastric environment, it is sensitive to pepsin. 3 Similarly, the degradation of small peptide therapeutics in gastric fluid has been shown to be largely pepsin-dependent. 70 Thus, both V565 and AMP16 delivery can be greatly improved by inhibiting pepsin activity during digestion.

[0407] Enhanced drug yield -Drug yields in cells will be enhanced by increasing gene expression and increasing prodrug levels in culture. To increase gene expression, cells will be cultured with increased levels of the selective antibiotic puromycin to select cells in which the transgene has been inserted into a more transcriptionally active locus. Our previous carotenoid work has shown that this can increase gene expression (as shown by GFP expression) by about two-fold, and subsequent carotenoid levels increase by about 3-fold (Figure 14B). In order to increase prodrug levels of V565 and AMP16, the culture medium will be supplemented with the most common amino acids in these two drugs, as amino acid depletion is a potential bottleneck in therapeutic protein production. 71 Specifically, glycine, leucine, and serine are the three most common amino acids in V565 (representing more than 30% of the total sequence), and therefore the culture medium will be supplemented with additional G, L, and S (100-200% of standard culture medium levels). For AMP16, isoleucine, arginine, and proline together represent 100% of the total sequence, and therefore the culture medium will be supplemented with these amino acids (100-200% of standard culture medium levels). Drug yield will be analyzed as previously described.

[0408] Reduce gastric degradation - As previously described, pepsin inhibition will be engineered into cells by producing filaggrin and engineering using the Flp-In system (ThermoFisher) 72. Briefly, the silk enzyme inhibitor protein Tsp03044 sequence (Genbank accession number XM_003379333) will be codon optimized and cloned into the pcDNA5 / FRT plasmid (ThermoFisher). This plasmid and the pOG44 plasmid (ThermoFisher) encoding the Flp recombinase will be doubly transfected into engineered cells expressing V565 or AMP16. Flp-mediated RMCE will promote the insertion of Tsp03044 and the hygromycin resistance gene (from the pcDNA5 / FRT plasmid) into cells producing V565 and AMP16, and therefore treating the cells with puromycin and hygromycin will ensure the production of V565 or AMP16 and Tsp03044. Tsp03044 expression will be verified by RT-PCR. The efficacy of the silk enzyme inhibitor protein in maintaining drug activity will be analyzed by in vitro digestion and activity analysis as previously described. The results will be compared with undigested cell lysates and cell lysates treated with pepsin alone.

[0409] Alternative IBD-targeted drugs can also be expressed in mammalian cells, including the peptide PTG-200 73 or microbial anti-inflammatory molecules (MAMs) or their constitutive peptides, which have been shown to provide anti-inflammatory activity in a murine colitis model 74 Alternative antibiotics may include other small peptide antibiotics or small molecule antibiotics, such as penicillin 75 Alternatively, small molecule therapeutics could be explored, including cannabidiol or anti-inflammatory compounds such as curcumin or the immunosuppressant FK506. 53,76,77 If puromycin treatment proves ineffective in increasing drug yield, protein copy number can be increased by engineering the plasmid to contain multiple copies of the drug sequence, either in a polycistronic format separated by 2A sequences, or with different promoters for each copy. If protein stability is insufficient after silk enzyme inhibition of protein synthesis, cells can be encapsulated in alginate or chitosan scaffolds to slow enzymatic degradation, which are promising scaffolds for cultured meat production. 13,78 Finally, alternative cell types may be considered, such as transdifferentiated bovine adipocytes, immortalized bovine muscle cells, or immortalized mouse muscle cells (C2C12).

[0410] Disease-responsive drug formulation engineering Many pathologies cause alterations in the intestinal enzyme profile. Specifically, stool profiling has shown a >5-fold increase in trypsin-like proteases in patients with IBD compared to healthy patients, and Salmonella enterica infection has been shown to elevate elastase levels by approximately 2-fold. 5,6Given this, protease-triggered drug release / activity could allow for the tuning of drugs to achieve disease-responsive activity in edible therapeutics. Disease responsiveness was engineered into the V565 and AMP16 systems for IBD and Salmonella enterica infection, respectively.

[0411] IBD reaction engineering modification of V565 -Disease response in IBD will utilize previously reported epitope masking strategies 7 . Specifically, V565 will be synthesized in conjunction with a fragment of its target antigen, TNFα, in order to mask the ability of V565 to TNFα in tissues. The linker used will be easily cleaved by trypsin, so when this construct is exposed to the intestinal environment rich in trypsin (as seen in IBD), the antigen will be released and V565 will be free to bind to tissue TNFα. In order to engineer these systems, the human TNFα sequence will be codon-optimized for bovine expression and attached to the V565 sequence along with a flexible linker (GGG SGG GSG GGS GGKGGK GGK GGK GGG SGG GSGAQG; SEQ ID NO: 9), which has many lysine residues to promote trypsin cleavage. The cloned sequence will be engineered into cells as described above (including RMCE-mediated silk enzyme inhibitory protein integration). In order to analyze the drug response to trypsin, cells will be cultured, collected (10 million cells, before or after differentiation), heated or not, dissolved, and treated with a range of trypsin concentrations. Drug activity will be analyzed by competitive ELISA as described previously. Concurrently, cells will be harvested, cooked, and digested in vitro with varying levels of trypsin, and activity will be assessed.

[0412] Salmonella response engineering of AMP16 - The response to Salmonella enterica infection will similarly exploit altered enzyme levels during illness. Specifically, it has been shown that Salmonella enterica infection is associated with increased intestinal elastase. Therefore, the elastase-cleaving linker NPV will be engineered into the AMP16 peptide sequence. 8 Specifically, 10× repeats of AMP16 with NPV sequences between each 28-mer peptide will be assembled and cloned into a plasmid. Cells will be transfected, modified by RMCE to include Tsp03044, cultured, harvested (10 million cells, before or after differentiation), heated or not, and lysed as described above. Cell lysates will be treated with different levels of elastase, and drug activity will be analyzed by inhibition zone analysis as described above. Simultaneously, cells will undergo harvesting, cooking, and in vitro digestion in different levels of elastase, and drug activity will be assessed.

[0413] Combining drugs into a disease-responsive system-In order to engineer a truly "smart" system that can target many pathological changes in a disease-responsive manner, we will combine the above components into a single cell line. Specifically, the V565-epitope, 10xAMP16, and GFP will be connected by a 2A sequence to form a single polycistronic fragment. This fragment will be cloned into the SleepingBeauty transposon vector and transfected into cells as described above. The cells will undergo transfection and RMCE to produce a single cell line containing all previously described disease-responsive drug components. The cells will be cultured, collected (10 million cells, before or after differentiation), heated or not, and processed in vitro by digestion at a range of trypsin and / or elastase concentrations to represent patients suffering from IBD, enteric Salmonella infection, both, and neither. V565 and AMP16 drug activity will be analyzed as described above.

[0414] Alternatively, copies of V565 with a trypsin-cleavable linker could be explored as a way to mask the binding domains of these Nanobodies. Alternatively, if attachment of the AMP16 peptide proves ineffective in conferring disease responsiveness during Salmonella enterica infection, then the use of antimicrobial Nanobodies with activity against E. coli infection could be explored with enzyme-cleavable epitope masking similar to that explored for V565. 79 Additionally, alternative enzyme-cleavable linkers or environmental means (such as pH changes) can be used to engineer disease responsiveness. 3,80-83 If synthesis of two drug systems in a single cell proves challenging, two single-drug system cell populations could be developed and subsequently combined into a multidrug food.

[0415] In vitro evaluation of drug bioactivity - Functional in vitro 3D human intestinal models are a promising option for early validation of edible drug formulations due to their ability to use human cells and mimic relevant tissue features and geometries 84 To this end, our group previously developed a 3D intestinal tissue model (Figures 15A-15L). This model will be used to evaluate the efficacy of engineered therapeutic foods in vitro.

[0416] cell Human colonic organoids previously isolated and cultured by our group will be cultured in Matrigel droplets and appropriate culture medium as previously described 55 Human monocytes previously isolated and cultured by our group will be cultured in appropriate media as previously described. 55 Monocytes will be differentiated into macrophages by treatment with 50 ng / mL macrophage colony stimulating factor; for M1 polarization, macrophages will then be cultured in medium supplemented with lipopolysaccharide (LPS) and the interferon interferon gamma (IFNγ).

[0417] IBD 3D Model - The intestinal model will be made and seeded with human cells as previously described 55 . Briefly, a silk fibroin solution extracted from Bombyx mori cocoons will be poured into a PDMS cylindrical mold containing a 2 mm diameter Teflon-coated steel wire, which is inserted through the cross-section of the mold to form a channel. The solution will be frozen, freeze-dried, and high-pressure treated to induce beta-fold formation. The scaffold will be immersed in water and cut into 8 mm segments. A biopsy punch will be used to cut out an "inner scaffold" (8 mm in length, 6 mm in outer diameter, and 2 mm in lumen) and an "outer scaffold" (8 mm in length, 10 mm in outer diameter, and 6 mm in inner diameter). For scaffold inoculation, human colon organoids will first be inoculated into a 2 mm cavity, following a previously reported method. 55 Briefly, the silk scaffolds will be coated with collagen gel, human colon organoids will be dissociated in trypsin-EDTA, and the cell suspension will be pipetted to also coat the lumen of the inner scaffold. These scaffolds will be cultured for one week in appropriate culture medium as previously reported. Next, monocytes will be suspended in the collagen gel and seeded throughout the outer scaffold body. Monocytes will be differentiated into uncommitted macrophages by six days of culture in appropriate culture medium as previously reported. 55 The outer scaffold will then be cultured in macrophage culture medium with LPS and IFNγ to induce polarization. The cell-seeded outer scaffold will be combined with the cell-seeded inner scaffold to form a complete IBD model. As previously described, the model will be validated by immunofluorescence, cytokine analysis, and mucus thickness measurement, and subsequently used to test the efficacy of therapeutic foods. 55 .

[0418] Salmonella Infection 3D Model - Scaffolds will be prepared and seeded as previously described, but without LPS or IFNγ treatment. The model will be validated by immunofluorescence to ensure accurate intestinal representation and to gain an understanding of the number of cells lining the lumen. With this information, the lumen of the scaffold will be infected by inoculating Salmonella enterica at a multiplicity of infection of 10 to 100, and the dose will be adjusted based on the epithelial cell response over a period of up to one week in culture. 85 .

[0419] Disease Model Drug Delivery- All forms of drug delivery will be explored in the 3D model, including pure compounds, cell-encapsulated therapeutics without disease responsiveness and with or without excipients, and cell-encapsulated therapeutics with disease responsiveness and excipients (alone or in cells engineered with all drug components). Cells will be cultured, collected (10 million cells, before or after differentiation) and heated or not, as described above. Samples will be dissolved or digested in vitro with a range of trypsin and / or elastase concentrations. The culture medium will be removed from the scaffold and replaced with the digest for 2, 3, or 4 hours to obtain a range of feasible intestinal retention times, after which the digest will be removed and replaced with cell culture medium. The drug efficacy of the scaffold will be analyzed one hour, two hours, six hours, and 24 hours after treatment.

[0420] Analyze drug effects - The effects of drugs on IBD will be analyzed by profiling inflammatory cytokines in treated and untreated scaffolds. Specifically, interleukins 1β and 6 (IL-1β and IL-6), monocyte chemoattractant proteins 1 and 2 (MCP-1 and MCP-2), and macrophage inflammatory protein 1β (MIP-1β / CCL4) will be measured using commercially available chemiluminescent arrays. Additionally, epithelial integrity will be analyzed by immunohistochemistry for mucin-2, CD68, and ZO-1. The effects of drugs on Salmonella enterica infection will be analyzed by homogenizing scaffolds in a lysis solution containing Triton-X, serially diluting the homogenate, and determining colony-forming units of Salmonella enterica by plating on LB agar plates. 86 Results will be compared across all drug types, samples, and conditions.

[0421] If the 3D disease model proves to be unsuitable for this study, then 2D studies can be performed using Caco-2 intestinal cells and a Transwell system. If a single dose proves ineffective in producing a response, then administration with a larger cell collection volume, or repeated administration of the edible therapeutic agent (i.e., twice to three times a day for a week at "meal time") can be performed. Finally, if the in vitro model proves ineffective, then ex vivo analysis can be performed using a biopsy obtained during a routine endoscopy of a consenting IBD patient. Specifically, the biopsy can be cultured ex vivo, treated with an in vitro digest of a therapeutic food sample, and analyzed for markers of inflammation and drug activity as previously reported. 3,87 Finally, in vivo animal models may be considered.

[0422] References:

[0423] 1.Renukuntla,J.,Vadlapudi,A.D.,Patel,A.,Boddu,S.H.S.&Mitra,A.K.Approaches for enhancing oral bioavailability of peptides andproteins.International Journal of Pharmaceutics 447,75-93(2013).

[0424] 2.Stout,A.J.,Mirliani,A.B.,Soule-Albridge,E.L.,Cohen,J.M.&Kaplan,D.L.Engineering carotenoid production in mammalian cells for nutritionallyenhanced cell-cultured foods.In Review

[0425] 3.Scott Crowe,J.,Roberts,K.J.,Carlton,T.M.,Maggiore,L.,Cubitt,M.F.,Clare,S.,Harcourt,K.,Reckless,J.,MacDonald,T.T.,Ray,K.P., A.&West,M.R.Preclinical Development of a Novel,Orally-Administered Anti-TumourNecrosis Factor Domain Antibody for the Treatment of Inflammatory BowelDisease.Scientific Reports 8,1-13(2018).

[0426] 4.Wang,J.,Song,J.,Yang,Z.,He,S.,Yang,Y.,Feng,X.,Dou,X.&Shan,A.Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria.(2019).doi:10.1021 / acs.jmedchem.8b01348

[0427] 5.Jablaoui,A.,Kriaa,A.,Mkaouar,H.,Akermi,N.,Soussou,S.,Wysocka,M., D.,Amouri,A.,Gargouri,A.,Maguin,E.,Lesner,A.&Rhimi,M.Fecal SerineProtease Profiling in Inflammatory Bowel Diseases.Frontiers in CellularandInfection Microbiology 10,21(2020).

[0428] 6.Nilsson,A.,Tervahartiala,T.,Lennebratt,D., A.,Sorsa,T.&Rautelin,H.Enhanced Systemic Response of Matrix Metalloproteinases and TheirRegulators in Campylobacter and Salmonella Patients.Diagnostics 8,82(2018).

[0429] 7.Donaldson,J.M.,Kari,C.,Fragoso,R.C.,Rodeck,U.&Williams,J.C.Designand development of masked therapeutic antibodies to limit off-target effects:Application to anti-EGFR antibodies.Cancer Biology and Therapy 8,2147-2152(2009).

[0430] 8.Raposo Moreira Dias,A.,Pina,A.,Dean,A.,Lerchen,H.-G.,Caruso,M.,Gasparri,F.,Fraietta,I.,Troiani,S.,Arosio,D.,Belvisi,L.,Pignataro,L.,DalCorso,A.&Gennari,C.Neutrophil Elastase Promotes Linker Cleavage andPaclitaxel Release from an Integrin-Targeted Conjugate.Chemistry-A EuropeanJournal 25,1696-1700(2019).

[0431] 9.DeCicco RePass,M.A.,Chen,Y.,Lin,Y.,Zhou,W.,Kaplan,D.L.&Ward,H.D.Novel Bioengineered Three-Dimensional Human Intestinal Model for Long-Term Infection of Cryptosporidium parvum.Infection and immunity 85,e00731-16(2017).

[0432] 10.Roh,T.T.,Chen,Y.,Paul,H.T.,Guo,C.&Kaplan,D.L.3D bioengineeredtissue model of the large intestine to study inflammatory boweldisease.Biomaterials 225,(2019).

[0433] 11.Manousiouthakis,E.,Chen,Y.,Cairns,D.M.,Pollard,R.,Gerlovin,K.,Dente,M.J.,Razavi,Y.&Kaplan,D.L.Bioengineered in vitro enteric nervoussystem.Journal of Tissue Engineering and Regenerative Medicine 13,1712-1723(2019).

[0434] 12.Chen,Y.,Lin,Y.,Davis,K.M.,Wang,Q.,Rnjak-Kovacina,J.,Li,C.,Isberg,R.R.,Kumamoto,C.A.,Mecsas,J.&Kaplan,D.L.Robust bioengineered 3D functionalhuman intestinal epithelium.ScientificReports 5,(2015).

[0435] 13.Brown,T.D.,Whitehead,K.A.&Mitragotri,S.Materials for oral deliveryof proteins and peptides.Nature Reviews Materials 5,127-148(2020).

[0436] 14.Usmani,S.S.,Bedi,G.,Samuel,J.S.,Singh,S.,Kalra,S.,Kumar,P.,Ahuja,A.A.,Sharma,M.,Gautam,A.&Raghava,G.P.S.THPdb:Database of FDA-approved peptideand protein therapeutics.PLOS ONE 12,e0181748(2017).

[0437] 15.Drucker,D.J.Advances in oral peptide therapeutics.Nature ReviewsDrug Discovery 19,277-289(2019).

[0438] 16.Charman,W.N.,Porter,C.J.H.,Mithani,S.&Dressman,J.B.Physicochemicaland physiological mechanisms for the effects of food on drug absorption:Therole of lipids and pH.Journal of Pharmaceutical Sciences 86,269-282(1997).

[0439] 17.Wanakule,P.&Roy,K.Disease-Responsive Drug Delivery:The NextGeneration of Smart Delivery Devices.Current DrugMetabolism 13,42-49(2012).

[0440] 18.Kotla,N.G.,Rana,S.,Sivaraman,G.,Sunnapu,O.,Vemula,P.K.,Pandit,A.&Rochev,Y.Bioresponsive drug delivery systems in intestinal inflammation:State-of-the-art and future perspectives.Advanced Drug Delivery Reviews 146,248-266(2019).

[0441] 19.Kagayama,A.,Tanimoto,S.,Fujisaki,J.,Kaibara,A.,Ohara,K.,Iwasaki,K.,Hirano,Y.&Hata,T.Oral Absorption of FK506 in Rats.Pharmaceutical Research:An Official Journal of the American Association of Pharmaceutical Scientists10,1446-1450(1993).

[0442] 20.Zimmerman,J.J.,Ferron,G.M.,Lim,H.K.&Parker,V.The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus(rapamycin).Journal of clinical pharmacology 39,1155-61(1999).

[0443] 21.Zgair,A.,Wong,J.C.M.,Lee,J.B.,Mistry,J.,Sivak,O.,Wasan,K.M.,Hennig,I.M.,Barrett,D.A.,Constantinescu,C.S.,Fischer,P.M.&Gershkovich,P.Dietary fats and pharmaceutical lipid excipients increase systemic exposureto orally administered cannabis and cannabis-based medicines.American Journalof Translational Research 8,3448-3459(2016).

[0444] 22.Varum,F.J.O.,Hatton,G.B.&Basit,A.W.Food,physiology and drugdelivery.International Journal of Pharmaceutics 457,446-460(2013).

[0445] 23.Juarez,P.,Virdi,V.,Depicker,A.&Orzaez,D.Biomanufacturing ofprotective antibodies and other therapeutics in edible plant tissues for oralapplications.PlantBiotechnology Journal 14,1791-1799(2016).

[0446] 24.Kalepu,S.,Manthina,M.&Padavala,V.Oral lipid-based drug deliverysystems-an overview.Acta Pharmaceutica Sinica B 3,361-372(2013).

[0447] 25.Salzman,C.,Kupfer,D.J.&Frank,E.Medication compliance in theelderly.in Journal of Clinical Psychiatry 56,18-23(1995).

[0448] 26.Shruthi,R.,Jyothi,R.,Pundarikaksha,H.P.,Nagesh,G.N.&Tushar,T.J.AStudy of Medication Compliance in Geriatric Patients with Chronic Illnessesat a Tertiary Care Hospital.JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH 10,FC40(2016).

[0449] 27.Lau,E.T.L.,Steadman,K.J.,Cichero,J.A.Y.&Nissen,L.M.Dosage formmodification and oral drug delivery in older people.Advanced Drug DeliveryReviews 135,75-84(2018).

[0450] 28.Stephens,N.,Di Silvio,L.,Dunsford,I.,Ellis,M.,Glencross,A.&Sexton,A.Bringing cultured meat to market:Technical,socio-political,and regulatorychallenges in cellular agriculture.Trends in Food Science and Technology 78,155-166(2018).

[0451] 29.Thorrez,L.&Vandenburgh,H.Challenges in the quest for‘clean meat’.Nature Biotechnology 37,215-216(2019).

[0452] 30.Bhat,Z.F.,Kumar,S.&Fayaz,H.In vitro meat production:Challenges andbenefits over conventional meat production.Journal of Integrative Agriculture14,241-248(2015).

[0453] 31.National Cattlemen's Beef Association.Industry Statistics.(2019).

[0454] 32.Fischer,R.&Buyel,J.F.Molecular farming-The slope ofenlightenment.Biotechnology Advances 40,107519(2020).

[0455] 33.Mishra,N.,Gupta,N.,Khatri,K.,Goyal,A.K.&Vyas,S.P.Edible vaccines:Anew approach to oral immunization.Indian Journal of Biotechnology 7,(2008).

[0456] 34.Tacket,C.O.,Mason,H.S.,Losonsky,G.,Estes,M.K.,Levine,M.M.&Arntzen,C.J.Human Immune Responses to a Novel Norwalk Virus Vaccine Delivered inTransgenic Potatoes.The Journal of Infectious Diseases 182,302-305(2000).

[0457] 35.Nielsen,J.Yeast cell factories on the horizon:Metabolicengineering in yeast gets increasingly more versatile.Science 349,1050-1051(2015).

[0458] 36.Heider,S.A.E.&Wendisch,V.F.Engineering microbial cell factories:Metabolic engineering of Corynebacterium glutamicum with a focus on non-natural products.Biotechnology Journal 10,1170-1184(2015).

[0459] 37.Sack,M.,Rademacher,T.,Spiegel,H.,Boes,A.,Hellwig,S.,Drossard,J.,Stoger,E.&Fischer,R.From gene to harvest:Insights into upstream processdevelopment for the GMP production of a monoclonal antibody in transgenictobacco plants.Plant Biotechnology Journal 13,1094-1105(2015).

[0460] 38.Davy,A.M.,Kildegaard,H.F.&Andersen,M.R.Cell FactoryEngineering.Cell Systems 4,262-275(2017).

[0461] 39.Ceroni,F.&Ellis,T.The challenges facing synthetic biology ineukaryotes.(2018).doi:10.1038 / s41580-018-0013-2

[0462] 40.Walsh,G.Biopharmaceutical benchmarks 2018.Nature Publishing Group36,(2018).

[0463] 41.Giddings,G.Transgenic plants as protein factories.Current Opinionin Biotechnology 12,450-454(2001).

[0464] 42.Rubio,N.R.,Fish,K.D.,Trimmer,B.A.&Kaplan,D.L.In Vitro InsectMuscle for Tissue Engineering Applications.ACS Biomaterials Science&Engineering 5,1071-1082(2019).

[0465] 43.Simsa,R.,Yuen,J.,Stout,A.,Rubio,N.,Fogelstrand,P.&Kaplan,D.L.Extracellular Heme Proteins Influence Bovine Myosatellite CellProliferation and the Color of Cell-Based Meat.Foods 8,521(2019).

[0466] 44.Kuo,H.H.,Gao,X.,DeKeyser,J.M.,Fetterman,K.A.,Pinheiro,E.A.,Weddle,C.J.,Fonoudi,H.,Orman,M.V.,Romero-Tejeda,M.,Jouni,M.,Blancard,M.,Magdy,T.,Epting,C.L.,George,A.L.&Burridge,P.W.Negligible-Cost and Weekend-FreeChemically Defined Human iPSC Culture.Stem Cell Reports 14,256-270(2020).

[0467] 45.Fish,K.D.,Rubio,N.R.,Stout,A.J.,Yuen,J.S.K.&Kaplan,D.L.Prospectsand challenges for cell-cultured fat as a novel food ingredient.Trends inFood Science and Technology 98,53-67(2020).

[0468] 46.Stice,C.P.,Xia,H.&Wang,X.-D.Tomato lycopene prevention ofalcoholic fatty liver disease and hepatocellular carcinomadevelopment.Chronic Diseases and Translational Medicine 4,211-224(2018).

[0469] 47.Meléndez-Martínez,A.J.,Mapelli-Brahm,P.&Stinco,C.M.The colourlesscarotenoids phytoene and phytofluene:From dietary sources to their usefulnessfor the functional foods and nutricosmetics industries.Journal of FoodComposition and Analysis 67,91-103(2018).

[0470] 48.Kim,S.-W.,Kim,J.-B.,Jung,W.-H.,Kim,J.-H.&Jung,J.-K.Over-productionof β-carotene from metabolically engineered Escherichia coli.BiotechnologyLetters 28,897-904(2006).

[0471] 49.Fiedor,J.&Burda,K.Potential role of carotenoids as antioxidants inhuman health and disease.Nutrients 6,466-88(2014).

[0472] 50.Wolk,A.Potential health hazards of eating red meat.Journal ofInternal Medicine 281,106-122(2017).

[0473] 51.Falowo,A.B.,Fayemi,P.O.&Muchenje,V.Natural antioxidants againstlipid-protein oxidative deterioration in meat and meat products:A review.FoodResearch International 64,171-181(2014).

[0474] 52.Devinsky,O.,Cilio,M.R.,Cross,H.,Fernandez-Ruiz,J.,French,J.,Hill,C.,Katz,R.,Di Marzo,V.,Jutras-Aswad,D.,Notcutt,W.G.,Martinez-Orgado,J.,Robson,P.J.,Rohrback,B.G.,Thiele,E.,Whalley,B.&Friedman,D.Cannabidiol:pharmacology and potential therapeutic role in epilepsy and otherneuropsychiatric disorders.Epilepsia 55,791-802(2014).

[0475] 53.Burstein,S.Cannabidiol(CBD)and its analogs:A review of theireffects on inflammation.Bioorganic andMedicinal Chemistry 23,1377-1385(2015).

[0476] 54.Carvalho, Hansen,E.H.,Kayser,O.,Carlsen,S.&Stehle,F.Designingmicroorganisms for heterologous biosynthesis of cannabinoids.FEMS YeastResearch 17,(2017).

[0477] 55.Roh,T.T.,Chen,Y.,Paul,H.T.,Guo,C.&Kaplan,D.L.3D bioengineeredtissue model of the large intestine to study inflammatory boweldisease.Biomaterials 225,119517(2019).

[0478] 56.Repass,M.A.D.,Chen,Y.,Lin,Y.,Zhou,W.,Kaplan,D.L.&Ward,H.D.NovelBioengineered Three-Dimensional Human Intestinal Model for Long-TermInfection of Cryptosporidium parvum.(2017).doi:10.1128 / IAI.00731-16

[0479] 57.Chen,Y.,Lin,Y.,Davis,K.M.,Wang,Q.,Rnjak-Kovacina,J.,Li,C.,Isberg,R.R.,Kumamoto,C.A.,Mecsas,J.&Kaplan,D.L.Robust bioengineered 3D functionalhuman intestinal epithelium.Scientific Reports 5,1-11(2015).

[0480] 58.Winstanley,P.&Orme,M.The effects of food on drugbioavailability.British Journal of Clinical Pharmacology 28,621-628(1989).

[0481] 59.Zayed,H.,Izsvák,Z.,Walisko,O.&Ivics,Z.Development of HyperactiveSleeping Beauty Transposon Vectors by Mutational Analysis.Molecular Therapy9,292-304(2004).

[0482] 60.Izsvák,Z.,Ivics,Z.&Plasterk,R.H.Sleeping Beauty,a wide host-rangetransposon vector for genetic transformation in vertebrates.Journal ofMolecular Biology 302,93-102(2000).

[0483] 61.Mcaleer,C.W.,Rumsey,J.W.,Stancescu,M.&Hickman,J.J.Functionalmyotube formation from adult rat satellite cells in a defined serum-freesystem.Biotechnology Progress 31,997-1003(2015).

[0484] 62.Gaidukov,L.,Wroblewska,L.,Teague,B.,Nelson,T.,Zhang,X.,Liu,Y.,Jagtap,K.,Mamo,S.,Tseng,W.A.,Lowe,A.,Das,J.,Bandara,K.,Baijuraj,S.,Summers,N.M.,Lu,T.K.,Zhang,L.&Weiss,R.A multi-landing pad DNA integration platformfor mammalian cell engineering.NucleicAcids Research 46,4072-4086(2018).

[0485] 63.Phan,Q.V.,Contzen,J.,Seemann,P.&Gossen,M.Site-specific chromosomalgene insertion:Flp recombinase versus Cas9 nuclease.Scientific Reports 7,17771(2017).

[0486] 64.Szymczak,A.L.&Vignali,D.A.Development of 2A peptide-basedstrategies in the design of multicistronic vectors.Expert Opinion onBiological Therapy 5,627-638(2005).

[0487] 65.Crowe,S.,West,M.,Roberts,K.,Carlton,T.,Maggiore,L.,Cubitt,M.&Ray,K.Polypeptides(US20170002069A1).(2017).doi:US20170002069A1

[0488] 66.Szymczak,A.L.,Workman,C.J.,Wang,Y.,Vignali,K.M.,Dilioglou,S.,Vanin,E.F.&Vignali,D.A.A.Correction of multi-gene deficiency in vivo using asingle‘self-cleaving’2A peptide-based retroviral vector.Nature Biotechnology22,589-594(2004).

[0489] 67.Chang-Shu Liu, Raymond P.Glahn,§and&Rui Hai Liu*, #.Assessment ofCarotenoid Bioavailability of Whole Foods Using a Caco-2 Cell Culture ModelCoupled with an in Vitro Digestion.(2004).doi:10.1021 / JF040028K

[0490] 68.Wang,S.,Li,P.,Zhang,T.,Wang,S.&Copeland,L.Trypsin and chymotrypsinare necessary for in vitro enzymatic digestion of rice starch.RSC Advances 7,3660-3666(2017).

[0491] 69.Ji,X.,Peng,Z.,Li,X.,Yan,Z.,Yang,Y.,Qiao,Z.&Liu,Y.Neutralization ofTNFα in tumor with a novel nanobody potentiates paclitaxel-therapy andinhibits metastasis in breast cancer.Cancer Letters 386,24-34(2017).

[0492] 70.Wang,J.,Yadav,V.,Smart,A.L.,Tajiri,S.&Basit,A.W.Toward oraldelivery of biopharmaceuticals:An assessment of the gastrointestinalstability of 17 peptide drugs.Molecular Pharmaceutics 12,966-973(2015).

[0493] 71.Carrillo-Cocom,L.M.,Genel-Rey,T.,Araíz-Hernández,D.,López-Pacheco,F.,López-Meza,J., M.R.,Ramírez-Medrano,A.&Alvarez,M.M.Amino acidconsumption in and recombinant CHO cell cultures:producers of amonoclonal antibody.Cytotechnology 67,809-820(2015).

[0494] 72.Zhang,Z.,Mao,Y.,Li,D.,Zhang,Y.,Li,W.,Jia,H.,Zheng,J.,Li,L.&Lu,Y.High-level expression and characterization of two serine proteaseinhibitors from Trichinella spiralis.Veterinary Parasitology 219,34-39(2016).

[0495] 73.Cheng,X.,Lee,T.-Y.,Ledet,G.,Zemade,G.,Tovera,J.,Campbell,R.,Purro,N.,Annamalai,T.,Masjedizadeh,M.,Liu,D.,Nawabi,R.&Kanwar,B.Safety,Tolerability,and Pharmacokinetics of PTG-200,an Oral GI-Restricted PeptideAntagonist of IL-23 Receptor,in Normal Healthy Volunteers.American Journal ofGastroenterology 114,S439-S440(2019).

[0496] 74.Breyner,N.M.,Michon,C.,de Sousa,C.S.,Vilas Boas,P.B.,Chain,F.,Azevedo,V.A.,Langella,P.&Chatel,J.M.Microbial Anti-Inflammatory Molecule(MAM)from Faecalibacterium prausnitzii Shows a Protective Effect on DNBS and DSS-Induced Colitis Model in Mice through Inhibition of NF-κB Pathway.Frontiersin Microbiology 8,114(2017).

[0497] 75.Cherkasov,A.,Hilpert,K.,Jenssen,H.,Fjell,C.D.,Waldbrook,M.,Mullaly,S.C.,Volkmer,R.&Hancock,R.E.W.Use of artificial intelligence in thedesign of small peptide antibiotics effective against a broad spectrum ofhighly antibiotic-resistant superbugs.ACS Chemical Biology 4,65-74(2009).

[0498] 76.Pham,J.V.,Yilma,M.A.,Feliz,A.,Majid,M.T.,Maffetone,N.,Walker,J.R.,Kim,E.,Cho,H.J.,Reynolds,J.M.,Song,M.C.,Park,S.R.&Yoon,Y.J.A review of themicrobial production of bioactive natural products and biologics.Frontiers inMicrobiology 10,(2019).

[0499] 77.Burge,K.,Gunasekaran,A.,Eckert,J.&Chaaban,H.Curcumin andintestinal inflammatory diseases:Molecular mechanisms ofprotection.International Journal of Molecular Sciences 20,(2019).

[0500] 78.Ng,K.K.S.,Petersen,J.F.W.,Cherney,M.M.,Garen,C.,Zalatoris,J.J.,Rao-Naik,C.,Dunn,B.M.,Martzen,M.R.,Peanasky,R.J.&James,M.N.G.Structural basisfor the inhibition of porcine pepsin by Ascaris pepsin inhibitor-3.NatureStructural Biology 7,653-657(2000).

[0501] 79.Harmsen,M.M.,Van Solt,C.B.,Van Zijderveld-Van Bemmel,A.M.,Niewold,T.A.&Van Zijderveld,F.G.Selection and optimization of proteolytically stablellama single-domain antibody fragments for oral immunotherapy.AppliedMicrobiology and Biotechnology 72,544-551(2006).

[0502] 80.Whitney,M.,Crisp,J.L.,Olson,E.S.,Aguilera,T.A.,Gross,L.A.,Ellies,L.G.&Tsien,R.Y.Parallel in vivo and in vitro selection using phage displayidentifies protease-dependent tumor-targeting peptides.Journal of BiologicalChemistry 285,22532-22541(2010).

[0503] 81.Sánchez-Navarro,M.,Garcia,J.,Giralt,E.&Teixidó,M.Using peptides toincrease transport across the intestinal barrier.Advanced Drug DeliveryReviews 106,355-366(2016).

[0504] 82.Nugent,S.G.,Kumar,D.,Rampton,D.S.&Evans,D.F.Intestinal luminal pHin inflammatory bowel disease:Possible determinants and implications fortherapy with aminosalicylates and other drugs.Gut 48,571-577(2001).

[0505] 83.Turk,B.E.,Huang,L.L.,Piro,E.T.&Cantley,L.C.Determination ofprotease cleavage site motifs using mixture-based oriented peptidelibraries.Nature Biotechnology 19,661-667(2001).

[0506] 84.Chen,Y.,Zhou,W.,Roh,T.,Estes,M.K.&Kaplan,D.L.In vitro enteroid-derived three-dimensional tissue model of human small intestinal epitheliumwith innate immune responses.PLoS ONE 12,(2017).

[0507] 85.Mickael,C.S.,Lam,P.K.S.,Berberov,E.M.,Allan,B.,Potter,A.A.& W.Salmonella enterica serovar enteritidis tatB and tatC mutants are impairedin Caco-2 cell invasion in vitro and show reduced systemic spread inchickens.Infection and Immunity 78,3493-3505(2010).

[0508] 86.Aabo,S.,Christensen,J.P.,Chadfield,M.S.,Carstensen,B.,Olsen,J.E.&Bisgaard,M.Quantitative comparison of intestinal invasion of zoonoticserotypes of Salmonella enterica in poultry.Avian Pathology 31,41-47(2002).

[0509] 87.de Filippis,D.,Esposito,G.,Cirillo,C.,Cipriano,M.,de Winter,B.Y.,Scuderi,C.,Sarnelli,G.,Cuomo,R.,Steardo,L.,de Man,J.G.&Iuvone,T.Cannabidiolreduces intestinal inflammation through the control of neuroimmune axis.PLoSONE 6,(2011).

[0510] 88.Ruiz de Huidobro,F.,Miguel,E.,Onega,E.&Blázquez,B.Changes in meatquality characteristics of bovine meat during the first 6 days postmortem.Meat Science 65,1439-1446(2003).

[0511] 89. Seideman, SC & Crouse, JD The effects of sex condition, genotype and diet on bovine muscle fiber characteristics. Meat Science 17, 55-72 (1986).

[0512] Example 4

[0513] The embodiments described herein demonstrate

[0514] Preliminary data To date, our group has explored several topics directly related to this proposal. From a culture system perspective, we have adapted serum-free growth of invertebrate muscle cells for use in cultured meat and established a protocol for generating a population of highly myogenic primary bovine satellite cells (BSCs) (Figures 16A-16B). 22,23 Based on the previously reported formulation, we have further confirmed the formulation of a serum-free, growth factor-based medium for BSC culture (B8) (Figure 16A) 24 With this formulation, we have observed superior BSC growth compared to serum-containing media and showed that growth is dependent on fibroblast growth factor 2 (FGF-2) in a concentration-dependent manner ( FIG. 16B ).

[0515] Furthermore, we have established an adipogenic transdifferentiation method that converts myogenic BSCs into lipid-accumulating adipocytes by treating the cells with a mixture of free fatty acids (FFA) ( FIG17A ). We have demonstrated robust lipid accumulation using this method, indicating that a single cell population (i.e., satellite cells) can be used to generate both muscle and fat in cultured meat, which could significantly simplify the industrial production process ( FIG17B ). 25 .

[0516] From a nutritional perspective, we have genetically engineered BSCs to endogenously synthesize the carotenoids phytoene, lycopene, and β-carotene and show that the resulting lipid oxidation (a key mechanistic driver linking red meat consumption and colorectal cancer; Figure 3) is reduced. 19,26 .

[0517] Finally, from a quality perspective, we have shown that exogenous heme proteins in the culture medium can improve the color similarity of cultured meat compared to conventional beef (Table 2). 23 .

[0518] Table 2: Color analysis of 3D BSC tissue cultures grown with or without the addition of 3 mg / mL hemoglobin (Hb) or myoglobin (Mb). Data for L* (lightness), a* (red / green spectrum), and b* (blue / yellow spectrum) were used to generate ΔE, a measure of color similarity to raw or cooked beef. Lower ΔE indicates greater similarity.

[0519]

[0520] method

[0521] Cell culture

[0522] Bovine Satellite Cells - Bovine satellite cells (BSCs) will be isolated from the Tufts Cummings School of Veterinary Medicine using a protocol approved by the Tufts University Institutional Animal Care and Use Committee (IACUC protocol number G2018-36) and reported by our laboratory. 23 Briefly, approximately 0.5 cm of the semitendinosus muscle was cut from Simmental bulls < 60 days old. 3 Muscles were harvested and transferred to a tissue culture laboratory in DMEM + Grotama with 1× penicillin / streptomycin. The tissue was minced and digested in a 0.2% collagenase II solution for one hour with regular grinding. The digestion was suspended with growth medium containing DMEM Grotama supplemented with 20% fetal bovine serum (FBS), 1% Primoxan, and 1 ng / mL human FGF-2, and the cells were filtered and plated at 100,000 cells / cm 2 After 24 hours of incubation at 37°C with 5% CO2, the unattached cells (including slowly adherent satellite cells) were moved to the culture flasks coated with 0.375 μg / cm 2 New tissue culture flasks containing recombinant laminin-511. Satellite cells will rest for three days, after which they will be replenished with growth medium every 2-3 days and passaged at 70% confluence. The medium will be supplemented with primoxone only for the first two weeks of culture.

[0523] To verify the cell nature, immunocytochemistry for satellite cell markers will be performed. Cells will be fixed with 4% paraformaldehyde, permeabilized with Triton-X solution, blocked, and stained for paired box 7 (Pax7). Positive staining for these markers will be considered to confirm the BSC phenotype as previously reported and as in Figure 1 Visible in 23 .

[0524] Myogenic Differentiation - To differentiate satellite cells into mature myotubes (in serum-containing conditions), cells were cultured to confluence and the medium was changed to differentiation medium containing DMEM Grotama supplemented with 2% FBS and 1% antibiotic-antimycotic. To differentiate satellite cells in serum-free conditions, a previously reported differentiation medium containing Neurobasal / L15 (1:1) basal medium supplemented with epidermal growth factor (EGF; 0.5 ng / mL), insulin-like growth factor 1 (IGF-1; 0.05 ng / mL), and 1% antibiotic-antimycotic was used. 54 Cells were differentiated for 1 to 2 weeks, fixed as described above, and stained for myosin heavy chain (MHC) as previously reported and as seen in Figures 16A-16B. 23 .

[0525] Adipogenic transdifferentiation - Although satellite cells are preferably myogenic, we successfully induced lipid accumulation using a differentiation medium containing a combination of free fatty acids (FFA) (Figures 17A-17B). Specifically, a 3-FFA mixture of linoleic acid, erucic acid, and elaidic acid at equal concentrations of 125 μM was used in cells for six days to induce a stable accumulation of intracellular lipids. This adipogenic transdifferentiation protocol will be further optimized by testing various concentrations of oleic acid, myristoleic acid, linoleic acid, erucic acid, and elaidic acid using a fractional factorial experimental design. Lipid accumulation will be qualitatively tested using Oil Red O staining and quantitatively analyzed using an AdipoRed plate reader (Lonza). Throughout this proposal, transdifferentiation of satellite cells into mature adipocytes will enable the muscle and fat components of cultured meat to be produced from a single cell source, thereby increasing protocol efficiency and impact.

[0526] serum-free medium

[0527] Medium Formulation for Serum Replacement - A growth factor-dependent serum-free medium (B8) will be generated based on a previously reported formulation and as successfully demonstrated by our group (preliminary data; Figures 16A-16B) 24 Briefly, B8 medium will consist of DMEM:F12 (1:1) supplemented with L-ascorbic acid 2-phosphate (200 μg / mL), insulin (20 μg / mL), transferrin (20 μg / mL), sodium selenite (20 ng / mL), FGF-2 (10 ng / mL), neuregulin 1 (NRG-1; 0.1 ng / mL), TGFβ-3 (0.1 ng / μL), and insulin-like growth factor 1 (IGF-1; 10 ng / mL). Formulations will also be produced that lack one or more growth factors, as well as formulations that lack all growth factors but contain a previously reported serum replacement composed of a rapeseed peptide fraction, maitake mushroom extract, and silk-derived sericin.

[0528] The culture medium containing the rapeseed peptide fraction was generated as previously described. 41 Briefly, rapeseed protein concentrate will be hydrolyzed with alkaline protease (Alcalase 2.4L) (Novozymes) at 60°C and a pH of 9.0 for five hours. The components will be precipitated at a pH of 4.0 and centrifuged. The supernatant will undergo ultrafiltration through a 3 kDa membrane and nanofiltration through a 0.5 kDa membrane. The nanofiltration retentate will again undergo ultrafiltration (1 kDa), and the retentate of this final filtration step will be added to a growth factor-free basal medium at a concentration of 10 mg / mL. The culture medium containing the Maitake mushroom extract will be produced as previously described. 55 Briefly, dried maitake mushrooms will be blended at a concentration of 0.2% w / v in a growth factor-free basal medium and sterilized by passing through a 0.2 μm filter. Finally, a culture medium containing sericin, which can be obtained from silk (i.e., as a byproduct of the textile industry) or recombinantly produced, will be produced by diluting purified sericin at a concentration of 30 μg / mL in the growth factor-free basal medium.

[0529] Formulations of different growth factor and serum replacement concentrations and combinations will be generated by combining the culture media. BSCs will be cultured in these media formulations as previously described.

[0530] Bioprocess Kinetics - To understand how media formulation affects bioprocess growth kinetics, cell growth curves will be generated using dsDNA-based fluorometric analysis of engineered and primary BSCs cultured in serum control media and media with serum and antibiotic replacement. To understand the impact of these culture systems on mitotic activity, cell cycle analysis will be performed simultaneously on an NC-3000 image cytometer (ChemoMetec). To explore cellular senescence in engineered cells, quantitative PCR for Pax7, a marker of BSC stemness, will be performed throughout culture in control cells and cells treated with serum and antibiotic replacement. 59 Based on preliminary data with B8, we anticipate achieving similar or superior cell growth compared to serum-containing media.

[0531] In conjunction with the mentioned cell-based assays, bioprocess kinetics will be tested throughout the culture by analyzing the culture medium for nutrient uptake and byproduct accumulation. Specifically, glucose uptake, glutamine uptake, lactate production, and ammonia production will be analyzed throughout the culture using enzyme assay kits for all medium formulations and all cell types. 60 .

[0532] Cell Differentiation Analysis - To understand the effect of medium composition on cell differentiation, cells cultured in all medium formulations will be differentiated (myogenic and adipogenic) as described above and analyzed for relevant markers. For myogenic differentiation, myogenic proteins and myosin heavy chain (MHC) expression will be assessed by immunostaining and quantitative PCR (qPCR), and myotube formation will be analyzed by determining the fusion index or the percentage of nuclei within fused myotubes. 63 For adipogenic differentiation, peroxisome proliferator-activated receptor gamma (PPARγ) expression will be analyzed by immunostaining and qPCR, and lipid accumulation will be analyzed by Oil-O red staining, extraction, and quantification. 64 We anticipate comparable differentiation capacity of cells cultured in serum-containing or serum-free medium formulations.

[0533] Genetic modification of serum replacement - To explore the development of cost-effective serum-free culture media orthogonal to the aforementioned serum replacement, BSCs will be engineered to endogenously produce growth factors and growth factor receptors. These "self-signaling" cells will require less medium input and thus further reduce culture costs. The target will correspond to B8. Specifically, the cells will be engineered to produce the growth factors FGF-2, TGFβ-3, NRG-1, and IGF-1, as well as the signaling and transport proteins insulin and transferrin.

[0534] Constitutive gene expression will be achieved through SleepingBeauty transposon-mediated gene insertion due to the non-viral nature of this system, its high efficiency, and its utility demonstrated in our preliminary work. 56,57 . Molecular cloning will be carried out using standard techniques. For gene insertion, the transposable element will contain the gene of interest (e.g., FGF-2) and a gene resistant to the selected antibiotic (i.e., puromycin) to enable selection of successfully transfected cells. Cell transfection will be carried out using Lipofectamine 3000 reagent (Thermo Fisher, #L3000008). Briefly, cells will be cultured to 85% confluence, washed with OptiMEM culture medium, and cultivated together with transfection reagent and purified plasmid. After 4 to 6 hours, growth medium will be added to the cells, and after 48 hours, selection pressure (i.e., puromycin) will be added to the culture medium. The cells will be cultured under selective pressure for one week, after which expression will be verified by immunocytochemistry, using fluorescent tags or polymerase chain reaction (PCR). When polycistronic expression is required (i.e., for the simultaneous expression of all growth factors), the genes will be connected by 2A peptide sequences to allow translation of multiple proteins from a single strand of RNA encoding multiple genes. 58In most cases, the 2A sequence will link the green fluorescent protein (GFP) to the expression cassette, allowing expression to be screened by simple fluorescence microscopy. Finally, the transgene will be inserted under the control of an inducible promoter that can be "turned off" for cell differentiation to stop the expression of pro-proliferation factors. Successfully engineered cells will be cultured in various growth factor-free medium formulations described herein.

[0535] Antibiotic-free culture medium

[0536] Culture medium formulation for antibiotic alternatives - Cinnamon, monolaurin (a derivative of coconut lauric acid), and honey are natural compounds that have shown potential as food-safe antimicrobial agents. 46,65,66 Each of these substances will be explored individually and in combination as a culture medium additive to prevent microbial contamination. They will first be added to B8 serum-free culture medium with growth factors and used to culture BSCs. A dose-response curve (DRC) will be generated to determine the effect of each additive on cell health and to identify the maximum concentration that can be used without hindering growth, survival, and differentiation. After evaluating antimicrobial activity, successful candidates will be incorporated into serum-free and growth factor-free culture medium as described herein and the effect on culture performance will be evaluated again.

[0537] Analysis of Antimicrobial Effect in Cell Cultures - The antimicrobial activity of the culture medium supplemented with cinnamon, monolaurin, and honey will be tested using an agar well diffusion test. Bacterial and yeast extracts will be spread over the entire surface of the agar plate, and a biopsy punch will be used to remove agar cylinders of 6 mm diameter. 100 μL of culture medium containing various concentrations of antimicrobial agents will then be added to the wells, and the inhibition zone will be measured after an 18 to 24 hour incubation period. 69 The efficacy of alternative antimicrobial agents was compared with the common cell culture antimicrobials penicillin-streptomycin (Pen-Strep) and antibiotic-antimycotic (Anti-Anti).

[0538] Analysis of Antimicrobial Effects in Cooked Products - To further evaluate the efficacy of alternative antimicrobials and their utility in the commercial production of cultured meat, we will test the ability of target antimicrobials to inactivate E. coli and / or enhance heat destruction of E. coli in cell-based and conventional meat samples. Antimicrobials used as culture medium additives will be tested (cinnamon, fatty acids, honey). In addition, cell-based samples containing engineered cells will be tested without the addition of exogenous compounds. All samples will be inoculated with a mixture of E. coli strains isolated from meat and dairy products, treated with various concentrations of each antimicrobial when appropriate, and then stored at 4°C for 5 days. E. coli O157:H7 content will be quantified by surface plating of homogenized samples and colony counts before and after cooking at multiple time points.

[0539] Assays for Cell Growth and Differentiation - The effect of each alternative antimicrobial agent on cell proliferation will be assessed (i.e., growth curve analysis using dsDNA-based fluorometric analysis and nutrient / waste uptake / production analysis using enzymatic assays). The effects on myogenic and adipogenic differentiation will be assessed by immunostaining for myosin heavy chain (MHC) or oil-O red staining and qPCR for MHC and PPARγ. These assays will be used to determine the concentrations of cinnamon, honey, and monolaurin that can be added to the culture medium without adversely affecting performance.

[0540] Genetic Modification of Antibiotic Alternatives - As a secondary strategy for the culture medium additives described herein, metabolic engineering of the BSC will be used to achieve constitutive endogenous production of food-safe compounds with antimicrobial activity. Specifically, metabolic pathways for the synthesis of cinnamaldehyde and limonene from common precursor molecules will be engineered into the BSC using SleepingBeauty transposon-mediated gene insertion, as utilized in our previous work. The synthesis of cinnamaldehyde from the precursor phenylalanine will be achieved by inserting a three-enzyme pathway: phenylalanine ammonia lyase, 4-coumarate-CoA ligase, and cinnamoyl-CoA reductase. The synthesis of (+)-limonene from the precursor geranyl pyrophosphate will be achieved by inserting a single enzyme: (R)-limonene synthase. The concentrations of cinnamaldehyde and limonene secreted into the culture medium will be assessed using high performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GM-MS), respectively. 67,68 Cell health and development will be analyzed as previously described.

[0541] Food quality analysis

[0542] Protein and Amino Acids - Engineered and primary cells will be cultured in all media formulations and harvested before and after myogenic and adipogenic differentiation. Bulk protein will be quantified using the Pierce BCA protein assay. Amino acid composition will be quantified by HPLC as previously described.70,71 . Briefly, cells will be homogenized by sonication, spiked with a known concentration of the internal standard norvaline, hydrolyzed with HCl, and quantified by HPLC relative to amino acid standards (also spiked with norvaline) after pre-column derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate. Samples will be separated on a Nova-Pak C18 (Waters) column and analyzed using fluorescence detection with excitation at 250 nm and emission at 395 nm. Bulk protein and amino acid composition will be correlated with DNA content (CyQuant analysis; Thermo Fisher) to compare undifferentiated and differentiated cells. Conventional meat samples will be analyzed and compared with cultured cells.

[0543] We expected that the bulk protein in bovine cells would be similar to that found in commercial beef, but that reduced extracellular protein accumulation would result in lower protein levels. We expected the amino acid profile to be a combination of that of the cell growth medium and that of the commercial product.

[0544] Fat and fatty acid-lipid analysis will be performed using liquid chromatography-mass spectrometry (LC-MS) as previously described. 72 . Briefly, undifferentiated and differentiated (myoblast and adipogenic) BSCs from all culture conditions will be homogenized by ultrasonic treatment, and lipid internal standards will be added to the homogenate (comprising phosphatidylcholine (PC), phosphatidylethanolamine (PE), ceramide (Cer), phosphatidylserine (PS), phosphatidic acid (PA) and monoacylglycerol, diacylglycerol and triacylglycerol (MG, DG and TG)). Cellular lipids will be extracted with a solution of chloroform and methanol (2: 1, v / v), centrifuged, and the lower phase will be collected and merged with an external standard (comprising isotope-labeled TG and PC). Samples will be separated by LC-MS in a BEH C18 column (Waters) relative to lipid standards, followed by quadrupole time-of-flight detection for quantification. Fatty acid profiles will be standardized using internal and external standards and relative to DNA and protein quantification. Again, samples will be analyzed at different levels of differentiation and compared with store-bought products. Based on previous data comparing murine adipose tissue and murine adipocyte progenitors before and after differentiation, we expected that the lipid profile of bovine fat before differentiation would be significantly different from that of store-bought beef, but similar after differentiation. 73 .

[0545] Cholesterol will be analyzed by fluorometric assay (Abcam, #ab65390) and compared to total lipids measured by fluorometric assay (Abcam, #ab242307). Samples will be analyzed at different levels of differentiation and again before and after cooking compared to store-bought product. Based on published data, we expect cholesterol to represent approximately 1 mg / g lipid in bovine adipocytes.74 .

[0546] Micronutrients - Water-soluble and fat-soluble vitamins (vitamins A, B1, B2, B3, B5, B6, B9, B 12 , E, K, D, E, C). Techniques will include HPLC, spectrophotometric measurement of enzyme activity, radiometric analysis or colorimetric analysis, as required and previously described and performed by NEL 75,76 Iron and zinc will be quantified using an iron assay kit (Abcam, #ab83366) and a zinc assay kit (Abcam, #ab102507), respectively. Again, micronutrient results will be compared with those obtained from store-bought beef products.

[0547] Although the bovine genome contains pathways for the synthesis of vitamins B3, D, and C, these functions are primarily performed in the liver or skin, respectively, and tissue concentrations of niacin are generally controlled by the liver. 77,78 Therefore, we expect that the vitamin composition will be primarily defined by the culture medium. Similarly, since minerals are only available exogenously, we expect that zinc and iron will be similarly defined by the culture medium. This may not be the case if the culture medium is supplemented with some plant extracts (such as the main Maitake mushroom extract), as it is likely that it will contain some micronutrient components that will be incorporated by the cells.

[0548] Myoglobin content - Myoglobin content will be analyzed using a modified Warriss method 82 BSCs and store-bought beef before and after differentiation will be mechanically homogenized in PBS, centrifuged at 5,000 x g for 30 minutes, and filtered (Whatman No. 1 filter paper) to obtain extracts. The extracts will be oxidized with 60 mM K3F(III)(CN)6 and then treated with 80 mM NaCN to induce a color change from yellow to red. The absorbance will be measured at 540 nm, and the myoglobin concentration will be determined using the cyanmetmyoglobin molar extinction coefficient (11300).

[0549] We expect myoglobin levels to be significantly lower in BSC than in store-bought beef. 23 We expect myoglobin content to be higher after differentiation 83 The average myoglobin content in beef is 8 mg / g, which is associated with the "cherry red" color. The values ​​for lamb and pork are 6 mg / g (light red) and 2 mg / g (pink), respectively.84 Strategies used to modulate myoglobin content in vitro include induced hypoxia, lipid supplementation, and direct exogenous myoglobin supplementation and can be explored in the presence of insufficient myoglobin. 23,85 .

[0550] Gelation Properties - Thermal gelation properties will be evaluated using actomyosin extraction followed by gel strength and dynamic rheology measurements. Actomyosin (actin / myosin complex) will be extracted from pre- and post-differentiation bovine satellite cells and commercial beef using a modified Ogawa method. 86 . The samples will be mechanically homogenized in cold separation buffer (50 mM KCl, 20 mM K2HPO4 / KH2PO4) and filtered (0.9 mm mesh). The suspension will be centrifuged at 10,000 x g for 5 minutes, and the pellet will be homogenized in 0.6 M KCl buffer. After another round of centrifugation and filtration, the supernatant will be mixed with 20 mM potassium phosphate buffer, and the precipitate will be collected by centrifugation and resuspended in separation buffer. The final centrifugation step will provide actomyosin fragments; their concentration will be determined by the biuret reaction. The gel strength will be determined by texture analysis. The actomyosin concentration will be standardized, and the samples will be sealed in a beaker and heated to 80°C for 20 minutes, then cooled and refrigerated overnight (4°C). The gel will be acclimatized to ambient temperature and evaluated by a penetration test (1 mm / s) on a texture analyzer. The actomyosin gel will also be evaluated by dynamic rheological analysis during heating from ambient temperature to 80°C (1°C / min). 87 .

[0551] Food quality optimization - depending on the results of the nutritional and meat quality analysis, the culture system will be adapted for deficiencies. For example, in the case of nutritional deficiencies (e.g., insufficient essential amino acids), the culture medium will be supplemented with relevant nutrients in order to increase the cell concentration. In addition, metabolic engineering techniques, such as those used in our preliminary carotenoid work, can be used to increase nutrient levels through endogenous production (e.g., incorporation into essential amino acid biosynthetic pathways). In the event that the meat science metrics in the culture sample are insufficient compared to conventional meat, several techniques may be used to adjust the cultured meat characteristics. For example, as previously mentioned, myoglobin content can be adjusted by exogenous culture medium supplementation or by culturing cells under hypoxic conditions. 44,85 In cases where the metabolite profiles differ significantly, key metabolic processes can be modulated by metabolic pathway engineering (as demonstrated by nutrient engineering in our group's BSC) or by treatment with small molecules. 19,88,89 Finally, in cases where the gelling properties differ significantly from conventional meat, various mechanical means (e.g., via 3D tissue constructs) could be employed to increase myofiber formation and myosin expression. 90 .

[0552] References:

[0553] 1. Wyness, L. et al. Red meat in the diet: an update. Nutr. Bull. 36, 34 - 77 (2011).

[0554] 2. Purchas, R. W., Wilkinson, B. H. P., Carruthers, F. & Jackson, F. A comparison of the nutrient content of uncooked and cooked lean from New Zealand beef and lamb. J. Food Compos. Anal. 35, 75 - 82 (2014).

[0555] 3. D. et al. Composition differences between organic and conventional meat: a systematic literature review and meta - analysis. Br. J. Nutr. 115, 994 - 1011 (2016).

[0556] 4. Rizzo, G. et al. Vitamin B12 among Vegetarians: Status, Assessment and Supplementation. Nutrients 8, 767 (2016).

[0557] 5. Wood, J. D. Meat Composition and Nutritional Value. Lawrie′s Meat Sci. 635 - 659 (2017). doi:10.1016 / B978 - 0 - 08 - 100694 - 8.00020 - 0

[0558] 6. Godfray, H. C. J. et al. Meat consumption, health, and the environment. Science 361, eaam5324 (2018).

[0559] 7.Hoekstra,A.Y.&Mekonnen,M.M.The water footprint of humanity.Proc.Natl.Acad.Sci.U.S.A.109,3232-7(2012).

[0560] 8.Feskens,E.J.M.,Sluik,D.&van Woudenbergh,G.J.Meat Consumption,Diabetes,and Its Complications.Curr.Diab.Rep.13,298-306(2013).

[0561] 9.Schwingshackl,L.et al.Food groups and risk of type 2 diabetesmellitus:a systematic review and meta-analysis of prospectivestudies.Eur.J.Epidemiol.32,363-375(2017).

[0562] 10.Alshahrani,S.et al.Red and Processed Meat and Mortality in a LowMeat Intake Population.Nutrients 11,622(2019).

[0563] 11.Abete,I.,Romaguera,D.,Vieira,A.R.,Lopez de Munain,A.&Norat,T.Association between total,processed,red and white meat consumption and all-cause,CVD and IHD mortality:a meta-analysis of cohort studies.Br.J.Nutr.112,762-775(2014).

[0564] 12.Chan,D.S.M.et al.Red and Processed Meat and Colorectal CancerIncidence:Meta-Analysis of Prospective Studies.PLoS One 6,e20456(2011).

[0565] 13.Wang,X.et al.Red and processed meat consumption and mortality:dose-response meta-analysis of prospective cohort studies.Public HealthNutr.19,893-905(2016).

[0566] 14.Wolk,A.Potential health hazards of eating red meat.J.Intern.Med.281,106-122(2017).

[0567] 15.Klurfeld,D.M.Research gaps in evaluating the relationship of meatand health.Meat Sci.109,86-95(2015).

[0568] 16.Datar,I.&Betti,M.Possibilities for an in vitro meat productionsystem.Innov.Food Sci.Emerg.Technol.11,13-22(2010).

[0569] 17.Post,M.J.Cultured meat from stem cells:Challenges andprospects.Meat Sci.92,297-301(2012).

[0570] 18.Mattick,C.S.,Landis,A.E.,Allenby,B.R.&Genovese,N.J.AnticipatoryLife Cycle Analysis of In Vitro Biomass Cultivation for Cultured MeatProduction in the United States.Environ.Sci.Technol.49,11941-11949(2015).

[0571] 19.Stout,A.J.,Mirliani,A.B.,Soule-Albridge,E.L.,Cohen,J.M.&Kaplan,D.L.Engineering carotenoid production in mammalian cells for nutritionallyenhanced cell-cultured foods.Rev.

[0572] 20.Bhat,Z.F.,Kumar,S.&Fayaz,H.In vitro meat production:Challenges andbenefits over conventional meat production.J.Integr.Agric.14,241-248(2015).

[0573] 21.National Cattlemen's Beef Association.Industry Statistics.(2019).

[0574] 22.Rubio,N.R.,Fish,K.D.,Trimmer,B.A.&Kaplan,D.L.In Vitro InsectMuscle for Tissue Engineering Applications.ACS Biomater.Sci.Eng.5,1071-1082(2019).

[0575] 23.Simsa,R.et al.Extracellular Heme Proteins Influence BovineMyosatellite Cell Proliferation and the Color of Cell-Based Meat.Foods 8,521(2019).

[0576] 24.Kuo,H.H.et al.Negligible-Cost and Weekend-Free Chemically DefinedHuman iPSC Culture.Stem Cell Reports 14,256-270(2020).

[0577] 25.Fish,K.D.,Rubio,N.R.,Stout,A.J.,Yuen,J.S.K.&Kaplan,D.L.Prospectsand challenges for cell-cultured fat as a novel food ingredient.Trends inFood Science and Technology 98,53-67(2020).

[0578] 26.Wolk,A.Potential health hazards of eating red meat.J.Intern.Med.281,106-122(2017).

[0579] 27. J.&Reese,J.Cell-cultured meat:Lessons from GMO adoptionand resistance.Appetite 143,104408(2019).

[0580] 28.Tuomisto,H.L.&Teixeira de Mattos,M.J.Environmental Impacts ofCultured Meat Production.Environ.Sci.Technol.45,6117-6123(2011).

[0581] 29.Mattick,C.S.,Landis,A.E.,Allenby,B.R.&Genovese,N.J.AnticipatoryLife Cycle Analysis of In Vitro Biomass Cultivation for Cultured MeatProduction in the United States.Environ.Sci.Technol.49,11941-11949(2015).

[0582] 30.Bekker,G.A.,Fischer,A.R.H.,Tobi,H.&van Trijp,H.C.M.Explicit andimplicit attitude toward an emerging food technology:The case of culturedmeat.Appetite 108,245-254(2017).

[0583] 31.Stephens,N.et al.Bringing cultured meat to market:Technical,socio-political,and regulatory challenges in cellular agriculture.Trends in FoodScience and Technology 78,155-166(2018).

[0584] 32.Chriki,S.&Hocquette,J.-F.The Myth of Cultured Meat:AReview.Front.Nutr.7,7(2020).

[0585] 33.Specht,L.Creating a healthy,humane,and sustainable food supply.Ananalysis of culture medium costs and production volumes for cell-basedmeat.7-10(2019).

[0586] 34.Ben-Arye,T.&Levenberg,S.Tissue Engineering for Clean MeatProduction.Frontiers in Sustainable Food Systems 3,46(2019).

[0587] 35.Bryant,C.&Barnett,J.Consumer acceptance of cultured meat:Asystematic review.Meat Science 143,8-17(2018).

[0588] 36.Zhang,G.et al.Challenges and possibilities for bio-manufacturingcultured meat.Trends in Food Science and Technology 97,443-450(2020).

[0589] 37.O'Donoghue,E.,Hansen,J.&Stallings,D.USDA Agricultural Projectionsto 2028.(2019).

[0590] 38.Babcock,J.F.&Antosh,A.Partial Replacement of Chemically DefinedCHO Media with Plant-Derived Protein Hydrolysates.in Proceedings of the 21stAnnual Meeting of the European Society for Animal Cell Technology(ESACT),Dublin,Ireland,June 7-10,2009295-298(Springer Netherlands,2012).doi:10.1007 / 978-94-007-0884-6_44

[0591] 39.Benjaminson,M..,Gilchriest,J..&Lorenz,M.In vitro edible muscleprotein production system(mpps):stage 1,fish.ActaAstronaut.51,879-889(2002).

[0592] 40.Terada,S.,Sasaki,M.,Yanagihara,K.&Yamada,H.Preparation of silkprotein sericin as mitogenic factor for better mammalian cellculture.J.Biosci.Bioeng.100,667-671(2005).

[0593] 41.Farges-Haddani,B.et al.Peptide fractions of rapeseed hydrolysatesas an alternative to animal proteins in CHO cell culture media.ProcessBiochem.41,2297-2304(2006).

[0594] 42.Zhang,M.,Cao,T.-T.,Wei,Z.-G.&Zhang,Y.-Q.Silk Sericin Hydrolysateis a Potential Candidate as a Serum-Substitute in the Culture of ChineseHamster Ovary and Henrietta Lacks Cells.J.Insect Sci.19,(2019).

[0595] 43.Pietrzkowski,Z.et al.Constitutive expression of insulin-likegrowth factor 1 and insulin-like growth factor 1 receptor abrogates allrequirements for exogenous growth factors.Cell Growth Differ.3,199-205(1992).

[0596] 44.Simsa,R.et al.Extracellular Heme Proteins Influence BovineMyosatellite Cell Proliferation and the Color of Cell-Based Meat.Foods 2019,Vol.8,Page 5218,521(2019).

[0597] 45.Chu,L.&Robinson,D.K.Industrial choices for protein production bylarge-scale cell culture.Curr.Opin.Biotechnol.12,180-187(2001).

[0598] 46.Nabavi,S.et al.Antibacterial Effects of Cinnamon:From Farm toFood,Cosmetic and Pharmaceutical Industries.Nutrients 7,7729-7748(2015).

[0599] 47.Carpo,B.G.,Verallo-Rowell,V.M.&Kabara,J.Novel antibacterialactivity of monolaurin compared with conventional antibiotics againstorganisms from skin infections:an in vitro study.J.Drugs Dermatol.6,991-8(2007).

[0600] 48.Mandal,M.D.&Mandal,S.Honey:its medicinal property andantibacterial activity.Asian Pac.J.Trop.Biomed.1,154-60(2011).

[0601] 49.Guzman,J.D.Natural cinnamic acids,synthetic derivatives andhybrids with antimicrobial activity.Molecules 19,19292-19349(2014).

[0602] 50.Espina,L.,Gelaw,T.K.,de Lamo-Castellví,S.,Pagán,R.&García-Gonzalo,D.Mechanism of Bacterial Inactivation by(+)-Limonene and Its Potential Use inFood Preservation Combined Processes.PLoS One 8,(2013).

[0603] 51.Amalaradjou,M.A.R.et al.Enhancing the thermal destruction ofEscherichia coli O157:H7 in ground beef patties by trans-cinnamaldehyde.FoodMicrobiol.27,841-844(2010).

[0604] 52.Sharma,S.,Thind,S.S.&Kaur,A.In vitro meat production system:whyand how?J.FoodSci.Technol.52,7599-7607(2015).

[0605] 53.Post,M.J.Proteins in cultured beef.Proteins Food Process.289-298(2018).doi:10.1016 / B978-0-08-100722-8.00012-7

[0606] 54.Mcaleer,C.W.,Rumsey,J.W.,Stancescu,M.&Hickman,J.J.Functionalmyotube formation from adult rat satellite cells in a defined serum-freesystem.Biotechnol.Prog.31,997-1003(2015).

[0607] 55.Benjaminson,M.A.,Gilchriest,J.A.&Lorenz,M.In vitro edible muscleprotein production system(MPPS):Stage 1,fish.Acta Astronaut.51,879-889(2002).

[0608] 56.Ding,S.et al.Maintaining bovine satellite cells stemness throughp38 pathway.Sci.Rep.8,10808(2018).

[0609] 57.Gambhir,A.et al.Analysis of cellular metabolism of hybridoma cellsat distinct physiological states.J.Biosci.Bioeng.95,317-327(2003).

[0610] 58.Pala,F.et al.Distinct metabolic states govern skeletal muscle stemcell fates during prenatal and postnatal myogenesis.J.Cell Sci.131,(2018).

[0611] 59.Fortini,P.et al.The fine tuning of metabolism,autophagy anddifferentiation during in vitro myogenesis.Cell Death Dis.7,e2168-e2168(2016).

[0612] 60.Rubio,N.R.,Fish,K.D.,Trimmer,B.A.&Kaplan,D.L.In Vitro InsectMuscle for Tissue Engineering Applications.ACS Biomater.Sci.Eng.5,1071-1082(2019).

[0613] 61.Nierobisz,L.S.,McFarland,D.C.&Mozdziak,P.E.MitoQ10 inducesadipogenesis and oxidative metabolism in myotube cultures.Comp.Biochem.Physiol.-B Biochem.Mol.Biol.158,125-131(2011).

[0614] 62.Mátés,L.et al.Molecular evolution of a novel hyperactive SleepingBeauty transposase enables robust stable gene transfer invertebrates.Nat.Genet.41,753-761(2009).

[0615] 63.Geurts,A.M.et al.Gene transfer into genomes of human cells by thesleeping beauty transposon system.Mol.Ther.8,108-117(2003).

[0616] 64.Szymczak,A.L.&Vignali,D.A.Development of 2A peptide-basedstrategies in the design of multicistronic vectors.Expert Opin.Biol.Ther.5,627-638(2005).

[0617] 65.Balouiri,M.,Sadiki,M.&Ibnsouda,S.K.Methods for in vitro evaluatingantimicrobial activity:A review.Journal of Pharmaceutical Analysis 6,71-79(2016).

[0618] 66.Miller,J.A.,Hakim,I.A.,Thomson,C.,Thompson,P.&Sherry Chow,H.H.Determination of d-limonene in adipose tissue by gas chromatography-massspectrometry.J.Chromatogr.B Anal.Technol.Biomed.Life Sci.870,68-73(2008).

[0619] 67.Gursale,A.,Dighe,V.&Parekh,G.Simultaneous quantitativedetermination of cinnamaldehyde and methyl eugenol from stem bark ofCinnamomum zeylanicum Blume using RP-HPLC.J.Chromatogr.Sci.48,59-62(2010).

[0620] 68.Sengupta,S.et al.Hypoxia and Amino Acid SupplementationSynergistically Promote the Osteogenesis of Human Mesenchymal Stem Cells onSilk Protein Scaffolds.Tissue Eng.Part A 16,3623-3634(2010).

[0621] 69.Cohen,S.A.Amino Acid Analysis Using Precolumn Derivatization with6-Aminoquinolyl-NHydroxysuccinimidyl Carbamate.in Amino AcidAnalysisProtocols 039-047(Humana Press).doi:10.1385 / 1-59259-047-0:039

[0622] 70.Nygren,H., T.,Castillo,S., T.& M.Liquid Chromatography-Mass Spectrometry(LC-MS)-Based Lipidomics for Studiesof Body Fluids and Tissues.in 247-257(Humana Press,2011).doi:10.1007 / 978-1-61737-985-7_15

[0623] 71.Liaw,L.et al.Lipid Profiling of In Vitro Cell Models of AdipogenicDifferentiation:Relationships With Mouse Adipose Tissues.J.Cell.Biochem.117,2182-93(2016).

[0624] 72.Schreibman,P.H.&Dell,R.B.Human adipocyte cholesterol.Concentration,localization,synthesis,and turnover.J.Clin.Invest.55,986-93(1975).

[0625] 73.Rojas,A.I.&Phillips,T.J.Patients with Chronic Leg Ulcers ShowDiminished Levels of Vitamins A and E,Carotenes,and Zinc.DermatologicSurg.25,601-604(1999).

[0626] 74.Bernstein,M.A.et al.Higher dietary variety is associated withbetter nutritional status in frail elderly people.J.Am.Diet.Assoc.102,1096-1104(2002).

[0627] 75.Combs,G.F.&McClung,J.P.The vitamins :fundamental aspects innutrition and health.

[0628] 76.Dietary Reference Intakes for Thiamin,Riboflavin,Niacin,VitaminB6,Folate,VitaminB12,Pantothenic Acid,Biotin,and Choline.(National AcademiesPress,1998).doi:10.17226 / 6015

[0629] 77.Abraham,A.,Dillwith,J.W.,Mafi,G.G.,VanOverbeke,D.L.&Ramanathan,R.Metabolite Profile Differences between Beef Longissimus and Psoas Musclesduring Display.Meat Muscle Biol.1,18(2017).

[0630] 78.Cassim,S.,Raymond,V.-A.,Lapierre,P.&Bilodeau,M.From in vivo to invitro:Major metabolic alterations take place in hepatocytes during andfollowing isolation.PLoS One 12,e0190366(2017).

[0631] 79.Lin,X.et al.Metabolic effects of basic fibroblast growth factor instreptozotocin-induced diabetic rats:A 1H NMR-based metabolomicsinvestigation.Sci.Rep.6,1-9(2016).

[0632] 80.Kim,G.D.et al.The relationship between meat color(CIE L*and a*),myoglobin content,and their influence on muscle fiber characteristics andpork quality.Korean J.Food Sci.Anim.Resour.30,626-633(2010).

[0633] 81.Kanatous,S.B.&Mammen,P.P.A.Regulation of myoglobinexpression.Journal of Experimental Biology 213,2741-2747(2010).

[0634] 82.Aberle,E.&Forrest,J.Principles of Meat Science.(Kendall Hunt PubCo,2001).

[0635] 83.Peters,E.L.et al.IGF-1 attenuates hypoxia-induced atrophy butinhibits myoglobin expression in C2C12 skeletal musclemyotubes.Int.J.Mol.Sci.18,1889(2017).

[0636] 84.Li,K.,Liu,J.Y.,Fu,L.,Zhao,Y.Y.&Bai,Y.H.Comparative study ofthermalgelation properties and molecular forces of actomyosin extracted from normaland pale,soft and exudative-like chicken breast meat.Asian-AustralasianJ.Anim.Sci.32,721-733(2019).

[0637] 85.Li,K.et al.A comparative study of chemical composition,color,andthermal gelling properties of normal and PSE-like chicken breast meat.CYTA-J.Food 13,213-219(2015).

[0638] 86.Buchsteiner,M.,Quek,L.-E.,Gray,P.&Nielsen,L.K.Improving cultureperformance and antibody production in CHO cell culture processes by reducingthe Warburg effect.Biotechnol.Bioeng.115,2315-2327(2018).

[0639] 87.Kim,J.et al.Targeting aldehyde dehydrogenase activity in head andneck squamous cell carcinoma with a novel small molecule inhibitor.Oncotarget8,52345(2017).

[0640] 88.Somers,S.M.et al.Myoblast maturity on aligned microfiber bundlesat the onset of strain application impacts myogenic outcomes.ActaBiomater.94,232-242(2019).

[0641] 89.Clark,K.J.et al.Enzymatic engineering of the porcine genome withtransposons and recombinases.BMCBiotechnol.7,42(2007).

[0642] 90.Ramirez,R.D.et al.Immortalization of Human Bronchial EpithelialCells in the Absence of Viral Oncoproteins.Cancer Res.64,9027-9034(2004).

[0643] 91.Lobo-Alfonso,J.,Price,P.&Jayme,D.Benefits and limitations ofprotein hydrolysates as components of serum-free media for animal cellculture applications protein hydrolysates in serum free media.in ProteinHydrolysates in Biotechnology 55-78(Springer Netherlands,2010).doi:10.1007 / 978-1-4020-6674-0_4

[0644] 92. K., B.,Andlar,M.,Slivac,I.&Gaurina V.Adaptationand cultivation of permanent fish cell line CCO in serum-free medium andinfluence of protein hydrolysates on growth performance.Cytotechnology 68,115-121(2016).

[0645] 93.Reardon,W.et al.Mutations in the fibroblast growth factor receptor2 gene cause Crouzon syndrome.Nat.Genet.8,98-103(1994).

[0646] 94.Ding,S.et al.Maintaining bovine satellite cells stemness throughp38 pathway.Sci.Rep.8,10808(2018).

[0647] 95.Morgani,S.M.et al.A Sprouty4 reporter to monitor FGF / ERK signalingactivity in ESCs and mice.Dev.Biol.441,104-126(2018).

[0648] 96.Setzer,M.S.,Sharifi-Rad,J.&Setzer,W.N.The search for herbalantibiotics:An in-silico investigation of antibacterial phytochemicals.Antibiotics5,30(2016).

[0649] 97.Ohene-Agyei,T.,Mowla,R.,Rahman,T.&Venter,H.Phytochemicals increasethe antibacterial activity of antibiotics by acting on a drug effluxpump.Microbiologyopen 3,885-896(2014).

[0650] 98.Krumpochova,P.et al.Amino acid analysis using chromatography-massspectrometry:An inter platform comparison study.J.Pharm.Biomed.Anal.114,398-407(2015).

[0651] 99. M.,Liebisch,G.&Ekroos,K.Lipidomic Analysis.Anal.Chem.90,4249-4257(2018).

[0652] 100.Mancini,R.A.&Ramanathan,R.Effects of postmortem storage time oncolor and mitochondria in beef.Meat Sci.98,65-70(2014).

[0653] 101.Jiang,S.et al.Thermal gelling properties and structuralproperties of myofibrillar protein including thermo-reversible and thermo-irreversible curdlan gels.Food Chem.311,126018(2020).

[0654] 102.Alden,N.et al.Biologically Consistent Annotation of MetabolomicsData.Anal.Chem.89,13097-13104(2017).

[0655] 103.Ravishankar,S.et al.Carvacrol and cinnamaldehyde inactivateantibiotic-resistant salmonella entérica in buffer and on celery andoysters.J.Food Prot.73,234-240(2010).

[0656] 104.Nystoriak,M.A.et al.Comparative effects of parent and heatedcinnamaldehyde on the function of human iPSC-derived cardiacmyocytes.Toxicol.Vitr.61,104648(2019).

[0657] 105.Roberto,D.,Micucci,P.,Sebastian,T.,Graciela,F.&Anesini,C.Antioxidant Activity of Limonene on Normal Murine Lymphocytes:Relation toH2 O2 Modulation and Cell Proliferation.Basic Clin.Pharmacol.Toxicol.(2009).doi:10.1111 / j.1742-7843.2009.00467.x

[0658] 106.Lodish,H.F.Molecular cell biology.(W.H.Freeman,2000).

[0659] 107.Manner,W.,Maxwell,R.J.&Williams,J.E.Effects ofDietary Regimen andTissue Site on Bovine Fatty Acid Profiles.J.Anim.Sci.59,109-121(1984).

[0660] 108.Ackermann,T.&Tardito,S.Cell Culture Medium Formulation and ItsImplications in Cancer Metabolism.Trends in cancer 5,329-332(2019).

[0661] 109.Dale,J.C.,Burritt,M.F.&Zinsmeister,A.R.Diurnal Variation of SerumIron,Iron-Binding Capacity,Transferrin Saturation,and FerritinLevels.Am.J.Clin.Pathol.117,802-808(2002).

[0662] 110.Rükgauer,M.,Klein,J.&Kruse-Jarres,J.D.Reference Values for theTrace Elements Copper,Manganese,Selenium,and Zinc in the Serum / Plasma ofChildren,Adolescents,and Adults.J.TraceElem.Med.Biol.11,92-98(1997).

[0663] 111.Cho,Y.-E.et al.Cellular Zn depletion by metal ion chelators(TPEN,DTPA and chelex resin)and its application to osteoblastic MC3T3-E1cells.Nutr.Res.Pract.1,29-35(2007).

[0664] 112.Thorrez,L.&Vandenburgh,H.Challenges in the quest for‘clean meat’.Nat.Biotechnol.37,215-216(2019).

[0665] 113. Allan, SJ, De Bank, PA & Ellis, MJ Bioprocess DesignConsiderations for Cultured Meat Production With a Focus on the ExpansionBioreactor. Front. Sustain. Food Syst. 3, 44 (2019).

[0666] 114. Lynch, J. & Pierrehumbert, R. Climate Impacts of Cultured Meat and Beef Cattle. Front. Sustain. Food Syst. 3, 5 (2019).

[0667] 115.Quek,LE,Dietmair,S., JO&Nielsen, LKMetabolic fluxanalysis in mammalian cell culture.Metab.Eng.12,161-171(2010).

[0668] The invention has been described in terms of one or more preferred embodiments, and it should be understood that many equivalents, alternatives, variations and modifications besides those expressly stated are possible and within the scope of the invention. Sequence Listing <110> Trustees of Tufts College Stout, Andrew Kaplan, David, L. <120> Cultured meat products using genetically modified cells <130> 166118.00970 <150> US 62 / 855,698 <151> 2019-05-31 <150> US 62 / 861,606 <151> 2019-06-14 <160> 40 <170> PatentIn version 3.5 <210> 1 <211> 309 <212> PRT <213> Pantoea ananas <400> 1 Met Asn Asn Pro Ser Leu Leu Asn His Ala Val Glu Thr Met Ala Val 1 5 10 15 Gly Ser Lys Ser Phe Ala Thr Ala Ser Lys Leu Phe Asp Ala Lys Thr 20 25 30 Arg Arg Ser Val Leu Met Leu Tyr Ala Trp Cys Arg His Cys Asp Asp 35 40 45 Val Ile Asp Asp Gln Thr Leu Gly Phe Gln Ala Arg Gln Pro Ala Leu 50 55 60 Gln Thr Pro Glu Gln Arg Leu Met Gln Leu Glu Met Lys Thr Arg Gln 65 70 75 80 Ala Tyr Ala Gly Ser Gln Met His Glu Pro Ala Phe Ala Ala Phe Gln 85 90 95 Glu Val Ala Met Ala His Asp Ile Ala Pro Ala Tyr Ala Phe Asp His 100 105 110 Leu Glu Gly Phe Ala Met Asp Val Arg Glu Ala Gln Tyr Ser Gln Leu 115 120 125 Asp Asp Thr Leu Arg Tyr Cys Tyr His Val Ala Gly Val Val Gly Leu 130 135 140 Met Met Ala Gln Ile Met Gly Val Arg Asp Lys Ala Thr Leu Asp Arg 145 150 155 160 Ala Cys Asp Leu Gly Leu Ala Phe Gln Leu Thr Asn Ile Ala Arg Asp 165 170 175 Ile Val Asp Asp Ala His Ala Gly Arg Cys Tyr Leu Pro Ala Ser Trp 180 185 190 Leu Glu His Glu Gly Leu Asn Lys Glu Asn Tyr Ala Ala Pro Glu Asn 195 200 205 Arg Gln Ala Leu Ser Arg Ile Ala Arg Arg Leu Val Gln Glu Ala Glu 210 215 220 Pro Tyr Tyr Leu Ser Ala Thr Ala Gly Leu Ala Gly Leu Pro Leu Arg 225 230 235 240 Ser Ala Trp Ala Ile Ala Thr Ala Lys Gln Val Tyr Arg Lys Ile Gly 245 250 255 Val Lys Val Glu Gln Ala Gly Gln Gln Ala Trp Asp Gln Arg Gln Ser 260 265 270 Thr Thr Thr Pro Glu Lys Leu Thr Leu Leu Leu Ala Ala Ser Gly Gln 275 280 285 Ala Leu Thr Ser Arg Met Arg Ala His Pro Pro Arg Pro Ala His Leu 290 295 300 Trp Gln Arg Pro Leu 305 <210> 2 <211> 930 <212> DNA <213> Pantoea ananas <400> 2 atgaataatc cgtcgttact caatcatgcg gtcgaaacga tggcagttgg ctcgaaaagt 60 tttgcgacag cctcaaagtt atttgatgca aaaacccggc gcagcgtact gatgctctac 120 gcctggtgcc gccattgtga cgatgttatt gacgatcaga cgctgggctt tcaggcccgg 180 cagcctgcct tacaaacgcc cgaacaacgt ctgatgcaac ttgagatgaa aacgcgccag 240 gcctatgcag gatcgcagat gcacgaaccg gcgtttgcgg cttttcagga agtggctatg 300 gctcatgata tcgccccggc ttacgcgttt gatcatctgg aaggcttcgc catggatgta 360 cgcgaagcgc aatacagcca actggatgat acgctgcgct attgctatca cgttgcaggc 420 gttgtcggct tgatgatggc gcaaatcatg ggcgtgcggg ataacgccac gctggaccgc 480 gcctgtgacc ttgggctggc atttcagttg accaatattg ctcgcgatat tgtggacgat 540 gcgcatgcgg gccgctgtta tctgccggca agctggctgg agcatgaagg tctgaacaaa 600 gagaattatg cggcacctga aaaccgtcag gcgctgagcc gtatcgcccg tcgtttggtg 660 caggaagcag aaccttacta tttgtctgcc acagccggcc tggcagggtt gcccctgcgt 720 tccgcctggg caatcgctac ggcgaagcag gtttaccgga aaataggtgt caaagttgaa 780 caggccggtc agcaagcctg ggatcagcgg cagtcaacga ccacgcccga aaaattaacg 840 ctgctgctgg ccgcctctgg tcaggccctt acttcccgga tgcgggctca tcctccccgc 900 cctgcgcatc tctggcagcg cccgctctag 930 <210> 3 <211> 492 <212> PRT <213> Pantoea ananas <400> 3 Met Lys Pro Thr Thr Val Ile Gly Ala Gly Phe Gly Gly Leu Ala Leu 1 5 10 15 Ala Ile Arg Leu Gln Ala Ala Gly Ile Pro Val Leu Leu Leu Glu Gln 20 25 30 Arg Asp Lys Pro Gly Gly Arg Ala Tyr Val Tyr Glu Asp Gln Gly Phe 35 40 45 Thr Phe Asp Ala Gly Pro Thr Val Ile Thr Asp Pro Ser Ala Ile Glu 50 55 60 Glu Leu Phe Ala Leu Ala Gly Lys Gln Leu Lys Glu Tyr Val Glu Leu 65 70 75 80 Leu Pro Val Thr Pro Phe Tyr Arg Leu Cys Trp Glu Ser Gly Lys Val 85 90 95 Phe Asn Tyr Asp Asn Asp Gln Thr Arg Leu Glu Ala Gln Ile Gln Gln 100 105 110 Phe Asn Pro Arg Asp Val Glu Gly Tyr Arg Gln Phe Leu Asp Tyr Ser 115 120 125 Arg Ala Val Phe Lys Glu Gly Tyr Leu Lys Leu Gly Thr Val Pro Phe 130 135 140 Leu Ser Phe Arg Asp Met Leu Arg Ala Ala Pro Gln Leu Ala Lys Leu 145 150 155 160 Gln Ala Trp Arg Ser Val Tyr Ser Lys Val Ala Ser Tyr Ile Glu Asp 165 170 175 Glu His Leu Arg Gln Ala Phe Ser Phe His Ser Leu Leu Val Gly Gly 180 185 190 Asn Pro Phe Ala Thr Ser Ser Ile Tyr Thr Leu Ile His Ala Leu Glu 195 200 205 Arg Glu Trp Gly Val Trp Phe Pro Arg Gly Gly Thr Gly Ala Leu Val 210 215 220 Gln Gly Met Ile Lys Leu Phe Gln Asp Leu Gly Gly Glu Val Val Leu 225 230 235 240 Asn Ala Arg Val Ser His Met Glu Thr Thr Gly Asn Lys Ile Glu Ala 245 250 255 Val His Leu Glu Asp Gly Arg Arg Phe Leu Thr Gln Ala Val Ala Ser 260 265 270 Asn Ala Asp Val Val His Thr Tyr Arg Asp Leu Leu Ser Gln His Pro 275 280 285 Ala Ala Val Lys Gln Ser Asn Lys Leu Gln Thr Lys Arg Met Ser Asn 290 295 300 Ser Leu Phe Val Leu Tyr Phe Gly Leu Asn His His His Asp Gln Leu 305 310 315 320 Ala His His Thr Val Cys Phe Gly Pro Arg Tyr Arg Glu Leu Ile Asp 325 330 335 Glu Ile Phe Asn His Asp Gly Leu Ala Glu Asp Phe Ser Leu Tyr Leu 340 345 350 His Ala Pro Cys Val Thr Asp Ser Ser Leu Ala Pro Glu Gly Cys Gly 355 360 365 Ser Tyr Tyr Val Leu Ala Pro Val Pro His Leu Gly Thr Ala Asn Leu 370 375 380 Asp Trp Thr Val Glu Gly Pro Lys Leu Arg Asp Arg Ile Phe Ala Tyr 385 390 395 400 Leu Glu Gln His Tyr Met Pro Gly Leu Arg Ser Gln Leu Val Thr His 405 410 415 Arg Met Phe Thr Pro Phe Asp Phe Arg Asp Gln Leu Asn Ala Tyr His 420 425 430 Gly Ser Ala Phe Ser Val Glu Pro Val Leu Thr Gln Ser Ala Trp Phe 435 440 445 Arg Pro His Asn Arg Asp Lys Thr Ile Thr Asn Leu Tyr Leu Val Gly 450 455 460 Ala Gly Thr His Pro Gly Ala Gly Ile Pro Gly Val Ile Gly Ser Ala 465 470 475 480 Lys Ala Thr Ala Gly Leu Met Leu Glu Asp Leu Ile 485 490 <210> 4 <211> 1000 <212> DNA <213> Pantoea ananatis <400> 4 atgaaaccaa ctacggtaat tggtgcaggc ttcggtggcc tggcactggc aattcgtcta 60 caggctgcgg ggatccccgt cttactgctt gaacaacgtg ataaacccgg cggtcgggct 120 tatgtctacg aggatcaggg gtttaccttt gatgcaggcc cgacggttat caccgatccc 180 240 ctgccggtta cgccgtttta ccgcctgtgt tgggagtcag ggaaggtctt taattacgat 300 aacgatcagg cccggctcga agcgcagatt cagcagttta atccccgcga tgtcgaaggt 360 tatcgtcagt ttctggacta ttcacgcgcg gtgtttaaag aagggtatct gaagctcggt 420 actgtccctt tttatcgtt cagagacatg cttcgcgccg cacctcaact ggcgaaactg 480 caggcatgga gaagcgttta cattaaggtt gccagttaca tcgaagatga acatctgcgc 540 caggcgttt ctttccactc gctgttggtg ggcggcaatc ccttcgccac ctcatccatt 600 tatacgttga tacacgcgct ggaacgtgag tggggcgtct ggtttccgcg tggcggcacc 660 ggcgcattag ttcaggggat gataaagctg tttcaggatc tgggtggcga agtcgtgtta 720 aacgccagag tcagccatat ggaaacgaca ggaaacaaga ttgaagccgt gcatttagag 780 gacggtcgca ggttcctgac gcaagccgtc gcgtcaaatg cagatgtggt tcatacctat 840 cgcgacctgt taagccagca ccctgccgcg gttaagcagt ccaacaaact gcagactaag 900 cgcatgagta actctctgtt tgtgctctat tttggtttga atcaccatca tgatcagctc 960 gcgcatcaca cggtttgttt cggcccgcgt taccgcgagc 1000 <210> 5 <211> 382 <212> PRT <213> Pantoea ananas <400> 5 Met Gln Pro His Tyr Asp Leu Ile Leu Val Gly Ala Gly Leu Ala Asn 1 5 10 15 Gly Leu Ile Ala Leu Arg Leu Gln Gln Gln Gln Pro Asp Met Arg Ile 20 25 30 Leu Leu Ile Asp Ala Ala Pro Gln Ala Gly Gly Asn His Thr Trp Ser 35 40 45 Phe His His Asp Asp Leu Thr Glu Ser Gln His Arg Trp Ile Ala Pro 50 55 60 Leu Val Val His His Trp Pro Asp Tyr Gln Val Arg Phe Pro Thr Arg 65 70 75 80 Arg Arg Lys Leu Asn Ser Gly Tyr Phe Cys Ile Thr Ser Gln Arg Phe 85 90 95 Ala Glu Val Leu Leu Arg Gln Phe Gly Pro His Leu Trp Met Asp Thr 100 105 110 Ala Val Ala Glu Val Asn Ala Glu Ser Val Arg Leu Lys Lys Gly Gln 115 120 125 Val Ile Gly Ala Arg Ala Val Ile Asp Gly Arg Gly Tyr Ala Ala Asn 130 135 140 Ser Ala Leu Ser Val Gly Phe Gln Ala Phe Ile Gly Gln Glu Trp Arg 145 150 155 160 Leu Ser Arg Pro His Gly Leu Ser Ser Pro Ile Ile Met Asp Ala Thr 165 170 175 Val Asp Gln Gln Asn Gly Tyr Arg Phe Val Tyr Ser Leu Pro Leu Ser 180 185 190 Pro Thr Arg Leu Leu Ile Glu Asp Thr His Tyr Ile Asp Asn Ala Thr 195 200 205 Leu Asp Pro Glu Arg Ala Arg Gln Asn Ile Cys Asp Tyr Ala Ala Gln 210 215 220 Gln Gly Trp Gln Leu Gln Thr Leu Leu Arg Glu Glu Gln Gly Ala Leu 225 230 235 240 Pro Ile Thr Leu Ser Gly Asn Ala Asp Ala Phe Trp Gln Gln Arg Pro 245 250 255 Leu Ala Cys Ser Gly Leu Arg Ala Gly Leu Phe His Pro Thr Thr Gly 260 265 270 Tyr Ser Leu Pro Leu Ala Val Ala Val Ala Asp Arg Leu Ser Ala Leu 275 280 285 Asp Val Phe Thr Ser Ala Ser Ile His Gln Ala Ile Thr His Phe Ala 290 295 300 Arg Glu Arg Trp Gln Gln Gln Arg Phe Phe Arg Met Leu Asn Arg Met 305 310 315 320 Leu Phe Leu Ala Gly Pro Ala Asp Leu Arg Trp Arg Val Met Gln Arg 325 330 335 Phe Tyr Gly Leu Pro Glu Asp Leu Ile Ala Arg Phe Tyr Ala Gly Lys 340 345 350 Leu Thr Leu Thr Asp Arg Leu Arg Ile Leu Ser Gly Lys Pro Pro Val 355 360 365 Pro Val Leu Ala Ala Leu Gln Ala Ile Met Thr Thr His Arg 370 375 380 <210> 6 <211> 1000 <212> DNA <213> Pantoea ananas <400> 6 atgcaaccgc attatgatct gattctcgtg ggggctggac tcgcgaatgg ccttatcgcc 60 ctgcgtcttc agcagcagca acctgatatg cgtattttgc ttatcgacgc cgcaccccag 120 gcgggcggaa atcatacgtg gtcatttcac cacgatgatt tgactgagag ccaacatcgt 180 tggatagcgc cgctggtggt tcatcactgg cccgactatc aggtgcgctt tcccacacgc 240 cgtcgtaagc tgaacagcgg ctacttctgt attacttctc agcgtttcgc tgaggtttta 300 ctgcgacagt ttggcccgca cttgtggatg gataccgcgg tcgcagaggt taatgcggaa 360 tctgttcggt tgaaaaaggg tcaggttatc ggtgcccgcg cggtgattga cgggcggggt 420 tatgcggcaa actcagcact gagcgtgggc ttccaggcgt ttattggcca ggaatggcga 480 ttgagccgcc cgcatggttt atcgtctccc attatcatgg atgccacggt cgatcagcaa 540 aatggttatc gcttcgtgta cagcctgccg ctctcgccga ccagattgtt aattgaagac 600 acgcactata tcgataatgc gacattagat cctgaacgcg cgcggcaaaa tatttgcgac 660 tatgccgcgc aacagggttg gcagcttcag actctgctgc gtgaagaaca gggcgcctta 720 cccattaccc tgtcgggcaa tgccgacgca ttctggcagc agcgccccct ggcctgtagt 780 ggattacgtg ccggtctgtt ccatcctacc accggctatt cactgccgct ggcggttgcc 840 gtggccgacc gcctgagcgc acttgatgtc tttacgtcgg cctcaattca tcaggccatt 900 acgcattttg cccgcgagcg ctggcagcag cagcgctttt tccgcatgct gaatcgcatg 960 ctgtttttag ccgggcccgc cgatttacgc tggcgggtta 1000 <210> 7 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 7 Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Ser His 20 25 30 Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Glu Leu Glu Trp Leu 35 40 45 Ser Glu Ile Asn Thr Asn Gly Leu Ile Thr His Tyr Gly Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asn Asn Ala Ala Asn Lys Met Tyr 65 70 75 80 Leu Glu Leu Thr Arg Leu Glu Pro Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Ala Arg Asn Gln His Gly Leu Asn Lys Gly Gln Gly Thr Gln Val Thr 100 105 110 Val Ser Ser 115 <210> 8 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 8 Ile Arg Pro Ile Ile Arg Pro Ile Ile Arg Pro Ile Ile Arg Pro Ile 1 5 10 15 Ile Arg Pro Ile Ile Arg Pro Ile Ile Arg Pro Ile 20 25 <210> 9 <211> 36 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 9 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Lys Gly 1 5 10 15 Gly Lys Gly Gly Lys Gly Gly Lys Gly Gly Gly Ser Gly Gly Gly Ser 20 25 30 Gly Ala Gln Gly 35 <210> 10 <211> 310 <212> PRT <213> Pantoea ananatis <400> 10 Met Val Asn Asn Pro Ser Leu Leu Asn His Ala Val Glu Thr Met Ala 1 5 10 15 Val Gly Ser Lys Ser Phe Ala Thr Ala Ser Lys Leu Phe Asp Ala Lys 20 25 30 Thr Arg Arg Ser Val Leu Met Leu Tyr Ala Trp Cys Arg His Cys Asp 35 40 45 Asp Val Ile Asp Asp Gln Thr Leu Gly Phe Gln Ala Arg Gln Pro Ala 50 55 60 Leu Gln Thr Pro Glu Gln Arg Leu Met Gln Leu Glu Met Lys Thr Arg 65 70 75 80 Gln Ala Tyr Ala Gly Ser Gln Met His Glu Pro Ala Phe Ala Ala Phe 85 90 95 Gln Glu Val Ala Met Ala His Asp Ile Ala Pro Ala Tyr Ala Phe Asp 100 105 110 His Leu Glu Gly Phe Ala Met Asp Val Arg Glu Ala Gln Tyr Ser Gln 115 120 125 Leu Asp Asp Thr Leu Arg Tyr Cys Tyr His Val Ala Gly Val Val Gly 130 135 140 Leu Met Met Ala Gln Ile Met Gly Val Arg Asp Asn Ala Thr Leu Asp 145 150 155 160 Arg Ala Cys Asp Leu Gly Leu Ala Phe Gln Leu Thr Asn Ile Ala Arg 165 170 175 Asp Ile Val Asp Asp Ala His Ala Gly Arg Cys Tyr Leu Pro Ala Ser 180 185 190 Trp Leu Glu His Glu Gly Leu Asn Lys Glu Asn Tyr Ala Ala Pro Glu 195 200 205 Asn Arg Gln Ala Leu Ser Arg Ile Ala Arg Arg Leu Val Gln Glu Ala 210 215 220 Glu Pro Tyr Tyr Leu Ser Ala Thr Ala Gly Leu Ala Gly Leu Pro Leu 225 230 235 240 Arg Ser Ala Trp Ala Ile Ala Thr Ala Lys Gln Val Tyr Arg Lys Ile 245 250 255 Gly Val Lys Val Glu Gln Ala Gly Gln Gln Ala Trp Asp Gln Arg Gln 260 265 270 Ser Thr Thr Thr Pro Glu Lys Leu Thr Leu Leu Leu Ala Ala Ser Gly 275 280 285 Gln Ala Leu Thr Ser Arg Met Arg Ala His Pro Pro Arg Pro Ala His 290 295 300 Leu Trp Gln Arg Pro Leu 305 310 <210> 11 <211> 382 <212> PRT <213> Pantoea ananatis <400> 11 Met Gln Pro His Tyr Asp Leu Ile Leu Val Gly Ala Gly Leu Ala Asn 1 5 10 15 Gly Leu Ile Ala Leu Arg Leu Gln Gln Gln Gln Pro Asp Met Arg Ile 20 25 30 Leu Leu Ile Asp Ala Ala Pro Gln Ala Gly Gly Asn His Thr Trp Ser 35 40 45 Phe His His Asp Asp Leu Thr Glu Ser Gln His Arg Trp Ile Ala Pro 50 55 60 Leu Val Val His His Trp Pro Asp Tyr Gln Val Arg Phe Pro Thr Arg 65 70 75 80 Arg Arg Lys Leu Asn Ser Gly Tyr Phe Cys Ile Thr Ser Gln Arg Phe 85 90 95 Ala Glu Val Leu Gln Arg Gln Phe Gly Pro His Leu Trp Met Asp Thr 100 105 110 Ala Val Ala Glu Val Asn Ala Glu Ser Val Arg Leu Lys Lys Gly Gln 115 120 125 Val Ile Gly Ala Arg Ala Val Ile Asp Gly Arg Gly Tyr Ala Ala Asn 130 135 140 Ser Ala Leu Ser Val Gly Phe Gln Ala Phe Ile Gly Gln Glu Trp Arg 145 150 155 160 Leu Ser His Pro His Gly Leu Ser Ser Pro Ile Ile Met Asp Ala Thr 165 170 175 Val Asp Gln Gln Asn Gly Tyr Arg Phe Val Tyr Ser Leu Pro Leu Ser 180 185 190 Pro Thr Arg Leu Leu Ile Glu Asp Thr His Tyr Ile Asp Asn Ala Thr 195 200 205 Leu Asp Pro Glu Cys Ala Arg Gln Asn Ile Cys Asp Tyr Ala Ala Gln 210 215 220 Gln Gly Trp Gln Leu Gln Thr Leu Leu Arg Glu Glu Gln Gly Ala Leu 225 230 235 240 Pro Ile Thr Leu Ser Gly Asn Ala Asp Ala Phe Trp Gln Gln Arg Pro 245 250 255 Leu Ala Cys Ser Gly Leu Arg Ala Gly Leu Phe His Pro Thr Thr Gly 260 265 270 Tyr Ser Leu Pro Leu Ala Val Ala Val Ala Asp Arg Leu Ser Ala Leu 275 280 285 Asp Val Phe Thr Ser Ala Ser Ile His His Ala Ile Thr His Phe Ala 290 295 300 Arg Glu Arg Trp Gln Gln Gln Gly Phe Phe Arg Met Leu Asn Arg Met 305 310 315 320 Leu Phe Leu Ala Gly Pro Ala Asp Ser Arg Trp Arg Val Met Gln Arg 325 330 335 Phe Tyr Gly Leu Pro Glu Asp Leu Ile Ala Arg Phe Tyr Ala Gly Lys 340 345 350 Leu Thr Leu Thr Asp Arg Leu Arg Ile Leu Ser Gly Lys Pro Pro Val 355 360 365 Pro Val Leu Ala Ala Leu Gln Ala Ile Met Thr Thr His Arg 370 375 380 <210> 12 <211> 494 <212> PRT <213> Europe <400> 12 Met Phe Glu Ile Lys Lys Ile Cys Cys Ile Gly Ala Gly Tyr Val Gly 1 5 10 15 Gly Pro Thr Cys Ser Val Ile Ala His Met Cys Pro Glu Ile Arg Val 20 25 30 Thr Val Val Asp Ile Asn Glu Ser Arg Ile Asn Ala Trp Asn Ser Pro 35 40 45 Thr Leu Pro Ile Tyr Glu Pro Gly Leu Lys Glu Val Val Glu Ser Cys 50 55 60 Arg Gly Lys Asn Leu Phe Phe Ser Thr Asn Ile Asp Asp Ala Ile Lys 65 70 75 80 Glu Ala Asp Leu Val Phe Ile Ser Val Asn Thr Pro Thr Lys Thr Tyr 85 90 95 Gly Met Gly Lys Gly Arg Ala Ala Asp Leu Lys Tyr Ile Glu Ala Cys 100 105 110 Ala Arg Arg Ile Val Gln Asn Ser His Gly Tyr Lys Ile Val Thr Glu 115 120 125 Lys Ser Thr Val Pro Val Arg Ala Ala Glu Ser Ile Arg Arg Ile Phe 130 135 140 Asp Ala Asn Thr Lys Pro Asn Leu Asn Leu Gln Val Leu Ser Asn Pro 145 150 155 160 Glu Phe Leu Ala Glu Gly Thr Ala Ile Lys Asp Leu Lys As...

Claims

1. An engineered mammalian cell that endogenously synthesizes phytoene and lycopene and comprises a heterologous polynucleotide encoding a phytoene synthase, a heterologous polynucleotide encoding a phytoene desaturase, and a heterologous polynucleotide encoding a lycopene cyclase, wherein the engineered mammalian cell comprises a modification that increases carotenoid synthesis in the cell.

2. The engineered mammalian cell of claim 1, wherein the modification that increases carotenoid synthesis in the engineered mammalian cell comprises a modification that reduces a pathway that competes for precursors for carotenoid synthesis.

3. The engineered mammalian cell of claim 1, wherein the modification that increases carotenoid synthesis in the engineered mammalian cell comprises a modification that decreases cholesterol synthesis.

4. The engineered mammalian cell of claim 1, wherein the phytoene synthase has a sequence at least 90% identical to SEQ ID NO: 1 or SEQ ID NO:

10.

5. The engineered mammalian cell of claim 1 or 2, wherein the phytoene desaturase has a sequence at least 90% identical to SEQ ID NO:

3.

6. The engineered mammalian cell of claim 3, wherein the modification that reduces cholesterol synthesis results in reduced yeast sterol synthesis.

7. The engineered mammalian cell of claim 4, wherein the lycopene cyclase has a sequence that is at least 90% identical to SEQ ID NO:5 or SEQ ID NO:

11.

8. The engineered mammalian cell according to any one of claims 1-7, wherein the cell is a Pax7 + Mammalian muscle precursor cells.

9. The engineered mammalian cell according to any one of claims 1-7, wherein the cell is actin + Myosin heavy chain (MHC) + Mammalian multinucleated myotubes.

10. The engineered mammalian cell of claim 3 or 6, wherein the modification to reduce cholesterol synthesis comprises contacting the cell with a cholesterol synthesis inhibitor.

11. A method of making an engineered mammalian cell according to any one of claims 1-8, comprising introducing into a cell that naturally synthesizes geranylgeranyl pyrophosphate (i) a heterologous polynucleotide encoding a phytoene synthase; (ii) a heterologous polynucleotide encoding a phytoene desaturase; and (iii) a heterologous polynucleotide encoding a lycopene cyclase and introducing into the cell a modification that increases carotenoid synthesis in the cell.

12. The method of claim 11, wherein the cells are Pax7+ mammalian muscle precursor cells.

13. A cultured meat product comprising a confluent serum-free culture comprising the engineered mammalian cells of any one of claims 1-10 seeded on a food-safe matrix.

14. The cultured meat product of claim 13, wherein the matrix is ​​a membrane.

15. The cultured meat product of claim 13, wherein the matrix is ​​a sponge or a three-dimensional matrix.

16. The cultured meat product of any one of claims 13-15, wherein the matrix is ​​a chitosan matrix.

17. The cultured meat product of any one of claims 13-16, wherein the cell culture comprises multinucleated myotubes derived from Pax7+ mammalian satellite cells.

18. The cultured meat product of claim 17, wherein the multinucleated myotubes express myosin heavy chain (MHC) and actin.

19. The engineered mammalian cell of any one of claims 1-5, wherein the lycopene production is from 10 μg / g protein to 500 μg / g protein.

20. The engineered mammalian cell of claim 6 or 7, wherein the β-carotene production is 25 μg / g protein to 300 μg / g protein.

21. The engineered mammalian cell of claim 10, wherein the cholesterol synthesis inhibitor comprises ketoconazole.